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Abstract 
Organophosphates are a known danger to human health with an array of biochemical targets and 
complex toxic effects. Phenyl saligenin phosphate (PSP) is an organophosphate and related phenoxy 
substituted organophosphates irreversibly bind to a variety of important enzymes causing the 
condition known as organophosphate induced delayed neuropathy (OPIDN). These compounds also 
potentially cause cardiac muscle damage but little is known about how this class of compounds 
effect cardiomyocytes. The identification of proteins targeted by these toxins is of interest. 
This study investigates the synthesis and application of novel fluorescently labelled 
organophosphates to investigate organophosphate interaction with H9c2 cardiomyoblasts. The 
synthesis of probes with BODIPY, pyrene and rhodamine fluorescent component is explored with 
success in preparation of pyrene and rhodamine probes.  The fluorescent behaviour of three 
rhodamine labelled phenyl saligenin phosphates probes with alkyl and PEG linkers is examined and 
the cytotoxicity of the probes assessed by monitoring MTT reduction, and LDH release from exposed 
H9c2 cardiomyoblasts. All three analogues showed cytotoxicity (4 h exposure; 100 µM). These 
probes were found to bind to proteins within mitochondria and spots from 2D-gel electrophoresis 
experiments, visualised at 532 nm, which are undergoing MS analysis. 
This project also describes progress towards a photoreactive-fluorescent probe to identify the site of 
action of the potassium channel opener, diazoxide, which activates cardioprotective pathways. The 
drug is believed to target mitochondrial KATP channels, but the protein structure of these channels 
has yet to be elucidated. The fluorescence labelling of whole cardiac cells with a dansyl fluorescent -
benzophnone-photoreactoive diazoxide probe has been demonstrated and the progress toward a 
rhodamine fluorescent analogue is presented. 
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1 Introduction  
1.2 Proteomics 
The understanding of protein profiles and interactions is fundamental to understanding 
biochemistry. Whilst great advances have been made in genetics and gene sequencing,1 the detailed 
study of all proteins within an organism is in its infancy. The study of these proteins and their 
interactions is called Proteomics. 
1.3 Functional Probes 
Functional methodology has developed to a point where biological systems can be probed through 
various techniques to gather information on protein functions. Chemically reactive fluorescent 
probes can profile enzymes and determine catalytic activity. Intact cells can be investigated and, 
using microscopy, the fluorescent probes can be visualised to identify where they have bound to 
receptors or enzymes. In addition to this, small molecules that may be selective inhibitors within 
enzyme families can be screened in, intact cells or crude lysates, and can then lead to new drug 
discoveries.2 
Mitochondrial-targeted fluorescent probes are a salient example of this approach. Mitochondria are 
the powerhouses of cells, and synthesise adenine triphosphate (ATP) the chemical energy for cellular 
processes. These organelles consume a large amount of oxygen in aerobic organisms, and produce 
cellular reactive oxygen species (ROS). Cancer, diabetes and heart disease have all shown links to 
elevated ROS. Although ROS are important for normal cellular functions, mismanagement and over-
release causes oxidative stress.3 The inner membrane of the mitochondrion4 is substantially more 
negatively charged than that of any other organelle in the cell by a factor of ten.5 This charge, 
combined with the universally negative charge on emitted radical species, means that probes with a 
positive charge congregate along the outside of the mitochondrial membrane. The most common 
way of staining mitochondria is through rhodamine-based dyes as these carry a permanent positive 
charge.6 
 16 
 
Hydrogen peroxide (H2O2) is produced when incomplete reduction of O2 to H2O occurs during 
electron transport. This species can be beneficial to metabolic function when specific ligand-receptor 
interactions are in control, but random fluctuations in H2O2 release can incite undesirable apoptosis.7 
Lipophilic moieties have been incorporated into the design of a cationic probe which detects H2O2 in 
vivo. MitoPY1 is a highly selective probe for H2O2 and features an aliphatic cationic 
triphenylphosphine group to target mitochondrial membrane (Figure 1).8 In this probe the peroxide 
induced loss of the boronate the rhodamine/fluorescein hybrid molecule switches from the non-
fluorescent closed form to the open form which is highly fluorescent. 
 
Figure 1. MitoPY1 – TPP targeting H2O2 probe featuring boronate hybrid rhodamine/fluorescein for activatable 
fluorescence. 
 
Halo fusion proteins are another powerful tool in probing particular intracellular compartments.9 
The HaloTag is a modified haloalkane dehalogenase, which covalently binds to synthetic ligands. 
Genetically transfecting cRNA into a cell allows for expression of a Halo fusion protein. When the 
HaloTag synthetic ligand is added, a response can be measured depending on the nature of the 
ligand. One example featuring this technique detects calcium ions (Ca2+). The ligand for the probe 
contains a 1,2-bis(O-aminophenoxy)ethane-N,N,N,N-tetraacetic acid (BAPTA) chelator with a 
rhodamine based TMR fluorophore. The ligand is only weakly fluorescent before chelation to a Ca2+ 
ion, when the fluorescence increases over 200-fold with the quantum yield rising to 0.29.10 
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Figure 2. Illustration of HaloTag calcium sensor taken from reference 6. (A) The Halo-H2B fusion protein 
expressed in cells is labelled with the calcium sensitive probe RhoCa-Halo. This probe measures the 
concentration of calcium ions found in the nucleus. The fluorescence emitted by this probe is significant when 
calcium ions are drawn into the nucleus by adenine triphosphate (ATP), stimulation. (B) Structure of the RhoCa-
Halo probe once chelated around calcium. 
 
Fluorescent tagging by covalent bond formation is a useful tool for retrieving desired proteins. The 
covalent bond is a permanent chemical connection and allows biological techniques such as gel 
electrophoresis, or protein chromatography to separate probed proteins from the unwanted, 
unlabelled proteins.11 
Mitogen-activated protein kinases (MAPKs) are enzymes that play a role in signalling cascades for 
normal cellular activity. Cancer cell survival pathways also make use of this protein and development 
of inhibitors could lead to new treatments for this disease.12 Currently, the inhibitors trialled 
regrettably target other bystander proteins with a similar or greater potency. 13 A team at the 
University of Texas has developed a probe for selectively tagging and inhibiting the p38α region of a 
MAPK. The inhibitor covalently binds to the Cys119 residue and avoids non-covalent interactions at 
the ATP-binding site. While not inherently fluorescent, a dialkynylimidazole (DiAm 1) has one N-
alkyne that binds to the free thiol of a cysteine residue, the other alkyne can then be used in azide-
alkyne Huisgen cycloaddition click chemistry with an Alexa fluorophore (Figure 3).14  
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Evidence of DiAm 1 binding to p38α was found in vivo, when cells were treated with 1 µM, 5 µM and 
50 µM of DiAm 1 and tagged via click reaction with 50 µM of Alexa 594. This gave a dark band on a 
gel produced by SDS-PAGE gel electrophoresis, and was compared with isolated p38α that had been 
tagged by click reaction with 50 µM of DiAm 1 in vitro. Validation of identity was determined by 
comparison of the protein bands between these two gels, followed by further confirmation via other 
assaying techniques, demonstrating the power a covalent fluorescent probe can have in proteomics.  
 
Figure 3. Mechanism of covalent tagging from DiAm1 onto p38α, followed by click-chemistry to attach 
fluorophore Alexa 594. 
 
Use of the fluorophore in this example allowed visualisation of the fluorescent protein bands found 
within a gel under a red-light source in a gel imager. In addition to identifying known proteins or 
detecting small molecules in vivo, fluorescent tagging may be useful in identifying novel targets of 
drugs and toxins. A fluorescent tag on a covalently binding toxin bound to a protein target is a new 
development in proteomic study. One family of toxins which are of interest are organophosphates.  
1.4 Organophosphates 
Organophosphates (OPs) have been widely used as pesticides, but also have other industrial uses. 
Many of these compounds target acetylcholinesterase (AChE) activity in the nervous tissue and 
there is concern about OPs widespread use due to the toxicity in humans, with numerous reports 
linking some OPs to various forms of delayed neuropathy.15  
VX nerve agent (3) is a particularly toxic organophosphate that was synthesised by British chemists 
working for ICI in 1952. It is the deadliest synthetic toxin known to man and was synthesised while 
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attempting to make a new type of pesticides. Research on compounds in this class ceased in the UK 
in 1955 when the extreme lethal potency to humans was discovered. VX is toxic enough that only 
10-µg of the oil on the skin, or inhaled as a vapour, is enough to kill within hours.16 
  
Figure 4. The chemical structures of VX gas, 3, and TOCP, 4. 
The Chemical Weapons Convention classifies VX gas as a weapon of mass destruction, and bans any 
use or storage beyond that of research.17 Tragic instances of use include the Halabja chemical attack 
in 1988 where Iraqi military, under Saddam Hussein, used VX gas against the Kurds. Thousands of 
civilians were killed and approximately 10 000 people were injured.18 Recently, the half-brother of 
the North Korean leader Kim Jong-un was assassinated using VX.19  
There are other, less dramatic, examples of organophosphate toxicity. In 1930s America, under the 
prohibition laws, an alcohol containing Jamaica Ginger based remedy known by the slang name 
“Jake”20 gave rise to nervous system damage. The drink, which was adulterated with tri-ortho-cresyl 
phosphate (TOCP) (Figure 4), was offered by bootleggers as an alcohol substitute. Although thought 
to be non-toxic, many who regularly ingested the drink lost the use of their hands and feet. This gave 
rise to a peculiar walk known as “Jake leg”, as the toes bent upward and calves softened and 
atrophied.21 
Aerotoxic syndrome is another disease which has been accredited to organophosphate exposure.22 
The organophosphate TOCP is also used as a lubricant in jet fuel. Cabin crew and frequent fliers can 
be at risk from air contaminated with engine fumes, which can leak into the pressurised cabin air.23 
The issue of poisoning is contentious, however there are many reports of crew ill health and 
premature deaths linked to TOCP. Official studies are yet to conclude if this is a genuine condition 
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caused by the engineering of the plane. Reports issued by both the House of Lords (2007),24 and a US 
Congress Committee on Air Quality in Passenger Cabins of Commercial Aircraft (2002), stated that 
evidence is inconclusive.25 The latter reference even states the dangers of a “nocebo effect leading 
to serious health problems”. However, many pilots and cabin crew believe there is a definite issue 
and, although the investigations are failing to detect even safe levels of engine fumes in the cabins, 
coroner Stanhope Payne has issued a report saying that a pilot’s death in 2012 was likely caused by a 
build-up of toxic organophosphates. 26  
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1.5 Mechanism of Toxicity 
Organophosphates are known to cause three distinct toxic effects: cholinergic syndrome, 
intermediate syndrome and organophosphate induced delayed neuropathy. The first, cholinergic 
syndrome, in which acetylcholinesterase, an enzyme responsible for the breakdown and reuptake of 
acetylcholine, is inhibited. This leads to a build-up of acetylcholine at nerve endings.  
The normal nerve impulse occurs in four stages (Figure 5 A). Acetylcholine travels across the synaptic 
cleft binding to a receptor (either a nicotinic acetylcholine receptor, or muscarinic acetylcholine 
receptor). An action potential travels down the axon to the terminal end. Release of acetylcholine 
into the next synaptic cleft, then causes a response to occur.  
This response can be a muscular response, as illustrated, or neuronal. The type of response is 
dependent on the type of nervous system where the action is occurring.  Generally nicotinic 
receptors are ligand-ion gated channels and muscarinic receptors function as G protein-coupled 
receptors that are ultimately used in cellular communication.27 
In a patient suffering cholinergic syndrome, the resultant excess of neurotransmitters causes 
involuntary and unmediated nerve impulse and responses (Figure 5 B). The physiological symptoms 
are numerous; seizures, coma and respiratory failure which may often lead to death upon acute 
exposure.28 This is the mode of toxicity associated with VX. 
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Figure 5. Mechanism of acetylcholinesterase inhibition by OP during an action potential. (A), normal nerve 
function. (B), nerve function featuring organophosphate interaction with acetylcholinesterase. 
 
Intermediate syndrome (IMS) is the second effect that may occur after cholinergic crisis and can 
commence approximately 24-96 hours after exposure.29 It is characterised by an acute ventilator 
insufficiency caused by paralysis or weakness of respiratory muscles. Patients normally require 
assisted ventilation at the onset of the syndrome, but after 5-18 days, full recovery is generally 
expected. This syndrome is biochemically understood and has exhibited two distinct types, clinically 
characterised by patient response to atropine. Type 1 responds to atropine treatment and is due to 
activation of muscarinic receptors, whereas type 2 does not respond to atropine and indicates an 
affliction of nicotinic receptors pathways.30  
  
A B 
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The third effect, which is less biochemically characterised, is termed Organophosphorus-Induced 
Delayed Neuropathy (OPIDN). The disease is associated with chronic organophosphate poisoning, 
and can be diagnosed by symptoms appearing 7-21 days after a single exposure.31 These symptoms 
include paralysis, ataxia and loss of function of motor axons, and damage to the central nervous 
system. Degeneration of myelin sheaths, cerebrospinal axons swelling, the disappearance of 
muscular tissue and even morphology changes in mitochondria have also been observed. OPIDN is 
the effect that was experienced by the drinkers of Ginger Jake in the 1930s.32 
1.6 Organophosphates’ Mechanism of Covalent Binding 
Several organophosphates are known to cause OPIDN in mammals. These include the 
aforementioned tri-ortho-cresyl phosphate 4 (TOCP) currently used as a fuel additive,33 the 
structurally related saligenin cyclic ortho-tolylphosphate 5 (SCOTP), and phenyl saligenin phosphate 
7 (PSP) (Figure 6). One pesticide known as chlorpyrifos 6, induces OPIDN effects but not IMS.34 TOCP 
is interestingly also a poor inhibitor of AChE. Many organophosphates that induce OPIDN are poor 
inhibitors of AChE and instead strongly inhibit the enzyme Neuropathy Target Esterase (NTE).35 
 
Figure 6. Commonly found organophosphates known to induce OPIDN. Tri-ortho-cresyl phosphate (TOCP) 4, 
saligenin cyclic ortho-tolylphosphate 5 (SCOTP), chlorpyrifos 6, and phenyl saligenin phosphate 7 (PSP).  
 
There are many organophosphates, from the severely toxic nerve agents (VX and Sarin), to 
compounds that have therapeutic uses, and even include the phosphate esters necessary for life, 
biomolecules such as DNA, RNA and ATP. This study focusses on the TOCP toxin and related 
compounds which can cause acute and prolonged toxic effects. 36  
Phenyl saligenin phosphate (PSP) is an organophosphate neurotoxin which is not a strong inhibitor 
of acetylcholinesterase. NTE has been identified as a primary toxicity target.37 In addition, SCOTP 
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was discovered to be a highly active metabolite of the neurotoxin, TOCP, which is actively converted 
in vivo via specific cytochrome P450 enzymes.38 Structurally PSP is analogous to SCOTP, and 
Hargreaves et al have shown that it inhibits neurite growth of mouse neuroblastoma in accordance 
with strong inhibition of NTE.39 
All these compounds feature a pentavalent phosphorous centre, with three substituent groups 
attached via a relatively weak P-O bond. Each has a phenol substituent which can be displaced 
during reaction with nucleophilic species, this allows the organophosphate to covalently bind to a 
protein target. Inhibition via this route is potentially chemically reversible, with treatments for acute 
organophosphate poisoning employing non-enzymatic reagents for the reactivation of enzymatic 
activity.40 
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1.7 Hydrolysis Products (Aging)  
Following the initial reaction of the organophosphate with its targeted protein, further reactions can 
take place, in a process termed aging. For example, an OP covalently binds in the active site of an 
enzyme by organophosphorylation of the serine oxygen. This causes enzyme deactivation; which in 
the case of acetylcholinesterase, leads to extreme muscle contractions to the point of paralysis and 
convulsions.41 Further to this, spontaneous cleavage of the auxiliary groups around the phosphate 
centre, generates a phosphate group permanently attached to the residues of the protein complex. 
This spontaneous dealkylation can occur any time from 2 minutes up to 16 hours post initial 
reaction, and can be observed with the partial loss of only one R-group. This is the case for many 
organophosphates, or can result in the complete loss of the R groups leaving phosphate moiety 
bound to a residue as seen with PSP (Figure 7).42  
Although, when partial hydrolysis occurs, studies have shown that an enzyme can spontaneously 
reactivate, regaining lost functionality.43 
 
Figure 7. PSP aging to leave a permanent phosphate group in active site of enzyme.44, 45 
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1.8 Interesting Targets for Organophosphates 
Chronic illness related to organophosphates binding to targets beyond the normal serine found in 
AChE can happen at low exposures.46 There is also evidence that organophosphates bind to exposed 
nucleophilic residues of tyrosine, lysine and histidine at high concentrations.35 This reactivity implies 
that organophosphates may interfere with a wide range of potential targets which have not yet been 
fully investigated with implications for the understanding of OPIDN. There is need to determine 
more information on the other targets involved in OPIDN through proteomic probing.  
One of the early established targets of organophosphates, other than AChE, is NTE, an integral part 
of neurons (except glia). NTE is a membrane protein regulating membrane traffic and hydrolysis of 
lipids. This enzyme has the most direct involvement with OPIDN. The active site consists of a serine, 
SER966 and two aspartate residues, ASP960 and ASP1086. Deacylation of endoplasmic reticulum-
membrane bound phosphatidylcholine to fatty acids and glycerophosphocholine is catalysed by NTE. 
The deactivation of this enzyme by structural changes caused by organophosphate binding, results in 
a build-up of phosphatidylcholine. 47  This build-up ultimately results in cell death due to abnormal 
membrane structure, influencing the disruption and interactions of axons.48 It is worth noting 
however, that organophosphate inhibitors of NTE that do not age, do not cause OPIDN, suggesting 
some non-classical enzymic role for NTE.49 
 
Figure 8. Two commonly occurring organophosphorus insecticides, diazinon and dichlorvos.  
In detailed mass spectroscopic studies, histidine and lysine residues have also been found to react 
with organophosphates. TOCP metabolite SCOTP, forms a stable o-hydroxybenzyl adduct with 
histidine and lysine residues found in albumin. 50 This study examined a forensic application which 
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can benefit from the measurement of OP-modified albumin as it does not undergo aging. Many 
nerve agents bind also to tyrosine residues found in albumin, and the mass spectroscopic analyses of 
albumin from suicidal patients who had ingested either just dichlorvos 9 (Figure 8),51 just 
chlorpyrifos 6 (Figure 6) or both chlorpyrifos and diazinon 8 have all found phosphate analogues of 
the toxins bound to tyrosine residues.52 However, there is little capacity for diagnostic use of 
albumin in cases of unknown OP poisoning, due to large volume of plasma required and 
comparatively slow binding rates. 
Figure 9 illustrates the reactive sites for cresyl saligenin phosphate (CBDP) on albumin. Tyrosine 
residues attack the phosphorous centre, displacing saligenin and are organophosphorylated. More 
nucleophilic histidine and lysine residues can be alkylated by attacking the benzylic carbon and 
displacing the O-cresyl phosphoryl moiety, as reported by Liyasova et al.53  
 
Figure 9. Binding route CBDP can take with albumin residues. 
The quite promiscuous reactivity of organophosphates with nucleophilic residues suggests that the 
target proteins for organophosphates are numerous and found in a range of different tissue types. 
Studying tissue that responds to acetylcholine via nicotinic receptors would be indicative as a target 
for organophosphates. Due to an interest in developing a probe for cardiovascular disease (Section 
2), cardiac muscle tissue is appropriate for this investigation into organophosphate toxicity. 
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1.9 Focus of Study – Myocardial Cells 
Cardiac muscle tissue and its interactions with organophosphates, have not been much explored and 
are the focus of part 1 of this study. Several studies have shown that occupational exposure to 
organophosphates has links to cardiac complications,54 and 35 patients died of fatal arrhythmias 
after ingesting Diazole in mass a suicide attempt in 1970.55  
The exact cause of cardiac arrhythmias is difficult to determine, but three stages are observed. 
Initially brief, and intense, tachycardia, followed by parasympathetic disturbances which can lead to 
ventricular fibrillation. Finally, the third stage is characterised by a variety of fluctuating tachycardia 
and may even result in sudden death.56,57 This last phase can be delayed for up to several days after 
the initial intoxication period, and parallels OPIDN in that sickness and death appear to be 
dependent on complex chemical pathways. 58 Myocardial cells express NTE in membranes, and this 
protein may be the target for organophosphates causing tachycardia, or other heart complaints.59 
However, it is likely that the target protein could be some other novel target and the processes that 
underpin these mechanisms are undiscovered. Mitochondria that have been exposed to 
organophosphates have reportedly received damage of some significant enzymes, notably succinate 
dehydrogenase, NADH dehydrogenase and cytochrome oxidase.60 Damage to the key respiratory 
components of a cell can cause apoptosis and tissue degradation.61 Targeting mitochondria may 
reveal the answers to organophosphate toxicity in cardiac tissue. Therefore, the focus of this study 
was to investigate potential new protein targets found within differentiated rat cardiomyoblasts 
(H9c2). 
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H9c2 cells 
The cardiomyocyte rodent cell line has widely been used as an in vitro model that displays similar 
physiological, morphological and biochemical properties to human cardiac myocytes.62 Derived from 
embryonic rat heart tissue, H9c2 cells have been used in the mitotic form in a number of studies as 
they express nicotinic acetylcholine receptors and possess a skeletal muscle-like phenotype.63 H9c2 
cells are able to differentiate into a cardiomyocyte-like phenotype. The phenotype is expressed 
when the culture medium has low levels of foetal bovine serum (FBS) and is supplemented with 10 
nM retinoic acid. These conditions encourage the H9c2 cells to undergo the physiological changes 
found in cardiac tissue.64 These changes include the physiological morphology, biochemical signalling 
and responses to stress not found expressed in the skeletal muscle-like phenotype. The 
morphological changes observed include the formation of elongated multinucleated myotubes, with 
branched fibres and characteristic actin filaments. Thus, studies looking at cardiomyocyte 
cytotoxicity often use this differentiated cell line as an in vitro model.65 
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1.10 The Potential Use of an Organophosphate Probe in Protein Identification 
1.10.1 Previous Work 
The objective of work presented in this thesis was to design a fluorescent organophosphate probe 
that could pick out target proteins in organophosphate poisoning and, in doing so, help to elucidate 
the mechanisms involved. In previous work, Smida et al prepared analogue dansylaminohexanol 
saligenin phosphate (DSP-10), an organophosphate fluorescently modified with dansyl amide (Figure 
10).66, 67 
 
Figure 10. Dansylated saligenin phosphate. 
The active saligenin phosphate centre here is linked via a primary alkoxy group. This moiety is a 
poorer leaving group than phenoxy, so there are only two likely hydrolysis products. It should have a 
similar mechanism and binding affinity with the organophosphates of interest (Figure 11).  
 
Figure 11. Proposed binding mechanism for alkoxy-fluorophore modified PSP on a serine residue, where R is a 
fluorophore.  
 
One of the problems found with this probe during the initial experiments performed was that the 
solubility of the DSP-10 in an aqueous environment was lower than desired. Clinically, 
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concentrations of 100 µM are irrelevant, however at this concentrations and above, the probe starts 
aggregating and then precipitating. This indicates that solubility is an issue when wishing to study 
their behaviour within certain experiments where concentrations of probe may be as high as 200 
µM.  
A proof of concept experiment was performed to ascertain if the DSP probe binds to known 
organophosphate protein targets.67 The probe was incubated with both trypsin and chymotrypsin, 
two enzymes that contain active site serine residues,68 which are an established target of PSP. These 
enzymes were then subjected to one dimensional gel-electrophoresis and visualized using UV light 
from a transilluminator. The results showed fluorescent bands at 25 kDa, corresponding to 
covalently labelled protease (Figure 12). The fluorescence of the bands containing chymotrypsin was 
greater than that of trypsin. This result suggested that the binding to chymotrypsin may be greater, 
and that the protein may contain more residues available for phosphorylation. However, the 
coomassie stained gel had much darker bands indicating that there was more protein occupying this 
band then with the corresponding trypsin band. 
 
Figure 12. Incubation of dansylated saligenin phosphate with trypsin and chymotrypsin. Chymotrypsin is a more 
potent substrate for PSP then trypsin, although, increased fluorescence could also be partly due to error in 
loading chymotrypsin wells with more protein then with trypsin wells. 
 
  
 32 
 
A second problem with the dansyl amide fluorophore is that it has a low extinction coefficient and 
quantum yield, (ε =4300 Ф =0.66,),69,70 and a brighter fluorophore than dansyl amide is desirable to 
explore PSP interactions with low concentration of proteins. Using a fluorophore which is 
photostable with a high extinction coefficient and quantum yield, should increase the sensitivity of 
the probe in gel electrophoresis experiments and confocal microscopy, ideally revealing protein 
targets of low abundance. 
Additionally, a third issue associated with using a dansyl fluorophore is one of interference from 
autofluorescence of the proteins. Certain tissues and proteins containing large amounts of 
fluorescently active amino acid residues, such as tryptophan, tyrosine and phenylalanine, can all be 
active over the same wavelength range as dansyl amide.71 To resolve this issue it is better to use 
probes which are excited and emit at wavelengths beyond green light (>490 nm).  
The inhibitory effect of PSP on trypsin and chymotrypsin enzymatic activity was demonstrated in 
competition reactions with two substrates, benzyl-L-arginine 4-nitroaniline hydrochloride (L-BAPNA), 
and N-Succinyl-Gly-Gly-Phe-p-nitroanilide (Suc-GGF-pNA).67 These substrates are peptides with 
fluorescent para-nitroaniline components that, when cleaved by either trypsin or chymotrypsin 
respectively, fluoresce in light at 415 nm. Inhibition of the protease by the OP probe was seen in the 
greatly reduced emission of light. The success of this work demonstrates the capability of the probe 
both in covalently binding to a protein target, but also in deactivation of the enzyme by the probe, it 
has also set benchmarks for biological activity for newly synthesised PSP probes. 
1.10.2 The Synthetic Route of an Organophosphate Probe  
The aim of the project was to fabricate an effective cardiac protein probe using organophosphates 
and a connected fluorophore. Whilst the previous probe is useful, labelling of low abundance targets 
in cell incubation experiments would benefit from a brighter fluorescent component than a dansyl 
group. The probe design starts with examining the simple components that are commercially 
available. A new fluorophore is needed along with a suitable moiety for linking the two. Linking units 
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can be aliphatic carbon chains with reactive groups on either end, or polar chains. Brief analysis of 
the literature identified three potential classes of brighter fluorophores appropriate for the purposes 
of the project: rhodamines, BODIPY dyes and pyrenes.72,73 This was based on the three identified 
problems: solubility, brightness, and selectivity. 
Selectivity 
Many studies have shown that toxicity is dependent on interactions with multiple targets, and the 
mechanisms of chemical hydrolysis are dependent on R group structure.74,42 Changing the nature of 
the R groups will change the toxicity of the compound, the high potency of VX 3 is due to the N,N-
diisopropylaminoethylthiol R group present. Phenyl saligenin phosphate 7 (PSP), was chosen as the 
organophosphate component of the probe. It is an acetylcholine esterase inhibitor with numerous 
other known targets.75 The primary R group in the compound PSP is a phenol, and it is worth noting 
that changing the secondary R group to a linker-fluorophore will either increase or decrease toxicity 
comparatively to PSP. There are three mechanisms to the hydrolytic product and as previously 
mentioned are dependent on aging, and will be influenced by R group change.  
Solubility 
Currently, aminohexanol 11, is incorporated into DSP-10. To increase the solubility of the probe, 
linkers featuring polar groups can be utilised. Two categories of linkers were chosen, polyethylene 
glycol (PEG) 12, and polyglycine 13.  
 
Figure 13. 6-aminohexan-1-ol, PEG, and polyglycine, three chains to linker fluorophore to OP. 
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Brightness 
Rhodamine dyes are cheap and can be used directly in coupling reactions. If commercial rhodamines 
couple effectively but do not function well as a fluorophore in biological testing, there is 
considerable scope to customize this skeleton and modify its properties. Rhodamine B 14 is bright 
with high extinction coefficients and quantum yield (ε =140,000 Ф =0.8). This fluorophore also has a 
high level of photostability, and absorbs and emits around 554 and 627 nm respectively; far beyond 
the autofluorescence limitations below green light. 76 These values highlight that the probe will be 
more selective for low abundance targets compared to a probe with lower brightness and quantum 
yield.  
 
Figure 14. Structure of rhodamine B in fluorescent cationic open form. 
Components 11, 12 and 13 could be coupled to 14 via peptide coupling agents to form an amide 
bond, linking the linker to the fluorophore (Figure 15). 
 
Figure 15. Rhodamine B coupled to three different linkers, 6-aminohexanol, 2(2-aminoethoxy)ethanol, 2(2[2-
aminoethoxy]ethoxy)ethanol.   
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With a fluorophore connected to a linker, saligenin chlorophosphate can then be added to the 
alcohol end of compounds 15, 16 and 17, (Figure 16). This then completes the synthesis of a novel 
organophosphate probe. With cardiac myocytes being of interest to this research group, the 
rhodamine organophosphate probe will be useful in discovering protein targets of PSP. 
 
Figure 16. Rhodamine B amidohexanol saligenin phosphate, a rhodamine B PSP probe. 
After synthesis of these organophosphate probes, biological testing can be performed. Assays to 
include cell proliferation, enzyme activity assays, and one or two-dimensional gel electrophoresis. 
These assays determine the efficacy of the probe when binding to organophosphate targets and 
inducing a biological response; measuring whether it is similar to the other organophosphates of 
interest e.g. PSP by using it as a positive control. The final step in analysis of the probes usefulness, is 
to extract a target protein via 2-dimesional gel electrophoresis and to carry out identification with 
mass spectrometry.  
2 Cardiovascular Disease 
2.1 Background 
Cardiovascular disease kills more than 17.3 million people yearly, approximately one third of all 
worldwide deaths.77 In 2013, 8.2 million people died due to ischaemic heart disease,78 and the 
disease accounted for 17.8% of deaths of men aged 50 to 64 in England and Wales during 2015 
(Figure 17).79 Ischaemia is the restriction of blood supply to tissues, causing oxygen starvation of 
cells, which causes a cascade of problems, due to shortage of nutrients as well as a failure to 
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adequately remove metabolic waste. Restoring blood flow can cause further damage called 
reperfusion injury, through rapid production of free radicals (·O2-2, ·O2- and ·OH), and reactive oxygen 
species (ROS) such as H2O2.80 These free radicals lead to cell death via uncontrolled oxidation of 
cellular components and as a result, ischaemia and cardioprotection are very important areas of 
research. 
 
Figure 17. Leading causes of death during 2015 for men and women in England and Wales from adapted from 
British government statistical data published by the Office for National Statistics in the online bulletin.79  
2.2 Ischaemia-Reperfusion Injury  
Ischaemia-reperfusion injury can affect any tissue type, and not just myocardial cells. Vascular 
endothelial cells are however more susceptible to injury.81 These cells regulate perfusion and 
reperfusion, leukocytes, platelet function and the control of inflammation and thrombosis during 
myocardial events.  
2.3 Preconditioning 
Strategies that aim to reduce the effects caused by ischaemia are given the term cardioprotective. 
Normally the goal of cardioprotectrive techniques is to activate pathways that endogenously reduce 
the damage caused by myocardial ischaemia-reperfusion injury. Ischaemic preconditioning (IPC) 
refers to the observation that brief periods of ischaemia in a tissue or organ can activate 
mechanisms of resistance which protect the cell when a subsequently damaging period of ischaemia 
arises (Figure 18).82 The role of this technique is clearly limited as it directly interferes with coronary 
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blood flow, potentially giving rise to lethal ischaemia or plaque rupture. The evidence that this 
technique clinically reduces myocardial infarction damage or mortality rates is also in doubt.83  
 
Figure 18. Block diagram highlighting IP. Four sequential periods of 5 minutes of ischaemia followed 
by 40 minutes of prolonged ischaemia were shown to decrease infarct size in anaesthetised dogs. 
The early preconditioning phase is up to 2 hours. A second window protection can be seen when this 
phase is increased to 24-72 hours before administering ischaemia and is called delayed 
preconditioning. Adapted from Murry et al.84 
 
The exact biochemistry of IPC and the processes that give rise to this phenomenon are not well 
elucidated. It has been suggested that early and delayed protection of cardiomyocytes are 
generated by cascades of intracellular signalling. A preconditioning stimulus, for example ischaemic 
insult, triggers IPC via endogenous activation of membrane receptors, protein kinase C (PKC), 
tyrosine kinase (TK), and mitogen activated protein kinase (MAPK) pathways.85 KATP channels in 
either or both the sarcolemma, and mitochondria can be opened, allowing potassium ions to leave 
the cell or organelle, hyperpolarising the membrane causing local cardiac muscle relaxation. 
Alternatively, release of the transcriptional nuclear factor κB (NF-κB) may also result in the synthesis 
of protective proteins such as heat shock proteins (HSPs), and the mitochondrial antioxidant enzyme 
superoxide dismutase (MnSOD). Release of nitric oxide (NO) and the two nitric oxide synthases, 
endothelial (eNOS) and inducible (iNOS), has also been shown to give both early and delayed 
cardioprotection (Figure 19).  
 38 
 
 
Figure 19. Diagram illustrating potential mechanisms of ischaemic preconditioning. Intracellular signalling 
cascades that lead to both early and delayed protection of cardiomyocytes. Ischaemic insult induces endogenous 
triggers to be released ultimately ending with ischaemic preconditioning (IPC). The interaction of these triggers 
with specific membrane receptors leads to protein kinase C (PKC), tyrosine kinase (TK) and mitogen activated 
protein kinase (MAPK) pathways being activated. This can result in several potential options: 1. KATP channels 
open within the sarcolemma, mitochondria, or both. 2. The increase in expression of genes leading to synthesis 
of effector proteins such as transcriptional nuclear factor kB (NF-kB) and protective heat shock proteins (HSPs) 
and mitochondrial antioxidant superoxide dismutase (MnSOD), which are then transported to the nucleus. 3. 
Nitric oxide (NO) is synthesised and released under the regulation of two forms of nitric oxide synthase, the 
endothelial (eNOS) and inducible (iNOS) forms. This also contributes to early and delayed cardioprotection.85 
2.4 Diazoxide – Pharmacological Preconditioning 
Diazoxide is a drug that has been known for many years as Proglycem86, and was originally 
prescribed as a hypotensive agent (Figure 20). Currently it is marketed to treat diabetes as it causes 
inhibition of insulin secretion. This is achieved by hyperpolarising the pancreatic tissue. In normal 
insulin release, increased levels of blood glucose in the β-cells causes a cascade of processes 
resulting in an increase in the ATP: ADP ratio. This increase in ATP causes KATP channels to close.87 
The membrane then steadily depolarises until voltage-gated Ca2+ channels open, allowing calcium 
ions to enter and insulin to be secreted. With a hyperpolarised tissue, the surface membrane is more 
negatively charged and therefore less sensitive to elevated glucose levels, inhibiting the release of 
insulin.88  
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This study is interested in diazoxide as it has shown cardioprotective qualities, as well as pancreatic, 
anti-diuretic benefits, and even synaptic enhancement. Unsurprisingly, with such a wide and varied 
pharmacological activity, it has been utilised as a lead compound in many drug discovery programs 
for over 50 years, and has led to the development of some promising analogues. 
  
Figure 20. Structure of diazoxide (Proglycem).  
The biological effect of this drug on rat aortic rings has been shown to delay stimulated contractions. 
Diazoxide depolarises cardiac membrane tissue and produces an effect similar to a period of 
ischaemic preconditioning. This leads to temporary changes in cell biochemistry that can be 
protective if substantial ischaemia occurs.89  
Given the recognised mode of action in pancreatic β cells,87 activating potassium channels found in 
cardiomyocytes would also hyperpolarize the cell membrane, delaying action potential and 
preserving residual energy. Alternatively, diazoxide may hyperpolarise the mitochondrial membrane, 
causing increased release of ROS into the cytosol.90 The increase of ROS may then stimulate other 
beneficial signalling pathways. 
It has been established that ROS scavengers administered before treatment with diazoxide can block 
the beneficial effects of protection upon ischaemic insult. This blocking effect suggests a link 
between diazoxide and ROS.91 However, the binding sites of diazoxide within the cell and the exact 
drivers of the cellular processes leading to cardioprotection are not known. Figure 21 illustrates the 
two potential mechanisms for protection mentioned above.  
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Figure 21. Diazoxide action, 1. Sarcolemma K+ channels induce a delayed action potential through activation of 
a Kca channel, allowing Ca2+ ions in. 2. Hyperpolarisation of mitochondrial membrane, as a result of which 
potassium channels release ROS into the cell. 
 
Identification of the protein targets for diazoxide, and establishment of the cellular location, will 
clarify whether diazoxide acts via a sarcolemma potassium channel or a mitochondrial channel 
activation, or indeed, via other unforeseen pathways. 
2.5 Potassium Channels 
2.5.1 Types of Potassium Channel 
Potassium ion channels are one of the most abundant ion channels found in cell biology, located not 
only on the plasma membrane but also on the membranes of intracellular components like 
mitochondria. These channels are involved in the modulation of a wide variety of processes and are 
integral to membrane transport, muscle contraction and neurotransmission.  
 
In general, transmembrane channels mediate the movement of ions across membranes and the K+ 
ions play a central role in many biological processes. The principal functions of potassium channels 
differ depending on the speciality of the tissue in which they are located. Nevertheless, all K+ 
channels regulate charge control across a membrane; either sarcolemma or located on an 
organelle.92 Membrane polarisation controls other functions beyond action potentials. For instance, 
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production of ROS in mitochondria is influenced by K+ ions hyperpolarising the inner membrane. 
However, the functions are multifarious and, as previously mentioned with insulin secreting tissue, 
these channels play a role in the management and secretion of hormones and proteins. 93 
 
There are four general types of K+ channels: Calcium-activated, , tandem pore domain, voltage-gated, 
and inwardly rectifying. Each of these four classes of potassium channels can be differentiated 
further into subclasses.94 
 
Calcium-activated potassium channel (KCa) are a type of K+ channel, comprising of eight different 
family members normally activated by Ca2+. Although some are further moderated by Na+ and Cl- , 
and the KCa1 channel is both voltage-gated and Ca2+ activated.  
Tandem pore domain potassium channels are part of the leak pathways, these are active at rest, and 
stabilize the membrane polarisation found in mammalian cells. Voltage-gated potassium channels 
manage the level of extracellular K+ during an action potential.95 
Inwardly rectifying potassium channels (Kir) form a family of seven K+ channels that are responsible 
for allowing positive charge to enter the cell during the refractory period.96 The pumping in of K+ ions 
helps establish the resting potential of neurons and is the target for many toxins. The roles of 
inwardly rectifying channels vary in accordance with the location. For example, the channels found 
on cardiac myocytes close on depolarisation causing a more prolonged cardiac action potential by 
slowing repolarisation. Whereas Kir channels found in the kidneys, act to remove surplus potassium 
and store it, either for excretion or to return to the system later. This is in contrast with typical 
neuronal potassium channels which are responsible for repolarising the cell after action potential. 
These allow K+ to leave the cell as opposed to entering it. The associated proteins of these types of 
channel are of interest due to an acknowledged role in cardioprotection.  
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2.5.2 Sarcolemma KATP Structure 
One further subtype of potassium channel is the ATP nucleotide gated channel. This can be found in 
the sarcolemma, mitochondria and the nucleus. The sarcolemma KATP channels are a complex 
formed from inwardly rectifying (Kir) channel subunits. The Kir6.2 subunits which are pore-forming 
and tetrameric in structure. The subunits are connected to two transmembrane units (M1 and M2), 
a form of ATPase, and sulfonylurea (SUR) receptors, all located within the sub-membrane space.97 
The connection to SUR is via transmembrane protein used to anchor the KIR unit.98 There are four 
variants of SUR receptor in these complexes: SUR1, SUR2A, SUR2B and SUR2C.99 The SUR2A receptor 
is present as a subunit in cardiac myocytes. Interestingly, overexpression of this subunit generates a 
resistance to ischaemia as seen in modified mice.100 The SUR2A makes up the ATP- binding cassette 
(ABC), and is octameric in structure. Consisting of three transmembrane domains (TMD), and a 
nucleotide binding domain (NBD), selective for ATP (Figure 22).101   
 
Figure 22. Schematic of KATP channel found on the sarcolemma. Sulfonyl urea (SUR2A) consists of three 
transmembrane domains (TMD), and nucleotide binding domains (NBD). Potassium inwardly rectifying subunits 
(KIR6.2) also contain two transmembrane domains, M1 and M2. 
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2.5.3 Mitochondrial KATP Structure 
The structure of mitochondrial KATP (mitoKATP), has not yet been fully elucidated, but mitoKATP 
channels are thought to have Kir6.1 and a type of SUR2 receptor.102 Early research by Ardehali et al, 
found that whilst investigating mitochondrial lysates via co-immunoprecipitation studies, 
components of mitoKATP channels were found alongside succinate dehydrogenase (SDH).103 This 
implies that SDH interacts with other mitochondrial proteins including: mitochondrial ATP-binding 
cassette protein-1 (mABC1), adenine nucleotide translocator (ANT), mitochondrial phosphate carrier 
(PIC) and ATPase (Figure 23). The complexes that these proteins make were partially purified and, 
after fusion with planar lipid bilayers, K+ currents were recorded. This activity was increased by 
diazoxide, and inhibited by ATP, 5-HD and glibenclamide, (5-HD, a postulated specific mitoK+ channel 
inhibitor, glibenclamide is in a class of sulfonylureas and inhibits KATP channels).104  
Diazoxide has also shown an affinity for SDH, which brings into question whether it directly 
influences mitoKATP or acts via a more indirect mechanism which features SDH. What is clear is that 
that there is a definite link between SDH, mitoKATP and diazoxide.105 
 
Figure 23. Schematic diagram of the diazoxide-sensitive complex containing SDH-PIC-mABC1-ATPase-ANT, the 
proteins associated with mitoKATP activity. K+ ions are capable of being transported with characteristics similar 
to those of mitoKATP. IMS, intermembrane space; Mito IM, mitochondrial inner membrane. Adapted from 
reference O’Rourke.103 
 
More recent studies suggest however that Kir6.1 units are not foumd in the mitochondrial inner 
membrane, and instead the membrane contains a renal outer medullary potassium channel or 
ROMK unit (Figure 24).106 Conversely, Lacza et al have suggested that mitoKATP contain structures 
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both like Kir6.1 and Kir6.2 subunits, but neither SUR1 nor SUR2, although there is the potential for 
some smaller light weight SUR2-like protein.107  
To date, the precise nature of the subunits found on mitoKATP channels and the interaction with 
diazoxide are unknown. Furthermore, the involvement of ROS in the mechanism for ischaemic 
preconditioning (IPC) is not clear.  
 
Figure 24. Structure of mitochondrial KATP channel on inner membrane. Glibencamide sensitivity highlights the 
likelihood of a short SUR2 type of subunit. Tertiapin Q is an established inhibitor of renal outer medullary 
potassium channel (ROMK) and has been shown to effect K+ levels indicative of decrease in activity of a mitoKATP 
channel. Adapted from reference 105. 
2.6 Mitochondrial Role in Cardiovascular Disease 
Mitochondria produce ATP, the stored chemical energy the body uses as fuel (Section 1.3), in a 
series of redox reactions that occur in the inner membrane of mitochondria. In this process, an 
electron is moved from a donor molecule such as nicotinamide adenine dinucleotide (NADH), to an 
electron acceptor (O2). The O2 is then reduced to produce a primary ROS, superoxide radical (O2
.-), 
which is reasonably reactive and is subsequently transformed into H2O2, a more stable compound 
through the activity of Mn, Cu and Zn superoxide dismutases (SOD). H2O2 may be metabolized by the 
mitochondria, however, in the event where it is not metabolized and the antioxidant systems have 
failed, H2O2 will degenerate into a hydroxyl radical HO·, which is extremely reactive.108 
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Intracellular Ca2+ ions control much of the bioenergetics of a mitochondrion and play an important 
role in the citric acid cycle, activation of pyruvate dehydrogenase, NADH formation and ROS release. 
Mitochondrial membrane potential can decrease following uptake of Ca2+, which can decrease ROS 
formation. However, excessive accumulation of Ca2+ is associated with mitochondrial stress and may 
lead to increased levels of ROS species. The mechanisms for ROS release via Ca2+ can be related to 
enhanced NADH formation which activates glycerol phosphate and ɑ-ketoglutarate dehydrogenase 
two ROS-generating enzymes. 109 
2.7 Structure and Reactivity of Diazoxide 
Given the historical interest as a drug lead, diazoxide has been subject to a great number of 
structure-activity relationship (SAR) studies. One aim of this project is to incorporate diazoxide into a 
probe. There are several positions for substitution around the diazoxide pharmacophore where the 
probe could feasibly be coupled (Figure 25). Adding groups to positions 3, 5 and 7, notably increase 
or decrease potency toward mitoKATP channels. With the knowledge gained from the variation of 
substitution, selectivity for channel subtypes such as Kir6.2 and SUR1 can be fashioned. 
Furthermore, incorporating diazoxide into any larger probe system may unfavourably change the 
reactivity of the diazoxide. Structural changes around the molecule need to be made in a position 
that bares no decrease in biological activity. An understanding of the structure and reactivity of 
diazoxide is essential for the current study. 
 
Figure 25. Diazoxide core structure with numbered locations for substituent change. 
2.7.1 Cardioprotective Derivatives 
In the 1970s, John Topliss and Milton Yudis synthesised numerous derivatives of diazoxide. They 
measured the ability of the drug to block norepinephrine-induced contractions of rat aortic rings.110 
Using Hanschs’ structure-activity analysis, equations were applied to determine the biological 
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efficacy after a substituent change, and then compared against observed values measured as an 
ED50. The ED50 (µl/ml) value vs. norepinephrine may be viewed as an in vitro measure of 
antihypertensive activity in this series of compounds. Stimulation of aorta causes contractions of the 
aortic rings which indicate membrane potential activity and regulation, and is indicative of 
diazoxides antihypertensive activity.111 The equations used in tandem with biological responses are a 
good indicator of how substituent change will affect efficacy of drug modifications.  
The results of substituent change, represented in arbitrary units, with higher values illustrating a 
greater decrease in norepinephrine-induced aortic ring contractions, suggests that both electronic 
and steric effects of substituents at position 3 have very little influence on biological activity. It also 
suggests that increasing lipophilicity of this position beyond an optimum value leads to reduced 
activity (Figure 26).  
 
Figure 26. Diazoxide analogues, with an R3 substituent change (values in arbitrary units), derived from equations 
calculating structure-reactivity changes on efficacy are compared with activity of observed values.  
 
In addition to this trend, Topliss et al go on to illustrate that there is an increase in activity for 
substitution of H for either a halogen, small ether, nitro, amine, trifluoromethyl or small alkyl chain 
about the 5,6,7 or 8 positions.109 Singly substituting chlorine in these positions achieves the largest 
increase in activity for mono substituted derivatives, with chlorine in the 7 position the highest. 
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Disubstitution of positions 6 and 7 with chlorines gives the second highest activity, whereas 
disubstitution in either positions 6 and 8 or 7 and 8 does not give as high an activity increase as 
mono-substituted chlorine at 7. Tri-substitution of 6,7, and 8 with chlorine grants the fourth largest 
increase in activity. However, 6,7-dichloro substitution and 6-CF3, 7-Cl produce the most potent 
derivatives (Figure 27).  
Detailed analysis of their results suggests that the activity is affected by both steric and electronic 
effects, and in the 6 position steric effects take priority. In the 7 position, F or Br substituents raise 
the activity significantly less than Cl does, indicating that group size has some influence. Whilst 
replacing position 7 with a CH3 only gives a modest rise in activity, this suggests that electronic 
effects are also important.  
 
Figure 27. Activity of diazoxide analogues calculated by Topliss et al in arbitrary units containing substituents at 
the R5, 6, 7 and 8 positions, where equations calculating structure-reactivity changes on efficacy are compared 
with observed values.109 
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It was calculated from this study that the most potent analogue theoretically was 7-chloro-3-
(cyclopent-3-en-1-yl)-6-(trifluoromethyl)-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide 20. With 
disubstitution at positions 6 and 7 and a Δ3-cyclopentenyl system at the 3 position(Figure 28). 
 
Figure 28. Highest theoretical activity diazoxide analogue from the Topliss studies.109 
Analogues 21 and 22 of diazoxide, bearing amines or sulphonyl ureas on positions 5 and 7 were 
synthesised by Smail Khelili et al. in 2003.112 These derivatives in comparison with diazoxide and the 
KATP channel opener cromakalim, were less effective at inducing vasodilation. However, when the 
sulphonylurea was attached via an SO2 group at the 7 position the potency increased greatly (Figure 
29).  
 
Figure 29. Sulphonyl urea based diazoxide as selective KATP channel openers. 
2.7.2 Derivatives with Cognitive Effects 
One group of diazoxide derivatives has shown effects on glutamate receptors in the brain. In 1994, 
Jimonet et al. were comparing 2H-1,2,4-benzothiadiazine-1,1-dioxide-3-carboxylic acid derivatives 
for their potency as antagonists against the NMDA (N-methyl-D-aspartate) glutamate receptor, and 
found that introduction of chlorine atom(s) to positions 5 and 7 enhanced binding affinity with the 
glycine active site.113 
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Glutamate is a neurotransmitter which is associated with learning and memory, and the receptors 
mediate synaptic plasticity.114 These receptors can be split into ionotropic and metabotropic types. 
Ionotropic glutamate receptors are ligand-gated cation channels which are non-specific, allowing K+, 
Na+, and Ca2+ ions to flow across the membrane. Both AMPA1 and KA2 receptors desensitise rapidly 
following glutamate exposure, and repolarisation of AMPA receptors is thought to be a mechanism 
for cognitive enhancement.115,116 AMPA, NMDA3 as well as the KA receptors are three ionotropic 
glutamate receptors and are responsible for different tasks. AMDA and NMDA stimulate fast and 
slow synaptic responses whilst the KA receptor physiological function is currently debated. 117  
In another study that looked at cyclothiazide is one of the most potent AMPA re-sensitisers and a 
potential synaptic enhancer, but it does not cross the blood-brain barrier. G. Puia et al from the 
University of Modena developed diazoxides analogues IDRA 21 (24) and IDRA 5 (25) that can travel 
across the blood-brain barrier and target AMPA receptors. (Figure 30). 
 
Figure 30. Diazoxide analogues with AMPA biological effects; cyclothiazide and blood-brain barrier crossing 
analogues, IDRA 21 a sensitiser and IDRA 5 a desensitiser.118 
 
IDRA 21 shows an effective increase in conductivity of KA-receptors and positively modulates AMPA 
receptors. Although, the latter not as effectively as cylothiazide. IDRA 5 however, has shown the 
opposite effects on both KA and AMPA receptors.119 Interestingly, removal of the double bond 
between the 3’ position and the sulphonamide helps this drug target glutamate receptors. 
Replacement of a hydrogen with a chloride, as in IDRA 5, completely changes the effect of the 
                                                          
1 α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid is the agonist for this receptor, and mimics glutamate. 
2 Kainate receptor, responds to glutamate. 
3 N-Methyl-D-aspartate is the agonist for this receptor, and mimics glutamate. 
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compound on its two targets. Pierre Francotte has more recently synthesised seven analogues which 
positively modulate AMPA receptors each with the fully saturated 3’ carbon.120 
2.7.3 Pancreatic β Cells Stimulation 
In-depth analysis of many isomers of the benzothiadiazine 1,1-dioxides can be found in the work of 
Pascal de Tullio et al. 121 In this study, the secretion of insulin from rat pancreatic islet cells was 
measured in addition to the induction of contractile activity by K+ in depolarised rat aorta rings. They 
studied compounds, with the addition of a 3 position side chain hydroxy group, creating a 
stereogenic centre on the R group. For their derivatives, the R enantiomers are generally more 
potent at inhibiting insulin release than the S enantiomers. The three most potent inhibitors (26, 27 
and 28) all inhibited at concentrations below the micromolar range (Figure 31). 
  
Figure 31. The most efficacious diazoxide analogues at stimulating pancreatic β-cells. 
The myorelaxant activity of each compound was given an EC50 value; the drug concentration giving 
50% relaxation of the 30 mM KCl-induced contraction of the rat aortic rings. The introduction of the 
amino chain on position 3 decreases the vasorelaxant effect of the hydroxylated derivatives in 
comparison with the non-hydroxylated. The 6,7-dichloro, non-hydroxylated derivative 27 was the 
most potent ultimately. The findings concluded that the stereochemistry of these side chains only 
had a weak effect on the pharmacological role.  
M. Dabrowski et al developed NNC 55-09216 (30) as a diabetes treatment. This compound and BPDZ 
44 (29) developed by B. Pirrotte et al are other potent insulin secretion inhibiting derivatives. NNC 
55-09216 is a selective opener of Kir6.2/SUR1 channels.122 BPDZ 44 is in a class of pyridothiadiazine 
analogues which use a pyridine ring instead of a phenyl ring with the N sitting at the 7 position 
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(Figure 32).123 Like other potential diabetes medications, they hyperpolarise the pancreatic β-cell, 
meaning inward Ca2+ ion transport is delayed, inhibiting insulin secretion.  
 
Figure 32. Insulin secretion inhibiting analogues of diazoxide. 
Notably across all these studies, structural changes that yield the largest differences in activity come 
from the chlorine positioned on the phenyl ring. Of any derivative of diazoxide in any role or 
location, chlorines are optimally positioned at the 6 or 7 position, with substitution at 5 or 8 
reducing potency.124 It is therefore the best course of actions to substitute at the 3 position to 
couple diazoxide to a probe. 
2.8 Non-Covalent Binding of Diazoxide to Protein Targets 
The targets of diazoxide are reported to be MitoKATP, the SUR, Kir and ROMK subunits, as well as 
sarcolemmal KATP. The documented effects of the compound are as a hyperglycaemic, hypotensive, 
anti-diuretic and insulin secretion inhibitor.125, 126 Unlike the organophosphates discussed earlier, 
diazoxide has no reactive central moiety with which to irreversibly bind to amino acid residues. 
Whatever the target of diazoxide may be, it is not covalently bound and therefore is difficult to 
identify in cell and tissue extracts. Many non-covalent drug-receptor interactions are characterised 
by up and down regulation of the genes that code for the target, or via introduction of competing 
inhibitors. It would seem simpler to determine protein targets by some means of labelling via a 
covalent bond. One way to induce covalent binding is through the use of photo affinity probes.  
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2.9 Photoaffinity Probes 
In the 1970s, Arnold Ruoho et al. at the University of California published a paper detailing a 
technique of permanent covalent binding of proteins via a photoaffinity label. 127 This technique 
follows on from Westheimer and co-workers’ original diazocarbonyl derivatives published in 1962, 
and utilises a photolytic reaction with a labelling component that converts to a reactive carbene 
intermediate.128 During a reversible binding of a ligand to an active site on a protein, the carbene 
irreversibly binds to the protein target. The rest of the ligand may now disassociate but will be 
covalently tagged onto the target protein.  
In a recent review, Yutaka Sadakane and Yasumaru Hatanaka discuss three carbene-generating 
reactive probes (Figure 33).129  The first, a nitrene based label, has the advantage of being easily 
synthesised and commercially available. The azide 31 is also small and represents minimal structural 
change biologically. A nitrene is more reactive than a carbene and can form more labile products. 
This could create undesirable non-specific crosslinking with other proteins and incorrect labelling. 
The second example is a carbene forming phenyldiazirine 33. The phenyldiazirine label has none of 
the non-specific crosslinking issues of the phenylazide and photolyses at 360 nm, a wavelength that 
is less damaging to biomacromolecules compared to the 300 nm of phenylazide. Previous work by 
the Garner group had prepared phenyldiazirine photo reactive probe but it required considerable 
synthetic effort.  
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The current study shall focus on the third example, benzophenone 35. This photoreactive 
component is commercially available, highly selective and creates a stable carbonyl group as a 
product of finding a C-H bond capable of being activated. The excited triplet state then inserts 
between a C-H bond, assuming correct geometry of attack. Excitation at 360 nm is favourable and 
the excited state can regenerate the ground state if no suitable bonds are available to react with. 
 
Figure 33. Three photoreactive labels and their excited intermediates. 
In the current study, the photoaffinity labels were used in conjunction with a fluorophore and the 
reversibly binding K+ channel activator diazoxide, the label covalently tagging the sub-unit target of 
diazoxide. 
2.10 The Potential Use of Labelled Diazoxide Probe 
Diazoxide and its analogues are generally accepted to reversibly act on ATP sensitive, inwardly 
rectifying potassium channels. This study was interested with the mechanism of ischaemic 
preconditioning associated with the drug, and therefore the binding locations found within 
mitochondria, or the sarcolemma. There is debate, as discussed previously, as to which potassium 
channels (or their sub-unit types) the diazoxide interacts with; mitochondrial KATP or sarcolemma 
KATP. Therefore, a way of permanently binding diazoxide to either of these channels, extracting the 
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related proteins and then determining where it has bound, would increase the body of useful 
information related to the IPC debate.  
Due to drugs binding through temporary electronic and steric effects to proteins (with factors based 
on tertiary structure and size), an activated photoaffinity label was used to tag those proteins 
permanently through covalent cross-linking. 
The plan for probing the potassium channel structure was to create and test diazoxide analogues for 
biological efficacy. Suitable analogues were then used to construct a probe featuring a photo affinity 
barb, and a fluorophore linked to the biologically effective analogues to facilitate identification of 
the targeted proteins. 
2.11 Aims 
1. Design and build new PSP probes, featuring bright, water soluble fluorophores. 
2. Test the efficacy of the PSP probes and determine whether they are suitably designed as a 
tool in proteomic identification of PSP-binding proteins. 
3. Probe cardiac myocytes for protein-PSP interactions using gel-electrophoresis and mass 
spectrometry. 
4. Incubate novel diazoxide analogue 109, with mitochondria and using gel-electrophoresis and 
mass spectrometry, identify protein targets that may provide information for mitoKATP 
channel structure. 
5. Build a fluorescently bright, selective diazoxide probe and test that with mitochondrial tissue 
samples. 
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3 Experimental Results  
The exploration of protein targets found in cardiomyocytes begins with considering 
organophosphate (OP) toxicity with respect to the myocytes. With biological and analytical 
techniques, such as proliferation assays and mass spectrometry, a probe can be built and used to 
identify targeted proteins.  
Based on the previously proposed mode of action in section 1.6, the covalent interactions OP’s have 
with exposed residues, no photoaffinity component will be needed. Construction of this probe 
would also shed light on an effective construction for the diazoxide probe. The purported design 
shown in Figure 121 and comprised of diazoxide coupled via an alkyl linker to a photoreactive 
benzophenone, and a rhodamine group. This is similar to Smida design67 but incorporating improved 
fluorescent component. 
3.1 Synthesis of Rhodamine B with 6 Carbon Alkyl Linker 
The starting point for the synthesis of an improved probe was the coupling of rhodamine B to the 
simplest alkyl linker 6-aminohexanol. A myriad of coupling agents were available, but initially DCC 
was explored as a standard reagent for this coupling. 
3.1.1 DCC Coupling 
N,N-dicyclohexylcarbodiimide can activate the carboxylic acid of rhodamine B. The N-terminus of the 
6-aminohexanol can then attack the carbonyl centre, displacing dicyclohexylurea (DCU) which is 
insoluble in DCM (Scheme 1). 
 
Scheme 1. Rhodamine B coupling, (i). DCC, TEA, DCM, 6-aminohexanol 
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Treatment of rhodamine B with DCC in dry DCM was followed by addition of 6-aminohexanol. After 
12h the solution was filtered, and following aqueous work-up, the solvent was then removed and, 
analysis by 1H NMR spectroscopy revealed an intractable mess of peaks, with no evidence of the 
coupled material in the mixture and TLC gave a pink smear.  
3.1.2 Benzoic Acid Trial Coupling 
This then led to a series of trial coupling reactions using benzoic acid and 6-aminohexanol and four 
different coupling reagents (Scheme 2). Firstly, investigations to see if the two would react with DCC 
in the presence of triethylamine. Dissolved in dry DCM and treated the same way as in the first 
attempted rhodamine B coupling, the 1H NMR again returned a spectrum with no coupling product.  
 
Scheme 2. Benzoic acid coupling trial reaction. (i). DCC, TEA, DCM, 0 oC, 12 h. Or, (ii). TsCl, Pyr, DCM, 0 oC, 8 h. 
Or, (iii). CDI, TEA, DCM, 0 oC, 12 h. Or, (iv). T3P, TEA, DCM, 0 oC, 12 h.  
 
Tosyl chloride was then explored as an activating agent for the benzoic acid. This acid was mixed 
with pyridine in dry DCM at 0 oC then had 6-aminohexan-1-ol added before being allowed to warm 
to room temperature over three hours. Analysis of 1H NMR gave no evidence of the desired amide 
product. 
The two water soluble reagents: 1,1-carbonyldiimidazole (CDI) and tripropylphosphinic anhydride 
(T3P)were then examined.130 These reagents underwent a variety of trial reactions with variation of 
base and reagent equivalents to determine if the water-soluble coupling reagents were effective. 
The by-products of using CDI are carbon dioxide and imidazole, both are easily removed from the 
reaction mixture by aqueous work-up. T3P activates the carboxylic acid oxygen turning it into a good 
leaving group. The amino alcohol can then attack displacing 1,5-dioxido-1,3,5-trioxo-1,3,5-
tripropyltriphosphoxane, a by-product that gets easily removed by aqueous work-up.  
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Experiment series 1 2 
Linker 
mg 
Acid mg DMAP % TEA 
equivalents 
T3P 
equivalents 
CDI 
equivalents 
10 10 1 0 2 2 
10 10 0 1 2 2 
10 10 1 1 2 2 
10 10 1 2 2 2 
10 10 0 2 1 1 
Table 1. Table of reagents for trial coupling reactions. 
The optimum of these reactions proved to be two equivalents of TEA with two equivalents of T3P. 1H 
NMR analysis of the crude reaction mixture showed that coupling with T3P cleanly gave the product. 
This then was chosen to be the coupling reagent of choice with rhodamine B and the linker.  
3.1.3 Water-Based Reagent Coupling  
Rhodamine B was dissolved in a solution of dry DCM and a T3P solution (50% in DMF) was added 
along with two equivalents of TEA and a catalytic amount DMAP at 0 OC. This mixture was stirred for 
ten minutes before addition of 6-aminohexanol in DCM. The mixture was allowed to warm to room 
temperature over 48 hours. After washing with water twice, the organic phase was evaporated to a 
residue then analysed by 1H NMR spectroscopy, which showed that only starting material had been 
returned. 
3.1.4 Succinimide Intermediary Compound 
Coupling reactions with rhodamine B then proceeded by the attempted to synthesis of a 
hydroxysuccinimide active ester intermediate compound. The reaction method followed a standard 
procedure where DCC, rhodamine B and TEA were all dissolved in dry DCM, and DMAP was then 
added and followed by a solution of N-hydroxysuccinimide. Analysis of 1H NMR after work-up with 
DCM and brine showed the presence of only starting material. 
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3.1.5 Rhodamine Acid Chloride Synthesis 
The preparation of rhodamine B acyl chloride has been reported.131 Following this literature 
procedure, rhodamine B in dichloroethane (DCE) was treated with phosphorous oxychloride (POCl3) 
and the mixture refluxed for 2h (Scheme 3).  
 
Scheme 3. Attempted rhodamine B acyl chloride synthesis. (i), POCl3, DCE, reflux, 10h. 
Monitoring the reaction by TLC did not suggest that any formation of the product occurred, even 
after eight further hours. The 1H NMR spectrum showed only starting material so it was concluded 
that any product that formed during the reaction either isn’t stable and the chloride is instantly 
substituted, or that product is unable to be formed due to formation of a closed form lactone 
rhodamine. 
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3.1.6 Benzotriazole Coupling 
Having explored simple activation methods without success, a further exploration of benzotriazole 
coupling reagents was made. Many of these reagents are expensive but have been shown to be 
effective in difficult coupling reactions.132 
 O-(Benzotriazol-1-yl) N,N,N’,N’-tetramethyluronium hexafluorophosphate (HBTU), is a popular 
coupling reagent in solid phase peptide synthesis and it was explored in coupling rhodamine B to 6-
aminohexanol.133 
 
Scheme 4. Rhodamine B coupling, (i). HBTU, TEA, 6-aminohexanol dry DCM, 0 oC, 24h. 
Rhodamine B was treated with 2 equivalents of TEA, 2 equivalents of HBTU and 1.1 equivalents of 6-
aminohexanol in dry DCM at 0 oC for 24 h. Aqueous work-up and partitioning with DCM, gave a 3:1 
mixture of starting material and product. Chromatography proved difficult (Section 3.1.8), however 
amide 15 was afforded in 26% yield (Scheme 4), and the identity confirmed by 1H. A shift in the 1H 
NMR spectrum of the 3 position H, ortho to the newly formed amide bond, from 8.3 ppm to 7.9 ppm 
was found to be indicative that the coupling had occurred. A shift in the triplet (2.6 ppm up to 3.1 
ppm) of the CH2 next to the NH also indicates that a new moiety had been formed. The presence of 
the peaks associated with 6-aminohexanol suggested a reaction between the two had occurred as 
the amine-alcohol was normally lost during work-up due to its solubility in water. 
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3.1.7 Protected Rhodamine Linker 
Problems encountered during purification caused by the polarity of the rho-linker product were 
addressed by examining the synthesis of a silyl protected amino alcohol coupled to rhodamine. It 
was anticipated that it would reduce the polarity of the product.  
Tert-butyldiphenyl silyl 39 (TBDPS) and tert-butyldimethyl silyl 40 (TBDPS) ethers were prepared 
from 6-aminohexanol and a corresponding silyl chloride, the protected alcohols were afforded in a 
low but un-optimised yield of 9.8% and 12.7% respectively (Scheme 5). 
 
Scheme 5. Synthesis of protected 6-aminohexanol. (i). TEA, DMF, TBDPSiCl, 72 h, r.t. (ii). TEA, DMF, TBDMSiCl, 
72 h, r.t. 
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Subsequent coupling of the TBDPS ether 39 was investigated with rhodamine B using HBTU in TEA 
and dry DCM at 0oC. 1H NMR of the crude product mixture after work-up gave a difficult to interpret 
mess of peaks. Column chromatography afforded two main fractions the first contained only the silyl 
protected linker and the second only rhodamine B starting material. Coupling of TBDMS ether 40 
did, however, yield protected rho-linker product 41 (13%) under similar conditions. This compound 
was purified by column using chromatography using DCM and 2% TEA on silica, the second pale 
yellow fraction was found to contain the product (Scheme 6). 
 
Scheme 6. Rhodamine B coupled to a protected silyl ether linker. (i). 52, HBTU, TEA, dry DCM, 0 oC, 24 h. 
The low yield of 41, accompanied by a large amount of starting material rhodamine and protected 
linker led the investigation to optimise purification conditions for the synthesis of the higher yielding 
rhodamine linker 15. 
3.1.8 Purification of Rhodamine B Species 
Rhodamine can exist as two tautomers,134 and is in equilibrium between a closed lactone and a 
zwitterionic open form. When protonated, the molecule prefers an open cationic form (Scheme 7). 
One of the major differences between the forms is deactivation of the closed form by internal 
conversion.135 This deactivation reduces the fluorescent properties of rhodamine, leaving it 
colourless and weakly fluorescent. 136 The cationic and zwitterionic forms exhibit minimal differences 
when comparing extinction coefficient (ε) and quantum yield (φ) with only a slight reduction in these 
properties for the zwitterion. There is however a hypsochromic shift and change in the fluorescence 
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and absorption maxima due to the inductive effect on the central carbon of the xanthene. 
Fluorescent properties for rhodamine B is displayed below, (Scheme 7).  
 
Scheme 7. Interconversion of rhodamine B forms.137,138 
Controlling tautomeric equilibrium of rhodamine dyes can be used in applications including ion 
sensors, (Section 1.3) such as with the peroxide probe. In addition to the pH dependence, the 
tautomeric equilibrium can be shifted by changing temperature or with application of UV light 
(Scheme 8). Increasing the temperature causes the molecule to close, giving the non-fluorescent 
state which can also be colourless depending on the particular rhodamine. Exposure to UV light will 
open the rhodamine into the cationic form, and the colour and fluorescent properties will return.139 
These temperature dependent form changes can also occur for substituted amides resulting in a 
lactam.133 
 
Scheme 8. Spirolactam /zwitterion equilibrium. 
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The major difficulty in the purification of rhodamine linkers such as 15, was that the products and 
starting material move poorly on silica and overlap, smearing. This made purification of often 
incomplete reactions very difficult.  
Many efforts were made to refine the process including a wide variety of solvent mixes, and use of 
reverse phase silica. All attempts led to poor separation and low purified yield. However, by 
exploiting the property of lactone ring closure under basic conditions, it was found that 2% TEA in 
2:1 acetone and toluene caused the closed form of the product to elute more quickly and without 
extensive trailing, due to a decrease in polarity (Figure 34). Warming the compound in the solvent 
mix gently until very pale prior to loading on the column, and using warm glassware and solvent 
throughout also aided the purification as well. 
 
Figure 34. Illustration of TLC plate monitoring purification of rhodamine linker rho-alkyl 15. 
3.1.9 Synthesis of Amide Glycol Rhodamines 
In order to examine how linker properties might change overall probe efficacy the synthesis of three 
other RhoB-linker systems was carried out using the HBTU coupling protocol. Treatment of 
Rhodamine B with triglycine, 2-(2-aminoethoxy) ethanol, or 2-(2-[2-aminoethoxy]ethoxy) ethanol 
(Figure 13), under similar conditions to the 6-aminohexanol coupling, gave derivatives 16 and 17 
respectively. After work-up, chromatography via the improved method described above, yielded the 
shorter glycol rho-PEG short 16 in 35% yield and the longer glycol rho-PEG long 17 in 67% yield 
(Scheme 9).  
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Scheme 9. Synthesis of rhodamine B glycol with (i). HBTU, TEA, dry DCM, 0 oC, 24 h, 2-(2-aminoethoxy)ethanol 
and (ii). BTU, TEA, dry DCM, 0 oC, 24 h, 2-(2-[2-aminoethoxy]ethoxy)ethanol. 
 
The reaction of triglycine hydrochloride with rhodamine B was also investigated (Scheme 10). 
However similar reaction conditions could not couple triglycine with rhodamine B via HBTU. Analysis 
of the crude compound by 1H NMR after washing with water and brine returned only a mixture of 
starting materials, with no shifts in the 3 position H peak of the rhodamine, nor a shift in the CH2 of 
the triglycine amine. Analysis of the TLC plate showed only the presence of starting material spots, 
and was considered as further evidence to the product not being formed. 
 
Scheme 10. Reaction of rhodamine B with triglycine, (i). HBTU, TEA, triglycine hydrochloride, dry DCM, 0 oC, 24h. 
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3.2 Synthesis of Saligenin Phosphate Probe 
3.2.1 Synthesis of Organophosphates 
With rhodamine B coupling to linker in progress, the synthesis of PSP was investigated (Scheme 11). 
PSP had previously been prepared from 2-hydroxybenzyl alcohol and phenyl phosphodichloridate in 
a one pot reaction. This was repeated and achieved in a moderate to good yield (70%).140   
 
Scheme 11. Synthesis of PSP i) THF, Et3N, 0 oC – RT, 4h 
The structure of the organophosphate probes all featured a saligenin phosphate centre, analogous 
to SCOTP.38 The synthesis of the intermediate structure can be achieved in one step from 
commercially available compounds (Scheme 12).  
Treatment of hydroxybenzyl alcohol with POCl3 and triethylamine gave saligenin chlorophosphate 45 
in 95% yield after filtration from precipitated triethylamine hydrochloride. The 31P NMR displayed a 
single peak at -5.38 ppm, which was anticipated. This compound was unstable in the air and could 
not be stored without decomposition. Further steps that incorporate this reagent relied on freshly 
prepared product. 
 
Scheme 12. i) saligenin, POCl3, TEA, dry DCM, -78 oC, 1h. 
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3.2.2 Synthesis of Dansyl Probe 
Future experimentation required a stock of the previously synthesised dansyl probe 10. The 
synthetic route designed by Smida et al was investigated to this end.67 
Synthesis commenced by addition of dansyl chloride to 6-aminohexanol (Scheme 13). These were 
added to dry DCM at 0 oC, and stirred at room temperature for 4 h. The reaction went to completion 
to yield compound 46 cleanly in 92% yield.  
This dansyl-linker 46 was then dissolved in dry DCM and cooled to -78 oC. A solution of saligenin 
chlorophosphate 45 was added dropwise. The mixture was allowed to warm to room temperature 
for 24 hours before work-up with toluene and column chromatography to give the dansyl probe 
(DSP), 10 in 22% yield as an orange oil (Scheme 13).  
 
Scheme 13. Synthesis of DSP-10, (i). TEA, 45, dry DCM, -78 oC, 24 h. 
3.2.3 Rhodamine Probe Synthesis  
With the synthesis of DSP-10 completed, PSP probe 18 was prepared by the same two-step process 
in which a reactive chlorophosphate was isolated, then further reacted with an alcohol (Scheme 14).  
Freshly prepared saligenin chlorophosphate 45 was then reacted with rhodamine amidohexanol 15. 
The dropwise addition of saligenin chlorophosphate 45 in dry DCM to a solution of 15, and 
triethylamine at 0 oC, was left to stir for 24 hours. Upon completion of the reaction, work-up 
proceeded with washes with water and brine, and extraction with DCM. The 1H NMR spectrum of 
the crude mixture showed peaks that did not belong to either of the starting materials, and a 31P 
NMR spectrum, with a single peak at – 9.06 ppm highlighting that the reaction had formed a fully 
 67 
 
oxidised phosphate. The compound was purified by column chromatography according to the 
previously optimised technique of warming the crude residue in a solution of 2% TEA and 2:1 
mixture of acetone in toluene until pale. Purification was achieved by column chromatography 
eluting with the same solvent system, collecting the first colourless fraction to give rho-alkyl PSP 18 
in 34% yield. CH2OP and POCH2R hydrogen peaks showed the expected ABX pattern for the 
diastereotopic hydrogens, due to three bonds coupling to the phosphorous stereogenic centre and 
the P=O bond giving rise to a tetrahedral structure (Figure 35). 
 
Scheme 14. Synthesis of rho-alkyl SP 18, (i). TEA, 45, dry DCM, -78 oC, 24 h. 
 
 
Figure 35. Zoomed in spectrum of rho-alkyl SP 18, highlighting the multiplet caused by the CH2 of the alkyl chain 
in blue; and the CH2 of the saligenin ABX splitting pattern in red. 
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3.2.4 Conversion of Hydroxyphosphate 
The unpurified material from the formation of 45 decomposes rapidly into saligenin 
hydroxyphosphate 47, and it was therefore carried onto the next reaction directly. Indeed, the 
crystalline hydroxyphosphate 47 could be isolated cleanly, and the conversion of this material to the 
chloride when needed for further synthesis was investigated (Scheme 15). Treatment of phosphate 
47 with oxalyl chloride and 10% DMF did not proceed cleanly enough to give the chlorinated product 
without needing further purification. In the interest of efficiency, the preparation of fresh saligenin 
chlorophosphate was more viable. 141 
 
Scheme 15. Conversion of the saligenin hydrogen phosphate to the chloride, (i). Oxalyl chloride, 10% DMF, DCM, 
r.t., 3h 
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3.2.5 Synthesis of Rhodamine Glycol Probes 
The successful synthetic approach was then applied to the preparation of a PSP probe featuring 
rhodamine glycol linkers 16 and 17, coupled to saligenin phosphate. This would achieve three probes 
each with varying properties. 
Freshly prepared saligenin chlorophosphate solution was added dropwise to a solution of rhodamine 
linker and triethylamine at 0 oC. After 24 hours the mixtures were worked-up with DCM and brine. 
Both were purified by column chromatography following the optimised route mentioned previously. 
This afforded rho-PEG short SP 48 and rho-PEG long SP 49 in 30% and 28% yield, respectively 
(Scheme 16).  
 
Scheme 16. Synthesis of rho-PEG short SP 48, and rho-PEG long SP 49, (i). TEA, 45, dry DCM, -78 oC, 24 h. 
With these three fluorescent PSP probes synthesised, the fluorescent characterisation of excitation 
and emission wavelength were measured. The tests were performed under conditions chosen to 
mimic the biological environment. Initial measurements were made in water at a concentration of 
100 µM to ensure they could be used.  
A comparison was also made with the dansyl probe DSP-10 at an excitation of 324 nm. 
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3.2.6 Fluorimetry of Probes 
The FLA5000 laser scanner from Fujifilm, has a green light laser measuring in the region of 532 nm. 
When the SDS-PAGE gels containing cell lysates, treated with the probe were visualised, this was the 
laser employed. This excitation wavelength should be selective for the rhodamine fluorophore, 
whereas auto fluorescence (ca. 270 – 400 nm), from the cell lysates was avoided.  
The results of this experiment shows that the peak absorbance and therefore the optimum 
frequency to excite the probes is 560 – 578 nm. Interestingly the probe rho-alkyl SP 18 and the 
probe rho-PEG long SP 49, absorb a much greater amount of light between 480 and 578 nm than the 
probe rho-PEG short SP 48.  
 
Figure 36. Absorption of the rhodamine B PSP probes. Red is rho-alkyl SP 18, Green is rho-PEG long SP 49, Yellow 
is rho-PEG short SP 48. Fluorescence measurements were made using a 1 cm3 fluorimetry cuvette; with a 100 
µM solution of each probe dissolved in distilled water, pH of 7.5, the solutions were excited from 400 nm up to 
580 nm by the fluorimeter. The emission strength in arbitrary units (AU) was recorded at 600 nm (n=3).  
 
The results shown in Figure 36 reveal that rho-alkyl SP 18 absorbs the greatest amount of light 
around 575 nm, with the slope falling off towards 700 nm. This means that under green light of 532 
nm, the probe will steadily fluoresce from the yellow to red region of the spectrum appearing 
orange. Rho-PEG short SP 48, absorbs less light and was expected to fluoresce significantly less than 
the other two linkers. This difference in absorption may be due to some radiationless exchange of 
0
50
100
150
200
250
300
350 400 450 500 550 600 650 700
In
te
n
si
ty
 A
U
Wavelength nm
Absorbance of Probes 18, 48 and 49
 71 
 
energy between the rhodamine B and the organophosphate. This exchange of energy and drop in 
fluorescence could be occurring in all three probes. However, the effect may be more pronounced in 
the shortest of the linkers due to the closer proximity of the organophosphate and rhodamine B. 
 
Exciting the probes at 532 nm and measuring the fluorescence emission indicates how bright the 
probes will be under green light on the gels. This will also give some indication of the detection limits 
that may be expected from the probe (Figure 37). 
 
 
Figure 37. Emission spectrum of the rhodamine probes. Red is rho-alkyl SP 18, Green is rho-PEG long SP 49, 
Yellow is rho-PEG short SP 48. Fluorescence measurements were made using a 1 cm3 fluorimetry cuvette; with 
a 100 µM solution of each probe dissolved in distilled water, pH of 7.5, the solutions were excited at 532 nm and 
the emission strength recorded in AU over a wavelength of 560 to 700 nm (n=3). 
 
Comparison of the three probes 18, 48 and 49, with the fluorescent behaviour of compounds 15, 16 
and 17 the rhodamine-linker precursors, shows the effect that adding the saligenin phosphate 
moiety has on the level of fluorescence (Figures 38, 39 and 40). With rho-alkyl SP 18 and its 
precursor rho-alkyl 15, we can see that the saligenin phosphate increases the amount of energy 
absorbed, but emitted energy, once excited at 532 nm, remains about the same.   
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Figure 38. Emission (circles) and excitation (triangles) spectrum for rho-alkyl SP 18 in red, and precursor rho-
alkyl 15 shown in blue. Fluorescence measurements were made using a 1 cm3 fluorimetry cuvette; with a 100 
µM solution of each probe dissolved in distilled water, pH of 7.5 (n=3).  
 
Probe rho-PEG short SP 48 was seven times less fluorescent with the addition of the 
organophosphate compared to its precursor rho-PEG short 16 (Figure 39). It is clear that with 
addition of saligenin phosphate the brightness of the rhodamine B is reduced. This same effect was 
not observed with rho-alkyl SP 18. This influence is likely caused by the distance from the 
organophosphate to the rhodamine. The average bond lengths have been calculated from 
crystallography data, 142 and the data gives average lengths of 6-aminohexanol as 12.1 Å, 2-(2-
aminoethoxy) ethanol as 8.8 Å and the longer glycol as 13.2 Å. This data confirms that rho-PEG short 
SP 48, is the shortest probe compared to the other two.  
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Figure 39. Emission (circles) and excitation (triangles) spectrum for rho-PEG short SP 48 in yellow, and precursor 
rho-PEG short 16 in blue. Fluorescence measurements were made using a 1 cm3 fluorimetry cuvette; with a 100 
µM solution of each probe dissolved in distilled water, pH of 7.5 (n=3). 
 
It was expected then, that the difference in fluorescence between the long chain PEG linker (rho-PEG 
long 17), and the subsequent probe (rho-PEG long SP 49), would be less. It can be seen from the 
graph (Figure 40) that there was less of a drop in fluorescence. This is interesting when compared to 
the first probe and its linker, where there was no drop in emitted light, but there was still less than 
half the original emitted output at 532 nm. 
 
Figure 40. Emission (circles) and excitation (triangles) spectrum for rho-PEG long SP 49 in green, and precursor 
rho-PEG short 17 in blue. Fluorescence measurements were made using a 1 cm3 fluorimetry cuvette; with a 100 
µM solution of each probe dissolved in distilled water, pH of 7.5 (n=3). 
 
0
50
100
150
200
250
300
350
400
450
500
300 400 500 600 700 800
In
te
n
si
ty
 A
U
Wavelength nm
Rho-PEG short SP 48 ex/ em. Vs rho-PEG short 16
0
50
100
150
200
250
300
350
400
450
300 350 400 450 500 550 600 650 700 750
In
te
n
si
ty
 A
U
Wavelength nm
Rho-PEG long SP 49 ex/ em. Vs rho-PEG long 17
 74 
 
There could be several reasons for the difference in intensity of fluorescence between the final 
probes, rhodamine B and the intermediate compounds. The initial difference between the three 
linkers is likely to do with solvent effects in interaction with the alkyl and the glycol chains. The glycol 
chains are miscible in water and the alkyl chain has a predicted solubility of ca. 2.65 mol/L.143 It was 
apparent from the graphs that PEG linkers rho-PEG short 16 and rho-PEG long 17 are at least twice 
as bright as the alkyl chain rho-alkyl 15. The effect of solubility may not be very prominent as there 
was only a small difference in fluorescence between the alkyl and PEG probes rho-alkyl SP 18 and 
rho-PEG long SP 49, highlighting that addition of organophosphate was causing a more noticeable 
effect. In terms of overall efficiency it is also worth noting that the two glycol probes are likely to be 
more bioavailable in cell tissue cultures due to the higher solubility.  
3.2.7 Investigation into Fluorescence Drop 
Due to the drop in emitted light between the glycol probes and their fluorophore linker precursors, 
the addition of saligenin phosphate must cause a change in the fluorescent properties of the probe. 
The absorbance of PSP 7 was next measured by UV-vis. The measurement was made to address the 
possibility that the PSP absorbs any of the radiation at 532 nm, or if there was an occurrence of 
Förster resonant energy transfer (FRET) where the absorbed energy of the rhodamine B is 
nonradiatively transferred to the PSP via some type of dipole-dipole overlap.144 Secondly, there 
could also be a quenching problem in which PSP can fluoresce out of phase with the rhodamine, but 
with the same wavelength, diminishing the strength of the fluorescence emitted by rhodamine B.  
FRET is characterised by a fluorescence behaviour where an excited donor fluorophore transfers its 
energy to a non-excited acceptor fluorophore.145 One example of this occurring intramolecularly 
with a rhodamine B fluorophore, is with a Cu2+ probe designed by Guan et al, (Figure 41).146 This 
probe has an inactivated closed-rhodamine system, connected to coumarin.147 Coumarin absorbs at 
410 nm, and without the presence of copper ions, blue light is emitted at 480 nm. When Cu2+ is 
detected the rhodamine opens up, and the absorbed energy by the coumarin is transferred to the 
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rhodamine, then emitting that energy at 580 nm. The amount of light emitted by the two 
fluorophores is directly proportional to the concentration of Cu2+ and, as this can be measured at 
two wavelengths, 480 nm and 510 nm making this a very sensitive probe. Defined as a ratiometric 
probe, this technique can withstand environmental pressures that can so often interfere with probe 
sensitivity.148  
  
Figure 41. Förster resonance energy transfer, of two fluorophores shown as a conjugate spectrum of  rhodamine 
B and coumarin. Excitation at 410 nm causes coumarin to fluoresce at 480 nm. In the presence of Cu2+ which 
this probe is sensitive for, the energy transfers to rhodamine B causing it to fluoresce at 580 nm. 
 
The first question of whether intermolecular FRET occurs in the current study of rho-PSP probes 
could be answered easily by a graphical comparison at different concentrations of the probes in 
water. The shape of the graph would change to illustrate a loss in intensity of light at shorter 
wavelengths, and an increase in intensity at longer wavelengths as concentration increases. This 
corresponds to more energy being transferred from rhodamine B to saligenin phosphate of another 
molecule without loss, as the proximity of the dipole-dipole of the molecules increases at growing 
concentrations. This energy should have then been emitted by the organophosphate. If any resonant 
energy transfer is occurring, then it was predicted that the peak at 570 nm will lower, and an 
increase in intensity further towards the red shifted region will appear, indicating FRET. 
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The results from increasing and decreasing the concentration of probe dissolved in water provided 
no evidence of FRET occurring. Further evidence to this fact was that there was no change in shape 
of emission seen in the graphs between the precursor rho-linker emission at 532 nm and the 
completed probe. This was true for all three pairs of linker and probe, so it is unlikely to be a 
nonradiative transfer of energy as seen in FRET. 
The second investigation was a simple UV-vis experiment. A reading of PSP was performed to see 
which wavelengths the compound absorbs, this would confirm whether the organophosphate is 
absorbing any of the excitation radiation from the sauce or emission radiation from fluorophore. 
This should have further clarified whether intramolecular FRET was possible or not.  
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A 10 µM solution of PSP dissolved in water was added into a cuvette and the methodology set out in 
5.2.6 was followed. The results of this test show that there was considerable interference in 
absorbance at 200 nm up to 300 nm, and then clear absorbance up to 350 nm followed by a sharp 
decline after this point (Figure 42). There was very little absorbance then across the visible spectrum 
and into the beginning of the infrared spectrum. It is unlikely that the very low levels of absorbance 
between 400 and 600 nm offer much in the way of reducing the effectiveness of rhodamine B as a 
fluorophore.  
This result led onto testing whether the pH has a any effect on the brightness of these probes.  
 
Figure 42. UV absorption of PSP in water, at room temperature. Measurements were made using a 1 cm3 UV-
VIS cuvette; with a 10 µM solution of PSP dissolved in distilled water, pH of 7.5 (n=3). 
 
Rhodamine B is sensitive to pH, and it can aggregate into dimers and trimers depending on 
temperature, solvent environment, and other factors that can affect π-π interactions.149 This 
aggregation can cause spectroscopic changes to photostability and efficiency, including fluorescence 
quenching, if the solvent is suitably hydrophobic and aggregation is high. 
An experiment was performed comparing the fluorescence emissions of each probe at four different 
pH. Assuming water is at pH 7.5 it was expected that the fluorescence would increase in acidic 
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conditions and decrease in alkaline, corresponding to the open and closed forms of the fluorophore 
(Scheme 7).  
Solutions were made up in centrifuge tubes, each containing 100 µM of each probe and then the pH 
was adjusted to the desired range with either 1M HCl or 1M NaOH. The various pH values were 
measured with a pH meter and the replicant solutions were found to be uniform at each pH. They 
were then added to a cuvette and excited at 532 nm in the fluorimeter according to the standard 
technique (Figures 43 -45).  
The results confirmed the hypothesis; the more acidic environment the more light was emitted 
(Figure 43), whilst increasing alkalinity encourages closing of the rhodamine reducing the output.  
 
Figure 43. Fluorescence emission of rho-alkyl SP 18, at 532 nm at four different pH. Fluorescence measurements 
were made using a 1 cm3 fluorimetry cuvette; with a 100 µM solution of each probe dissolved in distilled water 
and made to desired pH with: 1M NaOH, 1M HCl and 1M EtCOOH (n=3). 
 
The shape of the graph flattens as the alkalinity increases. In the case of rho-PEG short SP 48 the 
absorbance maxima shifts from 580 nm down to 555 nm (Figure 44).  
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Figure 44. Fluorescence emission of rho-PEG short SP 48, at 532 nm at four different pH. Fluorescence 
measurements were made using a 1 cm3 fluorimetry cuvette; with a 100 µM solution of each probe dissolved in 
distilled water and made to desired pH with: 1M NaOH, 1M HCl and 1M EtCOOH (n=3). 
 
Interestingly, the range of maximum emission for the rho-alkyl SP 18 probe is about 75 nm. This is 
the difference between the highest fluorescent output at pH 3 and a pH of 12. This value 
demonstrates the behaviour of the probes sensitivity to pH. The range of maximum emission points 
for the two glycol probes, rho-PEG short SP 48 and rho-PEG long SP 49 was equivalent to half the 
brightness of the probe in the most acidic environment (Figure 45). This indicated that the probe 
solutions must exist in an equilibrium between open and closed states of the rhodamine. 
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Figure 45. Fluorescence emission of rho-PEG long SP 49, at 532 nm at four different pH. Fluorescence 
measurements were made using a 1 cm3 fluorimetry cuvette; with a 100 µM solution of each probe dissolved in 
distilled water and made to desired pH with: 1M NaOH, 1M HCl and 1M EtCOOH (n=3). 
 
The fact that there was still fluorescence at 555 nm decreasing to 800 nm in a solution of pH12 (light 
green curve), would direct thoughts to the theory that these rhodamine B probes are not overly 
sensitive to comparatively subtle pH changes. Rhodamine analogues used in pH sensitive probes can 
almost completely lose fluorescence in alkaline conditions, and brightly fluoresce in slightly acidic 
conditions. This led the investigation onto comparing the rhodamine probes with the previously 
synthesised dansyl probe, and also a comparison with the rhodamine B starting material. 
Rhodamine B was dissolved in water in a variety of concentrations, starting at 100 µM and 
decreasing to 100 nM. The dansyl probe, DSP-10 was also dissolved in water at a concentration of 
100 µM. These solutions were poured into a cuvette and scanned on the fluorimeter following our 
standard technique. 
The results of this test are shown below, plotted with the three probes for direct comparison (Figure 
46). DSP-10 was excited at 324 nm, this is a blue light laser that is used to visualise gels containing 
lysates incubated with this probe. 324 nm is close to the optimum point to excite dansyl at 338 
nm.150 DSP-10 was approximately the same brightness as the rhodamine probes. This is problematic, 
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as the extinction coefficient (ε) of the dansyl group is very low compared to rhodamine B, 4,300 cm-
1/M80 vs 106,000 cm-1/M.151  Rhodamine B was selected for this high ε and photostability as a 
replacement for the dansyl amide probe. The rhodamine B peak is much larger and therefore 
brighter than any other peak featured. The large drop in fluorescence must be due to the addition of 
the linker.  
 
Figure 46. Fluorescence of 100 µM of the three rhodamine probes and 100 nM of rhodamine B (shown in pink) 
at 532 nm compared with 100 µM of DSP-10 (shown in blue) at 324 nm. Rho-alkyl SP 18 is shown in red, rho-
PEG short SP 48 is shown in yellow, and rho-PEG long SP 49 is shown in green. All measurements made at pH 
of 7.5 in a solution of distilled water, and added to a 1 cm3 fluorimetry cuvette (n=3). 
 
The equilibrium position between the ring closed and open forms of the rhodamine group is not 
easily discerned from 1H NMR spectra. However the 13C spectra allow identification of the major 
tautomer. 
Analysis of the 13C NMR spectrum of 18, 48 and 49, show the major form in CDCl3 is the closed form. 
Diagnostic peaks at ca. 64 and at 153 ppm distinguish the two forms. The peak at 64 ppm arises due 
to the quaternary 9 position carbon being fully saturated, whereas the peak at ca. 153 ppm 
represents the open form sp2 hybridised carbon. In 18, 48 and 49, no 13C peaks at 153 ppm were 
found but peaks at 64 ppm were seen.  
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The investigation into the effects of pH indicates that the open and closed forms of the compound 
remain in equilibrium. Driving the fluorescence of the open forms with a chelating ion can increase 
the intensity of fluorescence, such that increasing temperature will not shift the compound to close, 
but will increase the intensity further.152 
Furthermore, a relative preference for ring closure of the 2-amido substituted Rhodamine 
derivatives, in comparison to the parent carboxylate containing Rhodamine, has also been reported, 
with sources stating that the lactam form is quite stable in polar solvents and will remain 
colourless.153  
 These observations are consistent with the diminished fluorescence response found in this work, 
where the linker derivatives, rho-alkyl 15, rho-PEG short 16 and rho-PEG long 17, and the PSP probes 
rho-alkyl SP 18, rho-PEG short SP 48 and rho-PEG long SP 49 are significantly less bright compared to 
rhodamine B.  
The origins of a thermodynamic preference for the closed lactam over the corresponding lactone is 
not immediately obvious and, in collaboration with the Cross Group, calculations were performed to 
investigate the origin of this thermodynamic preference. 154  It has been established that the 
equilibrium between the fluorescent ring open cation and the inactive cyclised form is pH 
dependent, with acidic conditions favouring the ring open, fluorescent cation. Therefore, it is 
simplest to compare the relative thermodynamic positions of the equilibria at the same pH; within 
the narrow physiological pH range that these probes are expected to function, the open form is most 
likely the cation and the ring closed form a neutral lactone or lactam (Scheme 17). Considerations 
regarding the different acidities of the NH and OH groups can be neatly side stepped by calculating 
the relative energies of the ring open cations and the corresponding lactone or lactam species; 
although these calculations do not provide an absolute value for the change in Gibbs energy for each 
ring closure, the thermodynamic preference for each reaction can be compared since the energetic 
contribution of hydroxide and water will be the same in both cases. To further simplify calculations 
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the, perhaps significant, effect of solvent was ignored in this preliminary study but it was hoped that 
any basis of an intrinsic bias might still be revealed. 
 
 
Scheme 17. Tautomeric Equilibrium of Rhodamine Derivatives at Physiological pH. 
Density Functional Theory at the B97xD/6-31G(d,p) level was used to compute the gas phase, 
minimum energy conformers of the model N-methyl rhodamine derivatives in both the cationic ring 
open forms A/B and ring closed neutral forms C/D; optimised structures are presented in Figure 47.  
The relative thermodynamic disposition for ring closure was calculated from the difference in free 
energy for each ring open cation and its ring closed form, as shown in Eq. 1. This calculation revealed 
that ring closure of the 2-amido derivative B is 9.6 kcal/mol more exergonic than ring closure of the 
carboxylic acid A, a preference that is in agreement with the experimental observation.   
ΔΔG = ΔG(lactone) – ΔG(lactam) = (GA – GC) – (GB – GD)    (Eq. 1) 
Close inspection of the optimised structures provided a rationale for this relative preference. In the 
ring open cation A, the carboxylic acid group is fully conjugated with the phenyl ring (ArC-C=O 
dihedral angle is 0°). In contrast, the amide cation B suffers a steric interaction between the carbonyl 
oxygen atom and the phenyl ring system, which is alleviated by a twisting of the ArC-C=O bond 
(dihedral angle is ca. 27°) and results in a loss of conjugation stabilisation; the conjugation of the 
carbonyl group with the phenyl ring is restored in the ring closed lactam D. 
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Figure 47. Computed structures for the lowest energy conformers of the ring open cations A and B, and the ring 
closed molecules C and D. Structures were optimised and energies calculated at the B97xD/6-31G(d,p) level of 
theory.  
 
A survey of X-ray crystal structure data revealed a single example of a ring open amide structure 
which also shows a significant ArC-C=O out of plane twist while a structure similar to the calculated 
carboxylate shows only minor deviation from the plane. The conformations observed in these 
structures may be controlled by crystal packing as well as the steric requirements of the carboxylate 
and amide groups but does provide support for the calculated conformational preferences. X-ray 
data was obtained from a substructure search of the The Cambridge Structural Database (Figure 
48).155 
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Figure 48.  X-ray Crystal structure of Rhodamine carboxylic acid ring open cation (CDS entry ADIGEB) and 
Rhodamine amide analogue in ring open form (CSD entry SETCEA01) illustrating out of plane C=O in the amide 
(ethyl and FeCl3 groups omitted for clarity). 
 
Studies show that probes have been designed with rhodamine but feature a component that blocks 
the lactam ring formation via alkylation of the amide nitrogen. Cincotta et al patented this technique 
with methylation, but others have expanded on it.156 Nguyen et al used a novel piperazine moiety 
coupled to the 2 position on the aryl ring of rhodamine B.157 Incorporation of a lactam blocking 
moiety should return the probe to equivalent fluorescent strength to rhodamine B. 
 
With the spectroscopic data gathered, the probes biological efficacy was then investigated.   
 
3.2.8 Biological Viability of Probes 
The biological effects of the three rhodamine probes on cell viability as an approximate measure of 
OP toxicity was investigated. It is known from preliminary work that PSP is cytotoxic to 
cardiomyoblasts from as little as 12 µM when incubated for 4 hours. This effect can be quantified 
with two assays: a metabolic assay featuring MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl 
tetrazolium bromide),158 and a cell viability assay measuring lactate dehydrogenase activity (LDH).159  
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MTT Assay 
The MTT assay was first described by Mosmann et al. This colourimetric assay measures the 
reduction of the yellow tetrazolium salt to insoluble purple formazan salt by mitochondrial 
dehydrogenases such as succinate dehydrogenase. This technique is commonly used to determine 
the remaining mitochondrial metabolic activity in living cells, allowing an accurate quantitative assay 
of living cells in a study.160  
Living cells produce the succinate dehydrogenase enzyme and therefore the amount of formazan 
produced is proportional to living cells and their viability (Figure 49). The formazan is a bright purple 
colour so results are obtained with a colourimeter measuring at 570 nm.  
 
Figure 49. Reduction of MTT to Formazan 
LDH Assay  
The lactate dehydrogenase (LDH) assay is another way of measuring viability of cells albeit indirectly, 
and is often performed alongside MTT. LDH is an enzyme which is released by dying and damaged 
cells into the culture medium, this cell death is caused mainly by necrosis, as cell membranes do not 
rupture during apoptosis. The activity of LDH is therefore an indicator of cell death, the 
measurement which can be used to evaluate the cytotoxicity of molecular compounds such as drugs 
or toxins, or even other environmental factors.161 
There is a two-step reaction that activates the reduction of NAD+ to NADH and H+ by oxidation of 
lactate to pyruvate. A diaphorase enzyme then reduces a tetrazolium salt to brightly coloured 
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formazan salt using NADH and H+ for the second step (Figure 50). The coloured product is then 
measured at 480 nm using a colourimeter. The intensity of the colour is proportional to the amount 
of damaged tissue or dead cells that are present. This assay is a useful indicator of chronic or acute 
tissue damage and can be used to help diagnose and monitor a heart attacks.162 
 
Figure 50. Mechanism of LDH assay 
 
Rhodamine B is known to show toxicity within certain tissues, so this fluorophore was investigated 
along with the intermediate compounds rho-alkyl 15, rho-PEG short 16 and rho-PEG long 17.163 The 
rationale for testing rhodamine B is to ensure observed toxicity is induced by the OP moiety and not 
just the rhodamine B component. This would impact the results, and control assays featuring 
rhodamine B, and the precursors would need to be performed. Ideally assaying these compounds 
would show minimal toxicity compared to the organophosphate probes. 
It was assumed that if the toxicity of the rhodamine B probes could only differ slightly from the 
parent compound PSP, the probes would interact in a similar way with the protein targets of 
interest. If this was to be the case, no toxicity would indicate very little or no interaction by the 
probe with the organophosphate targets, and would invalidate the design of the probe. 
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As mentioned previously, the focus of this study is on interactions with cardiac tissue. To this end, 
mitotic H9c2 cells can be differentiated so that the cardiomyocyte phenotype is expressed. This 
process elongates the cell structure into multinucleated myotubes with recognizable actin filaments 
and binds the cells together tightly resembling muscle tissue fibre. This normally occurs fully after 7 
days in foetal bovine serum (FBS) suppressed medium with increased retinoic acid levels of 10 nM.64  
MTT 
Rhodamine B, linkers 15, 16 and 17, probes: rho-alkyl SP 18, rho-PEG short SP 48, and rho-PEG long 
SP 49, had each been subjected to 4-hour and 24-hour tests as a treatment measuring cell toxicity 
for short and long exposures. In the MTT tests a 24-well plate was seeded with 15,000 cells per well 
and differentiation was induced over 7 days in the cells. After the 7 days, the differentiation process 
was completed, and the cell culture medium was changed to fresh medium containing a 
concentration of one of the compounds for treatment. Four of the wells were left (as a control) with 
only fresh medium added, the other twenty wells were split into five groups of four with each 
treatment occupying four wells per plate.  
The plates undergoing the short 4-hour time point were incubated for 3 hours before addition of the 
tetrazolium salt and further incubation for 1 hour. For the 24-hour time point, the plates were 
incubated at 37.5oC for 23 hours before having the tetrazolium salt added. Following this final hour, 
the medium was removed and replaced with DMSO, the solvent dissolves the insoluble formazan 
crystals precipitated by the cells, giving colourless, pink and purple coloured solutions dependent on 
the concentration of formazan. Finally, the contents of each well were transferred to a well on a 96 
well-plate to be scanned at 570 nm in a colourimeter. The absorbance reading recorded is 
proportional to the number of cells surviving the treatment and so reflects the cell viability and an 
assessment of the treatment toxicity can be made. 
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LDH 
Just as with the MTT tests, LDH tests were performed at two time points, 4 hours and 24 hours. Cells 
were prepared in a 96-well plate which was seeded with 5000 cells per well, and left for seven days 
during which, the cells had differentiated expressing the cardiomyocyte phenotype. Each treatment 
was then added to columns of wells on the plate as well as a column of wells containing fresh media 
as a control. This technique then proceeded as outlined in section 5.3.6.  
The lowest concentrations measured in each test was 6.25 µM of each compound. The highest 
concentration tested was 100 µM. Probe concentration of over 100 µM could not be evaluated due 
to low solubility and saturation of the solution in water causing the probes to aggregate.  
MTT and LDH Test Results 
4-hour tests 
The results of a 4-hour MTT test featuring a treatment of rhodamine B at varying concentrations 
showed very little toxicity (Figure 51). The only slightly significant result was at 100 µM where 25% 
of the cells are no longer metabolically viable.  
The three precursor linkers all showed some toxicity at 6.25 µM, except for rho-PEG short 16 where 
only a little toxicity was seen at 12.5 µM and no toxicity was seen at all at 6.25 µM. Linker rho-PEG 
long 17 was the most toxic out of the three. The differences in bioavailability, and in solubility, of the 
three linkers is likely responsible.  
The three organophosphate probes showed toxicity at concentrations of 12.5 µM and 6.25 µM for 
rho-alkyl SP 18, and rho-PEG long SP 49. However, the significance shown by t-test is low, and overall 
the toxicity between the precursor linkers and the organophosphate probes was similar, with the 
OPs showing more relevant toxicity at low concentrations. Rho-PEG long SP 49 is illustrating 
statistically significant toxicity at 6.25 µM until 25 µM where there is a consistent level of maximum 
toxicity.  
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Probe rho-alkyl SP 18 showed some toxicity from 6.25 µM, yet without the statistical significance of 
rho-PEG long SP 49, and yet rho-PEG short SP 48 was significant after 25 µM.  
The 4-hour LDH viability assay also indicated the low toxicity of rhodamine B as shown in the MTT 
assay. With only some non-significant increase in LDH of about ten percent measured at a 
rhodamine concentration of 100 µM (Figure 52). Compounds rho-PEG short 16 and rho-PEG long 17 
have caused a large release of LDH at 100 µM and some not statistically significant toxicity at 50 µM. 
Both glycol precursor compounds exhibited higher toxicity than the linker rho-alkyl 15. 
The three organophosphate probes show some cytotoxicity at concentrations of 6.25 – 25 µM 
between them and the precursors comparatively. There was an increase in toxicity up to 
concentrations of 100 µM for all three probes. The probe rho-PEG long 49 has caused the largest 
amount of LDH to be released.  Only a small statistically significant increase in LDH had been 
monitored in these probes, yet the inactivity of the precursors over a short period is promising. 
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Figure 51. 4-hour MTT tests, of; Rhodamine B, three precursor linkers: rho-alkyl 15, rho-PEG short 16, rho-PEG 
long 17. Three organophosphate probes: rho-alkyl SP 18, rho-PEG short SP 48, rho-PEG long SP 49. Data is 
expressed as a mean percentage of reduced MTT or LDH concentration measured colourimetrically relative to 
the control values where untreated wells represent 100%. The “*” represent the results of a t-test comparing 
significance (p) against the control response. *p<0.05, **p<0.01, ***p<0.005, ****p<0.001 the lower the value 
the more significant i.e. the larger the average difference between the two data sets, (n = 4, control data 
normalised to 100%).  
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Figure 52. 4-hour LDH tests of; Rhodamine B, three precursor linkers: rho-alkyl 15, rho-PEG short 16, rho-PEG 
long 17. Three organophosphate probes: rho-alkyl SP 18, rho-PEG short SP 48, rho-PEG long SP 49. Data is 
expressed as a mean percentage of reduced MTT or LDH concentration measured colourimetrically relative to 
the control values where untreated wells represent 100%. The “*” represent the results of a t-test comparing 
significance (p) against the control response. *p<0.05, **p<0.01, ***p<0.005, ****p<0.001 the lower the value 
the more significant i.e. the larger the average difference between the two data sets, (n = 6, control data 
normalised to 100%). 
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24-hour tests  
The results of the 24-hour MTT tests demonstrated that rhodamine B and the three precursor linkers 
display a small level of toxicity (Figure 53). Rhodamine B is effectively non-toxic below 25 µM but 
reaches over 50% cell death at 100 µM concentration. Comparatively, all three linkers began to 
inhibit cell metabolism at 25 µM with rho-alkyl linker 15 causing the most cell death at each 
concentration of treatment. Rho-PEG long 17 showed less signs of toxicity in the 24-hour time 
course which contrasts the 4-hour MTT tests. All three linkers are more toxic than rhodamine B at 
100 µM. This increased toxicity may be due to higher bioavailability of the more lipophilic linkers or 
an increase in the amount of ring closed, perhaps more toxic, rhodamine. 
The three organophosphate probes all exhibited toxicity in the 24-hour MTT tests. Rho-alkyl SP 18 
and rho-PEG long SP 49 exhibited a pronounced increase in toxicity from the precursor linkers, rho-
alkyl 15 and rho-PEG long 17. Rho-PEG long SP 49 started showing signs of toxicity at 6.25 µM 
concentration, and at 12.5 µM inhibition of cell metabolism had increased to 50%, however, as 
concentration continues to increase the toxic effect reached a plateau. Rho-PEG short 48, shows 
some minimal toxicity at 25 µM, but overall a decrease in toxicity above this concentration when 
compared to precursor rho-PEG short 16. The probe still retained some toxicity and only loses about 
15% effectiveness at 100 µM concentration comparatively between the two. 
The results of the 24-hour LDH test compliment that which has been shown in the 24-hour MTT tests 
(Figure 54). All three linker precursor compounds exhibited more toxicity than rhodamine B which 
after 24-hour treatment was still largely inactive. All three showed some small level toxicity at 6.25 
µM concentration, with significant toxicity at 100 µM. Rho-alkyl 15 indicated the highest amount of 
toxicity at 25, 50 and 100 µM. Whereas, rho-PEG short 16 had a higher average toxicity at 100 µM 
than rho-PEG long 17, this was in contrast with the results of the 4-hour LDH tests. Rho-PEG long 17 
having the highest toxic effect on average is still in keeping with the previous assay results. However, 
due to the amount of statistical error associated with the various concentrations of these two 
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treatments, the results are not significant. The trend still supports the hypothesis that the linker 
chains are increasing toxicity of the compounds compared to rhodamine B, where no significant 
toxicity at any concentration was seen by the 24h LDH tests. 
The results of 24-hour LDH test also showed a small drop in toxicity between the precursors and the 
final probes. Rho-PEG short SP 48 was only significantly toxic at a concentration of 100 µM, rho-alkyl 
SP 18 also showed a decrease in toxicity compared with its precursor linker, and is apparently only 
cytotoxic at 50 µM and above. Probe rho-PEG long SP 49 is toxic at 12.5 µM and above but overall 
has a drop of 20% toxic effectiveness at 100 µM whence compared with its precursor rho-PEG long 
17. It is worth noting that toxicity found in the LDH assays is due to necrotic cell death however, not 
apoptotic, so it is expected that high concentrations would produce LDH release, and low doses may 
still be effective as an enzymatic inhibitor, but that is not seen via this type of assay.  
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Figure 53. 24-hour MTT tests of; Rhodamine B, three precursor linkers: rho-alkyl 15, rho-PEG short 16, rho-PEG 
long 17. Three organophosphate probes: rho-alkyl SP 18, rho-PEG short SP 48, rho-PEG long SP 49. Data is 
expressed as a mean percentage of reduced MTT or LDH concentration measured colourimetrically relative to 
the control values where untreated wells represent 100%. The “*” represent the results of a t-test comparing 
significance (p) against the control response. *p<0.05, **p<0.01, ***p<0.005, ****p<0.001 the lower the value 
the more significant i.e. the larger the average difference between the two data sets, (n = 4, control data 
normalised to 100%). 
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Figure 54. 24-hour LDH tests of; Rhodamine B, three precursor linkers: rho-alkyl 15, rho-PEG short 16, rho-PEG 
long 17. Three organophosphate probes: rho-alkyl SP 18, rho-PEG short SP 48, rho-PEG long SP 49. Data is 
expressed as a mean percentage of reduced MTT or LDH concentration measured colourimetrically relative to 
the control values where untreated wells represent 100%. The “*” represent the results of a t-test comparing 
significance (p) against the control response. *p<0.05, **p<0.01, ***p<0.005, ****p<0.001 the lower the value 
the more significant i.e. the larger the average difference between the two data sets, (n = 6, control data 
normalised to 100%). 
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The IC50 and EC50 values of all seven compounds on H9c2 cells has been be calculated, and is 
displayed in below (Table 2). 
    IC50 (µM) 
MTT 
EC50 (µM) 
LDH Compound 
    4h SD 24h SD 4h SD 24h SD 
Rhodamine B >100 - >100 - >100 - >100 - 
Rho-alkyl 15 12 ± 0.16 98 ± 0.58 13 ± 0.07 18 ± 0.25 
Rho-PEG short 16 41 ± 0.16 56 ± 0.08 51 ± 0.13 38 ± 0.19 
Rho-PEG long 17 39 ± 0.39 52 ± 0.04 71 ± 0.28 33 ± 0.17 
Rho-alkyl SP 18 44 ± 0.15 29 ± 0.07 95 ± 0.13 37 ± 0.18 
Rho-PEG short SP 48 10 ± 0.09 67 ± 0.27 24 ± 0.03 36 ± 0.23 
Rho-PEG long SP 49 11 ± 0.19 12 ± 0.08 50 ± 0.07 12 ± 0.12 
Table 2. Calculations of mean IC50 (µM), determined from each assay. SD of the mean for each log, n=4 for the 
MTT and n=6 for LDH calculations.  
 
The values shown in this table illustrate that rhodamine B has no effect under 100 µM. The data for 
the assays with treatment of rhodamine B with H9c2 cells was such that an IC50 and EC50 values could 
not be determined within the scope of the assays. These high values have addressed the concerns 
that rhodamine B may be too toxic a fluorophore to use. 
In general, the organophosphate probes exhibited more toxicity than the precursor linkers seen in 
MTT tests. At the more clinically relevant concentration of 6.25 µM, the probes exhibited toxicity 
and over 24-hours this inhibition is likely due to apoptotic pathways being activated. At 
concentrations as high as 100 µM, inhibition of metabolism could be due to a necrotic cell death. It is 
interesting to note that in 24-hour assays the organophosphate probe rho-PEG long SP 49 exhibited 
more toxicity than with the corresponding linker rho-PEG long 17. 
In the LDH tests the results indicate that in general concentrations over 25 µM are toxic, and that 
the precursor linkers exhibit greater toxicity then the probes. This is indicative of cellular necrosis. 
For the rho-alkyl SP 18 probe, the toxicity has dropped with the addition of the PSP as measured by 
the LDH tests. This may be related to its ability to induce apoptosis in this cell line; apoptotic 
pathways are not easily highlighted in an LDH assay.66  
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However, the two glycol probes show a different pattern, rho-PEG short SP 48 was more toxic in the 
4-hour LDH test then the precursor without the organophosphate, although this was not the case 
with the 24-hour LDH test where the opposite occurred. Probe rho-PEG long SP 49 demonstrated an 
increase in EC50 in all four tests between it and its linker. 
The conclusion of this study in cell viability with the OP probes is that they are a worthwhile tool for 
cell culture assays, and inhibit cell metabolism at concentrations between 6.25 – 25 µM. Also at 
these concentrations only a small amount of LDH was released. Probe rho-PEG long SP 49 is the 
most potent of the probes on average and likely has a higher bioavailability than rho-alkyl SP 18 and 
rho-PEG short SP 48. This was the only probe that exhibited a high toxicity at a concentration of >25 
µM, and was more toxic over all the tests than its precursor linker rho-PEG long 17. 
This led the investigation onto gel electrophoresis studies. A test of the probes in the experiments 
they are designed to function in will prove the efficacy of each one. 
3.2.9 Protein Binding with Protease 
The three rhodamine organophosphate probes, were then tested for their ability to fluoresce in a 
polyacrylamide gel once bound to a peptide fragment. To reliably measure which probe was the 
most suitable in SDS-PAGE, a purified protein known to be an organophosphate target was used.  
SDS-PAGE was explored by exposure of each probe to protease chymotrypsin, followed by 
incubation and then by running on an SDS-PAGE gel, afforded three gels in which effectiveness of 
probe binding and fluorescence had been be qualified. These experiments were performed by first 
incubating 25 µg of chymotrypsin protein with three concentrations (25, 50 and 100 µM) of each 
probe on ice for 15 minutes. 20 µl of each probe/ protein solution was pipetted into its 
corresponding well on a 10% acrylamide, 1.5 mm gel cast, as described in experimental section 
5.3.7. The loaded gel was then electrophoresed, and upon completion the gel was then visualised on 
a 532 nm Fujifilm FLA5000 green light laser (Figure 55). Interestingly 100 µM of rho-PEG long SP 49 
seems to be the brightest compound of the three probes, but when compared to the whole protein 
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fractions more of rho-alkyl SP 18 seems to have bound, the chymotrypsin did not fluoresce at this 
wavelength, meaning autofluorescence is avoided (not shown).  
 
 
Figure 55. Probes rho-alkyl SP 18, rho-PEG short SP 48 and rho-PEG long 49 at concentrations of 100, 50 and 25 
µM in lanes 1, 2 and 3 respectively, with 10 µg of chymotrypsin, top bands are 25 kDa, with bottom bands at 11 
kDa smaller peptide fraction due to self-digestion of the chymotrypsin. Coomassie gel with ladder and lane 0 
containing 10 µg chymotrypsin (n=1). 
3.2.10 Probe Binding with Organophosphate Targets: Neuropathy Target Esterase and 
Transglutaminase 2 
With results obtained from exposure of chymotrypsin to the probes, a suitable experiment on 
interesting protein targets for organophosphates was then explored. Neuropathy target esterase 
(NTE), as previously mentioned is the target of organophosphates causing OPIDN, and determining 
whether this probe is sensitive to it within cardiac myocytes is of keen interest.59 Transglutaminase 2 
(TG2), is one interesting protein target for both the study of organophosphate interactions,164 and 
cardioprotection.165 Its cardioprotective properties are not yet well understood, but studies have 
shown an involvement with ATP mediation, and TG2 can be activated by protein kinases (PKC).166   
Rho-PEG short SP 48 Rho-alkyl SP 18 Rho-PEG long SP 49 
Probe-bound Chymotrypsin Autolysed peptide fragments 
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To continue with testing of the capabilities of the rhodamine organophosphate probes, TG2 and NTE 
proteins were chosen as targets. TRIS-buffered solutions of NTE and TG2 were incubated on ice with 
a 100 µM solution of rho-alkyl SP 18.  
The results of this gel when visualised firstly on a blue laser at 412 nm then secondly under green 
side lamps indicated that both proteins bind with probe rho-alkyl SP 18 (Figure 56). The weight of 
the fragments that the two proteins can be found at are; 22 kDa for NTE, and 80 kDa for TG2 
respectively. The blue laser interestingly also highlighted the background fluorescence of the 
proteins, as well as impurities and other protein fragments from the initial substrate these 
recombinants were taken from. Under green light this fluorescence disappears resulting in true 
emission from the probe. 
The results demonstrated that fluorescent bands can be seen at the expected locations on the gel, 
suggesting that the probe has bound to its target protein. In order to determine how well the probe 
binds to TG2 particularly, a second experiment that included a TG2 competition assay, where, rho-
alkyl SP 18, PSP and an irreversible TG2 inhibitor called ZDON (Benzyloxycarbonyl-(6-Diazo-5-
oxonorleucinyl)-L-Valinyl-L-Prolinyl-L-Leucinmethylester)167, compete for binding space with TG2. 
The assay had three solutions all incubated with TG2: 1) 25 µM probe rho-alkyl SP 18 with TG2 
control, 2) 25 µM rho-alkyl SP 18, with 25 µM PSP, 3) 25 µM rho-alkyl SP 18, with 25 µg of ZDON. 
These were buffered and boiled as mentioned previously and added to a well in each corresponding 
lane. On this gel, repetition of NTE binding with a lower concentration of rho-alkyl SP 18 was also 
attempted. 
The results of this experiment showed that when visualised on a green light laser (C), the band at 80 
kDa in lane 1 is clearly darker than the matching bands in lanes 2 and 3. This would indicate that the 
probe is competitively binding at the same active sites on TG2 as non-fluorescent PSP and ZDON. 
Lanes 6 and 7 of this experiment show, albeit very faintly, a band at 22 kDa illustrating the binding of 
rho-alkyl SP 18 to the established organophosphate target NTE.  
412 nm 532 nm 
 101 
 
 
Figure 56. SDS-PAGE of organophosphate targets; gel 1 (A and B), NTE and TG2, gel 2 (C and D), competition 
assay of TG2 and repeat of NTE. A) Blue light gel scanned by laser. Lane 1 contains 10 µg NTE with 100 µM of 
rho-alkyl SP 18. Lane 2 10 µg NTE control without probe. Lane 5, 10 µg TG2 with 100 µM of rho-alkyl SP 18. Lane 
6, 10 µg TG2 control. B) Green light isolating the rhodamine probe rho-alkyl SP 18 binding with protein targets. 
C) Lane 1, green light measurement of probe rho-alkyl SP 18, in 100 µM with 10 µg TG2. Lane 2, rho-alkyl SP 18 
with 10 µg TG2 and PSP. Lane 3, rho-alkyl SP 18 with 10 µg TG2 and 25 µg ZDON. Lane 6, 10 µg NTE with 25 µM 
of probe rho-alkyl SP 18. Lane 7, NTE control 10 µg. D) Coomassie staining of gel (C) (n=1 for each). 
Despite the effective brightness having not much improved on the dansyl PSP probe (DSP-10), the 
selectivity of these three probes still proved to be an advantage over DSP-10 due to the absorbance/ 
emission located in the green region of the visible spectrum. Tyrosine and tryptophan residues 
fluoresce and can be seen up to the blue region of visible light. The rhodamine probes can effectively 
label protein with a fluorescent response highlighting bands without showing background 
autofluorescence. 
3.2.11 2-Dimensional Gel Electrophoresis Studies 
One of the challenges that approaches proteomics is the study of the relative abundances of 
proteins present within the proteome, and reproducibly fractionate these tissues to elucidate both a 
qualitative and quantitative measure of the protein complexes.168 Gel electrophoresis performed 
across a charge dependent scale, isoelectric point (pI), for protein mixtures will separate them across 
a small gel strip dubbed isoelectric focusing gel (IEF).169 This gel can then be loaded onto a 
conventional SDS-PAGE gel, ready to be separated by protein mass. The result are isolated protein 
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clusters found as spots on the gel. With a fluorescent probe added to the mix prior to isoelectric 
focussing, should provide fluorescently labelled spots on a gel. 
The problem of background autofluorescence is of particular importance with analysing albumin 
depleted blood plasma protein which show notably high levels of autofluorescence. In a preliminary 
labelling experiment using DSP-10, it was seen that autofluorescence hides any targeted fluorescent 
bands from the dansylated organophosphate treatment. 
Factor 13 is a transglutaminase enzyme that is responsible for cross-linking fibrin.170 There is 
currently interest in organophosphates in targeting transglutaminases; a preliminary study using 
probe rho-alkyl SP 18 was carried out with the Hargreaves’ group. The hypothesis was that using 
green light side lamps of the FLA-4000 gel doc or the green laser and 532 nm filter of the FLA-5000 
will reveal any binding of blood serum proteins to the rhodamine probe, after incubating depleted 
blood plasma serum with rho-alkyl SP 18 and performing 2D-gel electrophoresis.  
In collaboration with the Hargreaves’ group, blood plasma serum was depleted of albumin following 
a known technique.171 This was then incubated with rho-alkyl SP 18 on ice for 30 minutes then in an 
incubator at 37 oC for a further 30 minutes. After that, the general protocol for 2D gel 
electrophoresis was carried out (Figure 57, (A) and (B)). 
Several clusters of proteins became visible due to the treatment, and there were no fluorescent 
proteins found on the control gels untreated with rho-alkyl SP 18. However, these gels need 
repeating several times until consistent results illustrate the same patterns, it is a positive sign that 
the probe behaves as intended. The Hargreaves group currently pursues this work with the intention 
of processing 2D-gel spots and preparing for mass spec analysis to determine the identity of the 
proteins. 
Within the remit of the current study of organophosphate interaction with mitochondria, a 2D 
experiment was also performed on a mitochondrial sample extracted from rat liver. Probe rho-PEG 
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long SP 49, was incubated at a concentration of 100 µM with 80 µg of mitochondria extract in a 
buffered solution on ice. After 15 minutes of incubation, the sample then underwent the 2D-gel 
electrophoresis protocol. (See Experimental 5.3.9 for details). 
Visualisation of the gel occurred using a 532 nm laser and a large – if faint – cluster of spots 
appeared around pI 4 – 6 and between 75 and 43 kDa. Staining with coomassie blue revealed all the 
protein clusters located in the gel (Figure 57, (C) and (D)). 
Revealing protein spots under green light signifies probe binding with proteins associated with 
mitochondria. These gels still need repeating before the identity of the spots can effectively be 
determined. These spots can be picked out of the gels and digested, and prepared for analysis by 
mass spectrometry.  
 
Figure 57. 2D SDS-PAGE gels. (A) Protein spots of 80 µg depleted serum albumin sample being revealed by 100 
µM of probe rho-alkyl SP 18 after incubation, visualised on a green light laser at 532 nm. (B) Staining of the same 
gel by coomassie blue staining highlighting protein clusters (n=2). (C) 100 µM of probe rho-PEG long SP 49 bound 
to 80 µg of protein targets associated with mitochondria, visualised at 532 nm. (D) Coomassie stained gel of 
mitochondria and rho-PEG long SP 49, highlighting many protein clusters (n=3).  
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The results of these gels are far from conclusive regarding probe efficacy. One fear is that the probes 
willingness to bind to a wide variety of free protein residues could yield it ineffective at revealing less 
abundant protein targets. However, as a test for the practicality of rhodamine as a fluorophore in 
labelling, it is appropriate for the task of 2D gels.  
A final test of the probes efficacy was with a protease activity assay. Many enzyme activity assays 
are a part of the toolkit of biological analysis for proteomic studies. The performance of the probes 
within an activity assay can be measured colourimetrically by the inhibition of proteases. 
3.2.12 Activity Assays 
Proteases such as trypsin and chymotrypsin are a recognised organophosphate targets.48 The 
binding of all three rhodamine B probes to chymotrypsin in the gel electrophoresis studies prove 
that there is still an affinity for the modified organophosphates to proteases (Figure 55).  
One assay that could be used to determine the efficacy of not only trypsin protease inhibition, but 
the probes suitability for an array of colourimetric assays, was a trypsin activity assay that utilises a 
protein complex containing a fluorescent substrate.172 Benzyl-L-arginine 4-nitroaniline hydrochloride 
(BAPNA), contains p-nitroaniline and is fluorescent at 415 nm, trypsin cleaves the amide bond 
between this and an arginine residue.  
Incubating an organophosphate of different concentrations with trypsin on ice for fifteen minutes 
prior to addition of BAPNA should inhibit the action of trypsin cleavage on the substrate, resulting in 
a low reading of fluorescence on a plate reader. 
A concentration of 25 µg/ ml of trypsin was chosen as the optimum concentration to be used to 
measure the rate of cleavage, determined via calibration trials (Figure 58). This trypsin solution was 
mixed with triplicates of six different probe concentrations and incubated on ice for fifteen minutes 
before the BAPNA solution was added as detailed in section 5.3.16. Readings were taken every 
minute for fifteen minutes. 
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Figure 58. Action of trypsin cleavage on a solution of BAPNA substrate (1% (w/v) 10 µl/well), to cleave p-
nitroaniline, at five different protease concentrations and a control solution lacking trypsin. The absorbance 
reading in arbitrary units (AU) measured at 415 nm on a standard plate reader, (n=3). 
 
The results of the inhibitory action of the probe rho-alkyl SP 18 on trypsin show that the higher 
concentration of the probe, the higher the fluorescence (Figure 59). This is counter to the hypothesis 
that the higher the concentration of the probe, the more inhibition of trypsin, therefore, a lower 
fluorescence is exhibited. It is likely that the rhodamine B fluorophore interfered with the 
colourimeter reading. At high concentrations of the probe, fluorescence emitted by rhodamine B 
increased the absorbance reading at 415 nm. That was, until the concentration dropped below 12.5 
µM of rho-alkyl SP 18, this indicated that the measurement of fluorescence was not truly 
proportional to p-nitroaniline. The selectivity of the two fluorophores (rhodamine and nitroaniline) is 
not great enough to distinguish the two at concentrations over 12.5 µM. 
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Figure 59. Action of trypsin cleavage on a solution of BAPNA substrate (1% (w/v) 10 µl/well), to cleave p-
nitroaniline inhibited the presence of probe rho-alkyl SP 18 at six concentrations, absorbance measured in 
arbitrary units at 415 nm, (n=3). 
 
Although this experiment is unreliable, calculating the gradient of each linear trend line for every 
concentration would have given the rate of substrate cleavage, and an overall trend for the 
inhibitory action of the probe could be seen. The rate units are in absorbance per minute at 415 nm 
and when plotted against concentration in µM gives an inhibition curve. Although, rhodamine B 
fluorescence increases absorbance results, invalidating the accuracy of measuring p-nitroaniline, the 
steepness of line still gave some information as to the trend in inhibition, albeit with a level of error.  
Processing the gradients and plotting on a graph displayed that the control, with its absence of 
organophosphate, has an activity of 0.01 Abs /min, the activity of the following concentrations all 
drop below 5 x10-3 Abs /min even when a concentration as little as 1.56 µM of inhibitor was added 
(Figure 60). 
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
0.18
0.2
0 2 4 6 8 10 12 14 16
A
b
so
rb
an
ce
 A
U
Time (min)
Cleavage of p-nitroaniline inhibited with rho-alkyl SP 18 over 15min
Rho-
alkyl 18
(µM)
0
50
25
12.5
6.25
3.13
1.56
 107 
 
 
Figure 60. Mean rate of inhibition of probe rho-alkyl SP 18 vs concentration of probe in µM, error in SD. 
This experiment was repeated for all three rhodamine B probes and using DSP-10. The results were 
plotted on a graph as absorbance against time, the gradient of each set of results was then plotted 
against concentration on one graph (Figure 61). The results of these calculations indicate that the 
organophosphate probes does inhibit trypsin activity. Probe rho-PEG short SP 48 had the least 
amount of inhibition, but compared to the control this was very high inhibitory effect vs trypsin 
cleavage.  
The probes did not seem appropriate for any quantitative measure of inhibition in a colourimetric 
assay. As a qualitative measure of inhibition or trends in results the probes may be appropriate. 
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Figure 61. Mean rate of absorbance measured at 514 nm per minute of BAPNA cleaved vs concentration of 
organophosphate probe, error bars not shown for clarity. DSP-10 is shown in yellow, rho-alkyl SP 18 in grey, rho-
PEG short 48 in orange, and rho-PEG long SP 49 is illustrated in blue. 
 
Following the investigations into biological efficacy of the rhodamine B organophosphate probes, 
the two other families of fluorophores, BODIPYs and pyrenes were then explored.    
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3.3 Synthesis of BODIPY Probe 
3.3.1 Background 
As determined by fluorimetry studies, rhodamine B is ineffective with maintaining the bright 
fluorescent properties of the open form, once an amide is incorporated on the 2 position. The best 
choice of fluorophore in this system would be one that shares the red-shifted excitation /emission 
properties, and high extinction coefficient (ε) and quantum yield (φ). A class of compounds known as 
4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY), have a high ε and φ, maintain their sharp 
banded fluorescence in a variety of pH’s and polarities, and are stable to different physiological 
conditions.173 Given their superior properties, the preparation of these fluorophores was then 
explored.   
Three asymmetric BODIPY analogues were the focus of this study (Figure 62). BODIPY FL –known for 
its spectral similarity to fluorescein, BODIPY TMR – similar to tetramethyl-rhodamine, and BODIPY 
558/568 are all commercially available, but due to expense, de novo synthesis was pursued. Each of 
these BODIPY’s possessed a carboxylate terminal side chain which was the site for coupling to a 
linker. Coupling would have been achieved ideally, via an amide bond, as previously made with 
rhodamine B.  
 
Figure 62. Structures of three BODIPY analogues; BODIPY FL 50, BODIPY TMR 51, and BODIPY 558/568 52. 
BODIPY FL is a green shifted fluorophore, with an overall neutral charge that aids practical 
measurements of biological systems where cellular charge is highly sensitive. It is a bright 
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fluorescent green, equivalent with fluorescein and exhibits a high extinction coefficient and 
quantum yield of ε = 80000 and φ = 0.97.174  
For future applications it would also be desirable to achieve a large stokes shift in excitation and 
emission in the orange/ red region. Two bright, red-shifted BODIPY analogues that met the criteria 
were; BODIPY TMR and BODIPY 558-568, (Figure 62). 
BODIPY TMR gets its name from its spectral similarity to tetramethylrhodamine (TAMRA). They both 
have the same excitation and emission wavelengths ex. 553 nm and em. 576 nm. 175 The BODIPY 
TMR absorbance is 542 nm, emission of 574 nm and an ε of 60,000. The higher quantum yield of 
BODIPY TMR, φ = 0.95 gives it an advantage over rhodamine’s yield of φ = 0.68. Its use biologically, is 
effective due to its overall positive charge and fatty properties, meaning it permeates membranes 
effectively. 176  
BODIPY 558/568 has been used in biological testing in experiments that looked into endothelial 
lipase activity. It was used for its bright red-shifted emission and for the fatty properties it has when 
bought at high expense with a dodecyl linker connected.177 BODIPY 558/568 has an extinction 
coefficient of 97000 and a quantum yield of φ = 0.8. This confirms that both BODIPY’s are brighter 
dyes than the previously used dansyl amide (extinction coefficient of ca. 4300, quantum yield 0.66). 
The synthesis consists of using the previously prepared pyrrole-2-ethyl propanoate, and a pyrrole 
thiophene prepared from a synthetic route based on Dale et al synthesis of BODIPY 630.178 
The synthesis of asymmetric BODIPY is generally made by coupling two pyrrole moieties and in situ 
insertion of the boron centre. The synthesis that was proposed is set out below (Schemes 18 and 
19).175,179 
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Scheme 18. Synthesis of BODIPY, (i). BF3.ethereate, POCl3, DIEA, DCM, (ii). THF, 33% HCl, water, 48h. 
Following preparation of the BODIPY carboxylic acid analogue, just as with the rhodamine B 
methodology, linker coupling reactions followed by saligenin chlorophosphate addition, would 
finalise synthesis of the probe (Scheme 19). 
 
Scheme 19. (i). 6-aminohexanol, DCC, TEA, DCM, (ii). TEA, saligenin chlorophosphate, DCM. 
3.3.2 Synthesis of Pyrrole-2-ethyl Propanoate 
The synthesis of all three BODIPY analogues started with pyrrole-2-propan ethanoate 53. The pyrrole 
analogue was synthesised by Wittig reaction with pyrrole carboxaldehyde and 
triethylphosphonoacetate. 1.1 equivalents of n-BuLi was added to the phosphonoacetate at -78oC, 
then pyrrole carboxaldehyde was added and stirred at 0oC for 2h before being allowed to warm to 
room temperature and left overnight. After work-up and evaporation the acrylate 55 was yielded as 
a yellow oil. 
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A reduction of the conjugated double bond in methanol with hydrogen at atmospheric pressure on 
palladium and activated charcoal then followed. After 2 days at room temperature the dark oily 
ester was isolated in a yield of 78%, and with an acceptable level of purity (Scheme 20).180 
 
Scheme 20. (i). n-BuLi, triethylphosphonoacetate, DCM, (ii). H2, Pd/cat, Methanol, 72 h. 
This experimental work synthesised the first half of a BODIPY structure. This half was expected to be 
coupled to a linker following deprotection of the ethyl ester, after formation of the BODIPY core 
structure.  
3.3.3 Carbonylation of Pyrrole 
Synthesis of 5-carboxy-2,4-dimethylpyrrole commenced with carbonylation of 2,4-dimethyl pyrrole 
giving compound 57 (Scheme 21). This proceeded via addition of POCl3 into DMF at 0 oC, then 2,4-
dimethylpyrrole was added and the mixture refluxed. A solution of NaOAc in water was added and 
the mixture refluxed again for 30 minutes further. Work-up and column chromatography with ethyl 
acetate gave the product in a good yield of 70%. 
 
Scheme 21. (i). POCl3, NaOAc, DMF, DCE, 0oC, reflux, H2O 
3.3.4 Formation of BODIPY FL 
The next step was to couple both pyrrole halves to form BODIPY FL 50 (Scheme 22). 
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Coupling of these two compounds with POCl3 then addition of the BF2 centre in a two-step one pot 
reaction gave the BODIPY core structure. Hydrolysis of the ester group yielded BODIPY FL.  
 
Scheme 22. (i). BF3.ethereate, POCl3, DIEA, DCM, (ii). THF, 33% HCl, water, 48h 
One equivalent of each half was added with POCl3 and cooled to 0 oC. The solution turned dark and 
was left reacting for 2 h. Following this, BF3.OEt2 and DIPEA was then introduced into the mixture 
and addition of the BF2 centre was complete. The solution fumes on addition of boron trifluoride and 
turned a dark green. Column chromatography with DCM gave a 52% yield of red crystals.  
The acid hydrolysis of the ester was then performed. BODIPY 58 was added to THF, water and HCl. 
After stirring for a few days this compound was worked up and purification occured on silica with 
DCM and a 0-5% methanol gradient with a yield of 34%. 
Both the initial coupling reaction to give the BODIPY core structure and the ester hydrolysis were low 
yielding (52% and 34%), so the synthesis was repeated several times to build up enough material to 
attempt to couple the 6-aminohexanol linker.  
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3.3.5 Synthesis of 2,4-Dimethyl Pyrrole Dimer 
Interestingly, the first eluted fractions in the BODIPY ester purification fluoresced bright green and 
after analysis it was found to be a 2,4-dimethyl pyrrole dimer 60, in a yield corresponding to 7% of 
the crude weight. 1H NMR matched the data from previously synthesised sources (Scheme 23).181 
 
Scheme 23. Synthesis of symmetrical BODIPY dimer, (i). POCl3, CH2Cl2, 25oC, 12h. (ii). BF3.OEt2, Et3N, CH2Cl2, 25oC, 
12h. 
 
The by product is plausibly derived from formation of an imidoyl chloride from one pyrrole 
carboxaldehyde. Which is then attacked by a second pyrrole carboxaldehyde. Elimination of the 
chloride via formation of carbon monoxide yielded the dipyrromethenium cation which the gives the 
pyrrole dimer 59 (Figure 63). 
 
Figure 63. Proposed mechanism for dimerization of pyrrole. 
The dimer 60 may be explored in future work, to investigate the possibility of attaching a linker to 
the 4 position of the BODIPY. However, for more BODIPY FL to be made on a larger scale commercial 
2,4-dimethyl pyrrole is expensive, so synthesis was examined.  
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3.3.6 Synthesis of 3,5-Dimethyl Pyrrole 
The literature synthesis of this pyrrole proceeded via oxidative condensation of amino keto acid 61 
and ethyl acetate 62 (Scheme 24).182 
 
Scheme 24. Knorr pyrrole synthesis for 2,4-dimethylpyrrole.183 (i). NaNO2, AcOH, Zn, 3 h, 0 oC (ii) KOH, H2O, 1 h, 
reflux. 
 
Closely following the literature procedure resulted in a poor yield due to the difficulty in controlling 
the reaction temperature when adding the zinc. The intermediate 63 once formed was also 
extremely sensitive to both air and light, this called for the reaction and work-up to progress in the 
dark. These factors meant that the intermediate was not synthesised in high yield or purity (40%), 
due to the tendency to decompose rapidly. The decarboxylation step only gave minor amounts of 
the dimethyl pyrrole which was lost during column purification. It was decided that further pursuit of 
this compound was uneconomic. 
The difficulties with this synthesis led the investigation to examine optimisation of the low yielding 
steps in BODIPY synthesis; primarily the hydrolysis of the ester group. 
3.3.7 Ester Hydrolysis of BODIPYs 
Synthetically, ester hydrolysis of the BODIPY was limited to acid catalysed hydrolysis, since strongly 
basic conditions and nucleophilic reagents lead to decomposition of the BODIPY core structure.  
Under the literature conditions used, hydrochloric acid in THF, it was observed that n-chlorobutanol 
was produced as a side product, which could not be removed by column chromatography (Scheme 
25).  
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Scheme 25. Reaction for acid catalysed hydrolysis of ethylester BODIPY FL. (i). Acid, miscible solvent mix, e.g. 
dioxane, THF. 
 
In order to avoid this side reaction a range of different concentrations of acids in dioxane was 
trialled, as dioxane is generally considered to be more stable in acidic conditions; sulphuric, 
hydrochloric, and polyphosphoric acids were used. Treatment of BODIPY ester 58 in dioxane with 
either of the acids 30% in a solution with water at room temperature for 48 hours gave BODIPY acid 
50. 
All acids successfully hydrolysed the ester group, though none of the reactions progressed cleanly, or 
in a high conversion. Subsequent purifications of the reaction mixture led to decomposition. None of 
the dioxane reactions offered any improvement over the original THF mix, with 30% HCl in water 
and optimisation of the reaction remains unresolved. 
3.3.8 Optimisation of Purification Conditions 
The purification of the hydrolysis reaction mixture was then explored. Standard conditions for 
elution of this polar dye was to elute from silica with DCM/ MeOH mixture. It was discovered that 
the fluorophores decompose on contact with methanol as the boron centre can undergo 
substitution reactions.184 Groves et al reported the synthesis of a BODIPY with a dimethoxy boron 
centre, with unsubstituted pyrroles but the reaction did not progress without being heated in the 
presence of NaOMe. 185 The products of that reaction were highly unstable and decomposed rapidly.  
During column purification, the eluting solvent was a 1% mix of methanol in DCM, and it is believed 
that methanol in this mix contributed to the low yielding purifications and the decomposition of 
compounds.  
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Solvent studies were then performed, to get the same solubility and polarity required for effective 
elution of the BODIPY acid. The following solvent mixes were tested (Table 3). 
Solvents Ratio Results 
DCM /acetone 1:1 Poor separation 
DCM /THF 1:1 Smeary separation 
Ethyl acetate /acetonitrile 9:1 Good separation on TLC, poor 
solubility inhibits higher scale 
DCM /acetonitrile 9:1 Good separation 
THF /acetonitrile 9:1 Good separation but smeary 
DCM /acetonitrile 1:1 Good separation, too much 
dead space 
Table 3. Table showing results of solvent analysis on column chromatography. 
A 9:1 mix of DCM in acetonitrile was then chosen as the optimised solvent mix for eluting the 
BODIPY acids in the following reactions. With the purification conditions refined, enough BODIPY FL 
could be brought through to coupling experiments. Note that these experiments were done on a 
small scale as the reactions leading up were still low yielding. Synthesis then progressed onto 
coupling attempts of BODIPY FL with 6-aminohexanol. 
3.3.9 Coupling of BODIPY FL with 6-Aminohexanol  
 
Scheme 26. Amide coupling reaction with BODIPY FL. (i) Coupling agent, TEA, 6-aminohexanol. 
Despite difficulties with the efficient preparation of BODIPY FL acid 50, coupling attempts to the 
amino linker commenced. Several coupling methods were examined without success. Treatment of 
acid 50 to isobutylchloroformate and base to generate a putative mixed anhydride, followed by 
addition of 6-aminohexanol afforded a complex mixture. Traditional peptide coupling using N,N’-
dicyclohexylcarbodiimide (DCC) with catalytic DMAP added to BODIPY FL and TEA. Followed by 6-
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aminohexanol gave a messy spectrum of 1H NMR peaks. Chromatography of the mixture did not 
afford the amide (Scheme 26). Close examination of the 1H NMR showed the BODIPY peaks 
accompanied with three distinctive multiplets at 1.50, 1.65 and 1.84 ppm, these were thought to 
belong to DCC. This means that either DCC elutes at the same fraction as the BODIPY, or it has not 
been substituted by the amide. 
3.3.10 Coupling of BODIPY FL N-Hydroxysuccinimide 
BODIPY dyes activated as a hydroxysuccinimide are commercially available at high cost, (BODIPY 66). 
The synthesis of this activated compound was examined using DCC, N-hydroxysuccinimide and 
catalytic DMAP (Scheme 27). This 1H NMR spectrum of the crude reaction mixture suggested that 
only a trace amount of hydroxysuccinamide ester was formed. 
 
Scheme 27. (i). DCC, DMAP, N-hydroxysuccinimide, TEA, CH2Cl2, 24h. 
3.3.11 Coupling with T3P and CDI 
Coupling of BODIPY FL to 6-aminohexanol using T3P and CDI was also examined. Treatment of 
BODIPY FL acid 50 with TEA, and either T3P 50% in ethyl acetate, or CDI followed by addition of 6-
aminohexanol returned only the starting material.  
3.3.12 Synthesis of BOIDPY TMR and BODIPY 558-568 
Since the functionalisation of BODIPY FL was proving problematic and time consuming, the 
preparation of two other BODIPY dyes was examined, in the hope that the steps to final compound 
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would be more successful. It was envisaged that BODIPY TMR 51 and BODIPY 558/568 52 might also 
be more stable to purification, and result in higher yields of product. 
The synthetic methodology of fabricating these two BODIPY, used the pyrrole propanoate right hand 
side pyrrole, to be converted to the acid for coupling reactions. The other pyrrole was synthesised 
from a starting acyl chloride forming an amide on addition with allyl amine. A pericyclic 
rearrangement formed the pyrrole, then carbonylation of the pyrrole followed this, as seen with 2,4-
dimethylpyrrole synthesis.175 
Synthesis of red-shifted BODIPY 51 and 52 started with the respective acyl chloride for each final 
compound, 4-methoxybenzoyl chloride 68, or 2-thiophenecarbonyl chloride 69. Allylamine and 
pyridine were added at 0 oC to the mixtures in dry DCM. Following aqueous work-up, the 
concentrated residues could be purified by addition of hexane. The product made an immiscible 
layer underneath, which with gentle heating turned the hexane layers cloudy with reaction 
impurities and the oil at the bottom could be extracted via pipette.  
The crude isolates extracted this way required no further purification and gave yields of 72% for allyl 
amide 69, and 57% for compound 70 (Scheme 28).  
 
Scheme 28. (i). Allyl amine, dry DCM, pyridine, 0oC, 4h. (ii). Phosgene, cat. DMF, Toluene, -78oC, 12h, K+ t-BuO, 
THF, 0oC, 1h. (iii). POCL3, DCE, reflux, 1h, NaOAc, reflux, 1h. (iv). 30% HCl, dioxane, H2O, 48 h. 
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Allyl amides were then converted to imidoyl chloride intermediates followed by base promoted ring 
closing rearrangement. Imidoyl chlorides were formed from phosgene and the amides 69 and 70 at -
78 oC in toluene and catalytic DMF over 12 hours. The solvent was then removed and the mixture 
dissolved in THF, cooled to 0 oC and three equivalents of sodium tert-butoxide were then added. The 
rearrangement was then left for 30 minutes. 
After work-up, these products needed to be purified immediately by column chromatography and 
due to the instability, the electron rich pyrroles were used in the next reaction straight away. The 
yields of the pyrroles were 61% for the paramethoxybenzyl pyrrole 71, and 69% for thiophene 
pyrrole 72. 
The substituted pyrroles were carbonylated by treatment with freshly prepared Vilsmeier reagent in 
a similar fashion to the dimethyl pyrrole in section 3.3.3. The paramethoxybenzyl pyrrole-2-
carboxaldehyde 73, as a yellow oil in 66% yield after column chromatography. The thiophene pyrrole 
74, was obtained as yellow diamond shaped crystals in 30% yield after chromatography. 
 (Chloromethylene)dimethyliminium chloride is the intermediate iminium cation formed from DMF 
and POCl3. Known as Vilsmeier reagent,186 it can be bought cheaply with the idea of increasing the 
reaction yield of the carbonylation step. Two equivalents of the reagent were added to DCE and 
refluxed with the pyrrole, before being cooled and the water sodium acetate mix then being added 
brought up to reflux again. After work up and purification the yield was ca. 40%. This was less than 
the yield following the original technique, so further use of this reagent was abandoned. 
Pyrrole 53 was used as one half of the BODIPY core structure. The coupling of the two halves 
together and adding the boron difluoride centre, commenced as in section 3.3.4 (Scheme 22). The 
yields were 39% and 28% after purification with DCM and acetonitrile for the ethyl ester protected 
derivatives of BODIPY TMR 75 and BODIPY 558/568 76.  
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Deprotection in dioxane, hydrochloric acid and column chromatography yielded the two red 
BODIPY’s, 28% for BODIPY TMR 51 and 36% for BODIPY 558/568 52. The low yields of the ester 
hydrolysis were comparable to BODIPY FL, and the synthesis of these two red-shifted BODIPY were 
no more efficient in time or yields, than synthesis of BODIPY FL. Coupling reactions were to be 
attempted with the purified BODIPY acids. 
3.3.13 Coupling of BODIPY TMR and 558/568 with Linker 
Coupling of BODIPYs 51 and 52 to 6-aminohexanol were explored. None of the other previously 
trialled coupling compounds gave the desired amide in reactions with BODIPY 558/568 52. T3P and 
HBTU resulted in an impenetrable mess of peaks when analysed by 1H NMR. This was the case even 
after extensive efforts to purify the mixture by column chromatography and clean product could not 
be obtained. CDI returned starting materials for both BODIPY TMR 51 and BODIPY 558/568 52. HBTU 
with BODIPY TMR 51, as with the reaction with BODIPY 558/568 52, gave a spectrum from which it 
was too difficult to determine the outcome.  
In one experiment coupling of BODIPY TMR 51 was achieved, using T3P 50% DMF, TEA, dry DCM.  
The scale was small, and the yield also very low (10%). 1H NMR indicated formation of product 77 
(Figure 64). The multiplet of peaks associated with the 8 central CH2 were present at 1.1 – 1.5 ppm. 
The terminal CH2 associated with NHC=O and OH were also present indicating the presence of bound 
6-aminohexanol. 
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Figure 64. Product 77 of coupling 6-aminohexanol to BODIPY TMR 51 via T3P in DMF. Coloured numbers refers 
to hydrogen environments around the molecule, and the corresponding peaks in the spectrum. 
 
Due to the difficulties with synthetically low yields, and difficulties with purification of asymmetrical 
BODIPYs, the research was not pursued further. A third fluorophore was explored; one that was 
cheaply commercially available.  
  
77 
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3.4 Pyrene Probe 
Schofield et al developed a photoreactive fluorescent probe incorporating a red-shifted analogue of 
pyrene 78. They used a photon mediated aryl azide that irreversibly transformed into a nitrene187 
moiety as part of the photoaffinity probe, and a sulphonamide selectivity function known to target 
human carbonic anhydrase II (HCA II) (Figure 65).188 Incubation with the HCA II followed by 
irradiation and gel purification gave a bright red fluorescent band in the expected region under UV. 
MALDI-TOF mass spectrometry then proceeded to yield the thee proteins containing the modified 
protein residue that was expected. 
 
Figure 65. Structure of HCA II probe utilising arylazide photoaffinity probe, and pyrene fluorophore. 
As the use of pyrene as fluorophore has already shown success in these experiments, the 
fluorophore was therefore deemed appropiate for use in this study on myocardial cells. 
3.4.1 Background 
To further understand the properties of fluorescence within our system and to continue probing for 
organophosphate targets, two new probes featuring alkyl chains of different lengths connected to 
pyrene will be synthesised. Studies into this class of fluorophore hope to shed light on the 
fluorescence reducing issues found with the rhodamine equivalents and their interaction with 
organophosphates. Although rhodamine quenching is currently attributed to being in an equilibrium 
between open and closed states, if the pyrene fluorophores emission is significantly reduced, then 
forms of resonance energy transfer may still be occurring. It is also expected that the synthetic 
stability issues found with BODIPY’s will not be prevalent with pyrene compounds.  
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Pyrene and its analogues can be bought for little expense; it is relatively bright with an extinction 
coefficient of ε = 54000 and a quantum yield of φ = 0.32 in cyclohexane.189 Pyrene butanol, and 
pyrene butyric acid are the starting compounds of interest and excite and emit at 341 nm and 376 
nm in methanol respectively (Figure 66).190 
 
Figure 66. Structure of pyrene butyric acid 79, and 1-pyrene butanol 80. 
3.4.2 Coupling of Pyrene to a Linker 
The first strategy employed was to determine if pyrene butanol 80 could be extended with 8-chloro-
1-octanol (Scheme 29), the alcohol end being used to complete the phosphate centre of the 
organophosphate probe. This was attempted with the presence of sodium hydride in DMF with 15-
crown-5 added, and heated to 80 oC for 12 h. 
 
Scheme 29. (i) 8-chloro-1-octanol, 2x NaH, dry DMF, 15-crown-5, heat. 
After work-up with LiCl to remove DMF, and extraction with ethyl acetate, crude 1H NMR was 
performed. This indicated that unreacted pyrene butanol was returned. 
The second attempt was to create a tosylate intermediary compound which would then be displaced 
by the alcohol yielding a hexanol ester. The 6-hydroxyhexanoic acid, TsCl, and TEA were placed into 
CH3CN with some catalytic DMAP and cooled to -5 oC for 30 minutes. Following this, the pyrene 
butanol in CH3CN was added by syringe and the flask was warmed to room temperature and left for 
2 h (Scheme 30).  
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Scheme 30. (i) 6-hydroxyhexanoic acid, TsCl, DMAP, TEA, CH3CN, -5oC, then add pyrene butanol and warm at 
25oC 2h. 
 
After work-up, the crude 1H NMR looked promising however, purification with ethyl acetate yielded 
two fractions; one fraction seemed to suggest that the tosyl group adds to the butanol chain of the 
pyrene. This was assumed as the spectrum between 7.6 - 8.2 ppm became a mess of peaks with a 
large integral comparatively to CH2 of the alkyl chain. The methyl group associated with the tosyl is a 
distinctive singlet peak at 2.33. The second fraction returned only starting pyrene butanol. 
Due to the difficulty of synthesising a long pyrene PSP probe using an alcohol moiety, pyrene butyric 
acid 79 was used as the starting analogue and utilising the same methodology for synthesising the 
rhodamine linker analogues, a mixture of HBTU and TEA in dry DCM was employed (Scheme 31). 
 
Scheme 31. Synthesis of 6-hydroxyhexyl pyrenebutamide using (i). HBTU, 2xTEA, 6-aminohexanol, dry DCM, at 
0 oC, 12h. 
 
After work-up and column chromatography the fraction containing the fluorescent pyr-alkyl 83 
which was collected and characterised by 1H NMR, 13C NMR, MS, IR, MP and fluorimetry. The 
product was a pale yellow crystalline solid with 78% a yield. 
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3.4.3 Synthesis of Long Pyrene Organophosphate Probe 
With the synthesis of the pyrene butamide linker pyr-alkyl 83 completed, synthesis then moved to 
the formation of a pyrene organophosphate probe (Scheme 32). This was achieved in the same 
fashion as with the rhodamine organophosphate probes in section 3.2.3. A cooled solution (-78 oC) 
of pyr-alkyl 83 with TEA had freshly prepared saligenin chlorophosphate 45 solution added dropwise 
and left to warm up over 12 h. After work-up crude 1H NMR showed the presence of the 
characteristic ABX splitting pattern at 5.24 and 5.72 ppm. Following column chromatography a yield 
of 42% was given for pyr-alkyl SP 84, 31P gave a single peak at -8.79 illustrating a fully oxidised 
phosphate centre. 
 
Scheme 32. Synthesis of 6-saligeninphosphatehexyl pyrenebutamide. (i). PSPCl, 2x TEA, dry DCM, -78oC, 12h. 
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3.4.4 Synthesis of Short Pyrene OP Probe 
Creating a short PSP probe was simply a matter of mixing pyrene butanol with TEA and adding 
freshly prepared saligenin chlorophosphate 44, dissolved in dry DCM dropwise at -78 oC and allowed 
to warm to room temperature over 12 h (Scheme 33). Work-up and column chromatography with 
ethyl acetate then yielded probe pyr-SP 85 24% product as a yellow oil, with characterisation made 
by 1H NMR, 13C NMR, 31P NMR, MS, IR, and fluorimetry. 
 
Scheme 33. Synthesis of 4-saligeninphosphatebutyl pyrene. (i). PSPCl, 2x TEA, dry DCM, -0oC, 12h. 
3.4.5 Fluorimetry of Pyrene Probes 
The absorbance and emissions were measured following the technique described in experimental 
section 5.2.5. Firstly, the absorbance of pyrene butanol 79 starting material was measured. The 
second highest peak of absorbance was at 326 nm. This was the chosen excitation frequency used 
for the rest of the fluorescence measurements on the two pyrene organophosphate probes pyr-alkyl 
SP 84 and pyr-SP 85. This was to avoid saturation of the detector without having to adjust the 
emission and excitation slits width between the analogues. The slit width for both emission and 
excitation measurements was set to 5 nm, with a scan rate of 600 nm /min.  
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The results of both excitation and emission measurements showed a drop in both absorbed and 
emitted light with the addition of saligenin phosphate 44 (Figure 67). The starting material was in a 
concentration of 100 nM, whereas the probes were 100 times more concentrated at 10 µM. The 
probe pyr-alkyl SP 84 featuring the furthest distance between the organophosphate and pyrene, was 
brighter than the short butanol probe pyr-SP 84, though this was only true up to 468 nm.  
This led to the most interesting effect observed, which was the red-shifted peak found for these 
probes; a large emission of light in the red region of the spectrum. This, compared to the starting 
material pyr-butanol 79 shows that the 350 – 425 nm region dropped significantly.  
The short probe pyr-SP 85 emitted slightly more in this red shifted region than probe pyr-alkyl SP 84. 
This effect was due to aggregation of the probes in water. At high concentrations pyrene forms 
aggregates where π-π interactions between the rings of delocalised electrons can exchange 
energy.191 The aggregate energy exchange results in a wavelength red-shift for the emission energy, 
increasing the intensity of emission.  
The effect has been used in the design of composite materials with spectral properties and biological 
sensors. One example of this is with the peptide nucleic acid probes (PNA).192 Pyrene units are 
introduced synthetically on to a PNA strand. These strands are complimentary to a specific gene, for 
example a mutated cystic fibrosis transmembrane conductance regulator (CFTR) gene. When 
hydrogen bonding to a specific matching base pair occurs, the pyrene units overlap and red-shifting 
can be measured by fluorescence. 
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Figure 67. Fluorimetry graph displaying the absorbance (triangles) of 100 nM of pyr-butanol 79 (shown in blue), 
10 µM of probes pyr-alkyl SP 84 (shown in green) and pyr-SP 85 (shown in red), and the emission (circles) of light 
for each compound at 326 nm. Fluorescence measurements were made using a 1 cm3 fluorimetry cuvette (n=3); 
with each probe dissolved in distilled water, pH of 7.5. 
 
The next fluorimetry experiment set out to explore how concentration effected the aggregation of 
the pyrene probes in water. Three concentrations of each probe were investigated: 100 nM, 1 µM 
and 10 µM, whilst irradiating at 326 nm.  
 
Figure 68. The effect of concentration of pyrene probe pyr-alkyl SP 84 on red-shifted emission. Fluorescence 
measurements were made using a 1 cm3 fluorimetry cuvette (n=3); with each probe dissolved in distilled water, 
pH of 7.5. 
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The emission spectra of probe pyr-alkyl SP 84, illustrates that 100 nM is too low a concentration for 
red-shifting to occur for this probe in water (Figure 68). At 1 µM red shifting starts to occur, but 
between 350 – 425 nm the curve shape still resembles the starting material, pyr-butanol 79. At 10 
µM red shifting becomes the dominant wavelength for fluorescence emission, and a large amount of 
light is released. 
This experiment was repeated for the pyrene probe pyr-SP 85 (Figure 69). This probe seemed more 
sensitive to π-π stacking and aggregation. Like pyr-alkyl SP 84, no red-shifting could be observed at 
the low concentration of 100 nM. At 1 µM the peak of emission was at 475 nm, not at 375 nm as 
found with the starting pyr-butanol 79 and 1 µM of probe pyr-alkyl SP 84. There was very little 
emission that was not in the red shifted region at 10 µM, indicating that pyr-SP 85 either aggregated 
more readily, or the increase in red-shifting could have been due to a closer intramolecular-distance 
between the pyrene rings, so more energy could be shared between the molecules in the aggregate.    
 
Figure 69. The effect of concentration of pyrene probe pyr-SP 85 on red-shifted emission. Fluorescence 
measurements were made using a 1 cm3 fluorimetry cuvette (n=3); with each probe dissolved in distilled water, 
pH of 7.5. 
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Whether the effect of red-shifting organophosphate probes will be useful in gel electrophoresis 
studies or not remains to be seen. The scale of aggregation in an enzyme or receptor found within a 
cardiomyocyte cell lysate or mitochondrial lysate is likely to be minimal depending on the location of 
the binding residue.  
An experiment to determine whether red-shifting occurs with a known fluorescent amino acid was 
explored. One such residue has been discussed previously and is commonly found to be inducing 
background autofluorescence, tyrosine. It was thought that the spectral properties of this residue 
could be mitigated, or even that the presence of tyrosine could enhance the red-shifting and probe 
emission through π stacking, this could have been a useful property to exploit.  
Mixing different concentrations of tyrosine with the pyrene solution in water could encourage probe 
aggregation incorporating the tyrosine. If aggregation occurs with π stacking any spectral change can 
be measured by the fluorimeter. 
Initially two control spectra were measured, 1 and 10 µM of tyrosine, and 1 µM of the pyr-alkyl SP 
84 (Figure 70). These results showed that at 315 nm the tyrosine peak emission was at 355 nm. This 
emission steadily declines to 500 nm, and there was very little difference between 1 µM and 10 µM 
of tyrosine solutions which would suggest little spectral change due to π stacking with itself.  
Following this experiment, four different concentrations of tyrosine were mixed with a 1 µM 
solution of pyr-alkyl SP 84. This is the concentration that did not present any red-shifting from 
aggregation, so any shifting that occurred, would be noticeable. 
At 377 nm pyr-alkyl SP 84 had an intensity of 57, yet with 10 µM of tyrosine added the intensity of 
this peak increased to 63; even at 5 µM the intensity increased to 62. The amount of red-shifting 
that occurred decreased as the concentration of tyrosine increased. 
 It was concluded that tyrosine inhibited the red-shifting effects of pyrene aggregates, and that the 
emission within its non-π-stacking region increased very slightly. Energy was likely being transferred 
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to the tyrosine via hydrophobic interactions or photoinduced electron transfer (PET), which leads to 
complete fluorescence quenching.  
Many kinase sensors use fluorescence quenching mechanisms, phosphorylation by the kinase on 
residues can mediate fluorescence. Tyrosine is known to quench fluorophores by π-π stacking 
interactions and PET; the phosphorylation of the OH on the aryl side chain can restore 
fluorescence.193 The phosphate size and charge disrupts the interactions of tyrosine and 
fluorophore; one study reports a significant increase in fluorescence using a tyrosine kinase.194 
 
Figure 70. The spectral effect of tyrosine (Tyr) concentration on 1 µM of pyrene probe pyr-alkyl SP 84 at 315 nm. 
Positive control of 1 µM pyr-alkyl SP 84 in green, 1 µM of Tyr in light grey, 10 µM of Tyr in dark grey. Light blue 
to dark blue represents 1 µM of both Tyr and pyr-alkyl SP 84, then 2 µM of Tyr with 1 µM probe, then 5 µM Tyr 
and 1 µM pyr-alkyl SP 84 and finally 10 µM Tyr 1 µM pyr-alkyl SP 84 in dark blue. Fluorescence measurements 
were made using a 1 cm3 fluorimetry cuvette (n=3); with each probe dissolved in distilled water, pH of 7.5. 
 
The Lawrence group demonstrated the increase in fluorescence over 4-fold when the tyrosine 
inhibiting pyrene was phosphorylated by a kinase.195 However, González-Vera et al claims that 
pyrene is an inappropriate fluorophore for the development of a sensor kit due to its short excitation 
and emission wavelengths, and the fluorescent interference that cellular components such as 
organelles and lysates can cause.196  These effects may moderate the effectiveness of any pyrene 
based probes. 
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3.4.6 Gel-Electrophoresis Studies of Pyrene Probes 
Notwithstanding the potential shortcomings of the pyrene probes, organophosphate binding to 
protease chymotrypsin in gel electrophoresis was explored. The Pyrene organophosphate probes 
were compared against rhodamine probe rho-PEG long SP 49 and DSP-10.  
The fluorescent bands found in this gel suggests that the control, PSP with chymotrypsin, was slightly 
visible on the blue laser light due to autofluorescence (Figure 71). The shorter pyrene probe pyr-SP 
85 seemed to be brighter at all concentrations than the lanes containing pyr-alkyl SP 84. Although, 
lane 6 contained the lowest concentration of pyr-alkyl SP 84 (25 µM), and was still clearly visible. The 
proposed reasoning for why the difference in brightness was so apparent here could be the binding 
efficiency of short pyr-SP 85. Its small size and length may have given it more access to residues on 
chymotrypsin, so more binds to the protein. Whereas, pyr-alkyl SP 84 would have impeded access to 
residues according to its length, and therefore less of the probe binds. 
 
     
Figure 71. Pyrene probes bound to 20 µg chymotrypsin, incubated on ice for fifteen minutes with three 
concentrations of both pyrene probes. After reduction with Laemmli buffer, 10 µl is loaded into each well, the 
gel was visualised after running at 412 nm (n=1). Lane 1, 100 µM of pyr-SP 85. Lane 2, 50 µM and lane 3, contains 
25 µM of pyr-SP 85. Lane 4, contains 100 µM, lane 5, 50 µM, and lane 6, 25 µM of pyr-alkyl SP 84 respectively. 
Lane 7, 100 µM PSP with chymotrypsin control. Coomassie staining of gel with lane 7 protein missing.  
 
  
Pyr-SP 85 Pyr-alkyl SP 84 PSP 7 
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This led to a second gel electrophoresis experiment directly comparing rho-PEG long SP 49 and DSP-
10 using the same method as in the last gel, but comparing the two pyrene probes to long glycol 
chain featuring rhodamine and dansyl. The visualisation of these two gels occurred on a UV-
transilluminator. This excitation was chosen so the dansyl could be seen fluorescing optimally and 
UV-transilluminators are common place in the majority of bioscience research labs. The results of 
this experiment indicated the practical brightness in standard conditions for the three families of 
probe. 
The rhodamine B probe rho-PEG long SP 49 was determined to be the second brightest compared to 
DSP-10. This was to be expected as the excitation frequency was about 312 nm, closer to the wide 
excitation range of dansyl of 300 – 400 nm which is not optimal for pyrene probes pyr-alkyl SP 84 
and pyr-SP 85. These probes were very faint comparatively, since the narrow excitation wavelength 
that pyrene responds to is 310 – 350 nm. Another explanation could be that the pyrene probes did 
not bind as efficiently to chymotrypsin as the other two probes. A way of measuring excess probes 
unbound to protein would need to be performed to consider this.    
 
Figure 72. Pyrene probes compared with rho-PEG long SP 49, and DSP-10. (A), probe rho-PEG long SP 49 of three 
concentrations, 100, 50 and 25 µM in lanes 1, 2 and 3. Probe pyr-SP 85 of the same three concentrations in lanes 
4, 5 and 6. (B), probe DSP-10 of three concentrations, 100, 50 and 25 µM in lanes 1, 2 and 3. Probe pyr-alkyl SP 
84 of the same three concentrations in lanes 4, 5 and 6, (n=1).  
 
The results of probe performance in SDS-PAGE experiments led onto a final experiment for the 
pyrene probe, where a solution containing 100 µM of pyr-alkyl SP 84, was incubated with 80 µg of 
mitochondrial lysate in extract buffer on ice. Following the same technique as found in previous 2D-
gel electrophoresis studies, the gel displayed in Figure 73 was obtained. Fluorescently labelled 
Pyr-SP 84 
Pyr-alkyl SP 85 
Rho-PEG long SP 
DSP-10 
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protein clusters could be seen, these are awaiting de-staining and mass spectrometry analysis to 
determine the bound protein target identity.  
 
Figure 73. 2D SDS-PAGE gel displaying: A) long pyrene probe pyr-alkyl SP 84 labelled to mitochondrial proteins 
in 2D-gel study and, B) Gel staining by coomassie blue, revealing all proteins present in the gel (n=1). 
 
This 2D gel suggested that the tagging efficiency of these probes was not compromised. However, 
enough information on fluorophore and probe behaviour means research into pyrenes has reached 
an end, and a new system featuring organophosphates will need to be designed with further 
optimisations.  
3.5 Synthesis of Bright Rhodamine Analogues 
3.5.1 Background 
The pursuit of fluorophores with desirable properties for these probes beyond maintaining biological 
effectiveness are good solubility and high brightness at low concentrations. The rhodamine skeleton 
lends itself to modifications and optimisations.  
The focus of this current study returned to literature analysis of analogues with the rhodamine core 
structure. Rhodamines as previously mentioned are highly varied and continue to be utilised for a 
wide variety of purposes. Since it has been discovered that using an amide on rhodamine B in the 2 
position causes the fluorescence to decrease in the organophosphate probes, it would be viable to 
try other analogues of rhodamine that will have high extinction coefficients. Also desirable would be 
useful absorption and emission properties, and ideally are more favoured to exist in the open form 
A
 
B
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and have a higher fluorescence yield than current use of rhodamine B, which prefers to form a 
closed lactam ring. 
Two other rhodamine core structures that were explored are rhodamine 101 and rhodamine Q. 
Preliminary work already suggested a water solubility issue with the probes. The rhodamine 
analogues being synthesised needed to have a useful level of water solubility. Rhodamine Q is the 
core structure for a few patented dyes currently on the market including Atto Rho 14,197 NVOC2-5-
carboxy-Rhodamine Q a metabolic label for cellular DNA,198 as well as other analogues found in DNA 
sequencing kits.199 
A synthetic methodology for a sulphonated rhodamine Q starts from the inexpensive 7-Hydroxy-3,4-
dihydro-2(1H)-quinolinone. The final step of sulphonation increases water solubility, and allows high 
concentrations (>100 µM) to be tested (Scheme 34).200 
 
Scheme 34. Synthesis of highly water soluble sulphonated rhodamine Q. (i). BH3.THF, THF, reflux, 24h (ii). 7-
Hydroxy-1,2,3,4-tetrahydroquinoline, phthalic anhydride, 85% H3PO4, 150 oC (iii). 30% SO3 in H2SO4, 0 oC, 12h. 
 
  
 137 
 
3.5.2 Synthesis of 7-Hydroxy-1,2,3,4-tetrahydroquinoline 
The first step explored in the synthesis was creating the amino phenol 87. The reaction was 
performed by 24 h reflux of compound 86 with borane THF, then with the solvent removed, was 
worked-up and analysed by 1H NMR returned starting material. This indicated that no reduction had 
occurred. It was likely that the borane used was no longer functional. 
As the reduction with borane THF did not afford the desired amine the experiment was repeated but 
with a different boron-centred reducing agent, borane dimethylsulphide.201 The desired product was 
achieved after refluxing the reactants for 6 hours followed by a further reflux with methanol for 30 
minutes. Work-up with the addition of a methanol wash and column chromatography in DCM gave 
the amino alcohol 87 as a green oil with a 55% yield.  
3.5.3 Synthesis of Rhodamine Q 
Compounds 87 and 88 were then mixed and heated to 150 oC for 3 h, 85% H3PO4 was then added 
and the mixture was refluxed for a further 3 h. There was a noticeable colour change however, from 
colourless to a deep red. This indicated that product 89 had been formed. Crude 1H NMR gave an 
unclear spectrum with some peaks indicating a trace product, this could not be isolated after column 
chromatography however.  
A second synthetic route was then explored. Using an O2 atmosphere, aminophenol 87 and phthalic 
anhydride 88 were dissolved in a mix of trifluoroethanol and water in a 4:1 ratio; followed by heating 
at 80 oC for 12 hours.202 After analysing the crude 1H NMR the spectra looked promising, displaying 
the key peaks documented by the literature. The product, if any had formed, could not be retrieved 
from the silica during column chromatography. 
Continued efforts to purify this crude with silica have not been fruitful. Using a 2:1 mix of acetone 
and toluene, and even treating with base prior to purification to close any formed rhodamine in the 
hope that it may run off the silica first, the compound was still lost.  
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Further exploration into the synthesis of rhodamine Q was abandoned. The next additional 
rhodamine fluorophores to be explored, 5 and 6-carboxy-X-rhodamine, now become the focus of 
synthesis (Figure 74). These are analogues of rhodamine 101.  
3.5.4 Synthesis of 5 /6-Carboxy-X-rhodamine 
Rhodamine 101 has excitation and emission wavelengths of 560 nm and 589 nm in methanol, and is 
used in many biological imaging experiments. Two synthetically simple analogues of interest exist, 5-
X-carboxy-rhodamine, and 6-X-carboxy-rhodamine. Both patented for many applications including 
cosmetics,203 assay kits,204 and temperature sensors205 and both analogues feature a carboxylic acid 
substituted on the phenyl ring, in either the 5 or 6 position.    
 
Figure 74. Structures of both carboxy-X-rhodamine derivatives. 
These two fluorophores both have a dicarboxy substituted phenyl ring. Synthetically bioconjugation 
is more readily achieved with the secondary carboxylic acid. The issue of the position of the 
equilibrium between open and closed forms should be dealt with by using the free carboxy group for 
amide coupling. It is energetically more stable to be open and with an overall neutral charge in 
aqueous solution.134  
The synthesis of 5-carboxy-X-rhodamine and 6-carboxy-X-rhodamine commenced with 8-
hydroxyjulolidine and trimellitic anhydride both dissolved in a mix of 4:1 TFE and water in an O2 
atmosphere. The mixture turned from a pale orange to a dark red after 4 hours. Analysis of the 
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crude 1H NMR gave a promising spread of peaks. Column chromatography with acetone, toluene and 
TEA, returned only starting material however.  
 
Scheme 35. Synthesis of 5 and 6-carboxy-X-rhodamine OP probes. (i). TFE, H2O, O2, 80 oC, 12h. (ii). HBTU, TEA, 
dry DCM, 0 oC, 12h. (iii). PSCl, TEA, dry DCM, -78 oC, 12h. 
 
Another synthesis for carboxy-X-rhodamine was then tried. This Scheme 35 was adapted from Uddin 
et al method where refluxing the starting components in butanoic acid and 2M H2SO4 for 12 hours 
produced the compound. 206 
In the following method however, butanoic acid was replaced with ethanoic acid. The crude 1H NMR 
again looked promising, though only starting materials were returned from the column. 
The reagents were optimised further as it was noticed that a grey precipitate was forming with 
addition of the 2M H2SO4. This was found to be a salt of the hydroxyjulolidine and the method was 
changed to incorporate two drops of concentrated HCl instead. The reaction was also modified to 
occur in a mix of dioxane and ethanoic acid. After work-up the crude once again showed peaks that 
were in the expected positions.  
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However, the product from the column retrieved was the wrong colour, a blue green residue instead 
of the expected purple crystals. 1H NMR suggested that only half of the 8-hydroxyjulolidine had 
coupled with the trimellitic anhydride in a 44% yield. The reaction was tried again with this 
intermediate product, and more equivalents of 8-hydroxyjulolidine, this time the reaction going to 
completion with the formation of a dark red crude mix. Purification in a MeOH DCM gradient gave 
two purple coloured fractions, the 5-carboxy-X-rhodamine 91 218 mg 34% and the 6-carboxy-X-
rhodamine 92 had a dried weight of 155 mg which is a 24% yield. 
3.6 Conclusions to the Organophosphate Studies 
Three rhodamine B organophosphate probes have been synthesised and tested; rho-alkyl SP 18, rho-
PEG short SP 48 and rho-PEG long SP 49. The emission of light when fluoresced at 532 nm was 
greatly diminished from that of rhodamine B starting material. It is suggested that a closed lactam 
ring is more thermodynamically and sterically favoured in water than the fluorescent amide open 
form. Evidence of the closed lactam form existing has been proposed with data illustrated in Figures 
47 and 48. Analysis of the 13C NMR spectrum with HMQC and HMBC experiments seems to suggest 
that the closed form quaternary carbon in position 9 of the xanthene ring can be seen with a 
distinguishable peak of ca. 64.9 ppm.  
Investigations into the biological interactions of all three probes, exhibited toxicity on differentiated 
H9c2 cardiomyocytes at a clinically relevant toxicity of 6.25 µM over 24 hours, illustrating the 
bioactivity of the probes. The LDH assays concluded that high doses of treatments are necrotic 
however, and low concentrations are largely inactive, this is demonstrated in the calculations of the 
IC50 (Table 2). The precursor linkers rho-alkyl 15, rho-PEG short 16 and rho-PEG long 17, in general 
had a higher toxicity than the organophosphate probes at concentrations over 25 µM, however, 
rhodamine B demonstrated a negligible toxicity over both 4 hours and 24 hours.  
Gel electrophoresis tests determined that the probes bind to protein residues found on 
chymotrypsin, NTE and TG2 (Figures 55 and 56), highlighting that there are interactions between 
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organophosphates and TG2. The problem of autofluorescence was also circumvented by use of 
these probes, visualising at 532 nm was useful in deciphering the protein spots found in 2D gel 
electrophoresis. Mass spectrometry of the protein clusters looking for organophosphate target 
proteins, are waiting to be performed. Completion of the studies of factor XIII and mitochondria with 
the probes will bring to light novel target proteins that may play a role in OPIDN and general 
organophosphate toxicity (Figures 57 and 73). 
Attempts to synthesise organophosphate probes that do not suffer from the quenching, that 
rhodamine amides experience, led the investigation onto BODIPYs and pyrenes. Work with the 
BODIPY fluorophores is inconclusive due to the synthesis and functionalisation revealing a rhapsody 
of problems.  
Further work will investigate synthesis of pyrroles featuring terminal alcohol chains that 
organophosphates can be extended on. The outcome of the pyrene studies is the synthesis of two 
novel probes, pyr-alkyl SP 84, and pyr-SP 85. These both bind to chymotrypsin, and have bound to 
novel organophosphate protein targets found in mitochondria. Although, the brightness of this 
family of fluorophores, and the excitation wavelength is far from optimum for what is required in 
this study. 
Ultimately this work will continue to seek to identify proteins targets found via probe binding in 2D 
gel electrophoresis tests. Synthesis of brighter organophosphate probes is also still being explored. 
One methodology could be to stop the closing of rhodamine amide via the incorporation of a 
piperazine ring coupled to the 2 position of the aryl ring, forming an amide that is unable to close. 
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4. Diazoxide 
4.1 Previous Work 
Alongside the work with organophosphates, research into the cardioprotective mechanisms of 
diazoxide 19 was explored (Figure 76).  
Previous work invested by Garner group et al in this field, was aimed at the synthesis of fluorescent 
tags using diazoxide as a protein bait. The biological study of cardioprotective properties of 
analogues of diazoxide was made in collaboration with Dr Manuel Galiñanes, Department of Cardiac 
Surgery, Area University Hospital Vall d'Hebron Pg, Spain. Ten analogues were synthesised with the 
following structures (Figure 75): 
 
Figure 75. Garner group diazoxide analogues synthesised at Nottingham Trent University by Fathi Smida.67 
The cardioprotective activity of the analogues was assessed by incubation with myocardial slices 
from the human right atrial appendage, in ischaemia/reperfusion experiments and the viability of 
the treated tissue was determined as described in the literatures.207,208  
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It was concluded that all the analogues displayed a varying level of physiological activity. Substituting 
positions 5 and 7 with two bromines biologically inactivated compound 108. Analogues 105 and 106 
both show significant cardioprotection, and when compared with analogues where the 3 position is 
methylated the results had indicated that side chain extension is not detrimental to activity. These 
results in general are in concordance with the suggested pattern of behaviour indicated by Topliss et 
al. although, no compounds for direct comparison are available.110,111 
The results of the tests performed previously formed the basis for diazoxide probe design, having an 
active analogue specific for cardiac cells, and not brain or pancreatic tissue for example.  
 
Figure 76. Bioactive diazoxide analogue designed by Garner group.67 
With the information from the previously mentioned SAR studies, analogue D-109 was synthesised. 
This has a similar core structure as the parent compounds 105 and 106, with the chlorine group in 
position 8 and a butanoic acid side chain in the 3 position. This, by no means was the optimum 
structure for potency, as previously mentioned in the SAR studies, having the chlorine at position 7 
and a trifluoromethyl at position 6 would have been ideal. For ease of synthesis, however, some 
compromises were made and this analogue should still have retained some activity. The butanoic 
side chain was added to allow coupling to the linker and the rest of the proteomic tool.  
Diazoxide probe DZX-110 was previously synthesised by this research group (Figure 77). This 
featured diazoxide analogue of D-109 that was coupled to a 6-aminohexanol linker, with a dansyl 
sulphonamide fluorescent component and a benzophenone photoaffinity label.  
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Figure 77. Photoreactive diazoxide probe DZX-110. 
 
Incubation of the probe with mitochondrial extract, irradiation at 360 nm for 30 minutes prior to 
running the samples in an SDS-PAGE gel electrophoresis study, also showed some fluorescent bands 
around 25 kDa (Figure 78).   
 
Figure 78. Previous work by Smida et al. illustrating DZX-110 labelling. A). SDS-PAGE gel showing fluorescent 
bands from the incubation of diazoxide probe DZX-110, centrifuged sample prior to irradiation DZX-110*, and 
low background fluorescence from the control of 110. B). The gel after staining with coomassie blue, the pigment 
showing all the protein bands. 
 
These previous experiments highlighted some of the efficacy of the probe. It was necessary to 
discovering whether probe DZX-110 was an effective cardioprotective agent in and of itself 
compared to the parent compound and analogue D-109. Assuming the probe was still biologically 
effective, it would interact with the mitochondrial proteins and the study moved onto to investigate 
this.  
The identity of the proteins can be found after the photoreactive component of the probe 
irreversibly binds with them and 2-dimensional gel electrophoresis is performed alongside mass 
Control           DZX-110           DZX-110*  Ladder     Control                          DZX-110   DZX-110*   
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spectrometry. Mitochondrial proteins found will include the components for the mitoKATP channel, 
and (if the probe is selective enough), the presence of the probe bound to these proteins will add to 
the body of information regarding what sub units these channels contain and whether DZX targets 
these channels.  
4.1.1 Confocal Imaging of Diazoxide Probe 
Confocal imaging is a powerful tool in the field of microscopy that utilises tuneable lasers to pinpoint 
a single plain on a sample to image. This allows for 3 dimensional cross sections of a cell to be 
viewed, as well as various fluorescent components to excite with high selectivity.   
The probe DZX-110 was incubated with cells 1 hour prior to irradiation on chamber slides which had 
been cultured with 5000 H9c2 cells per well, 7 days before the experiment began. This enabled the 
myocytes to be serum starved, causing differentiation and expression of cardiomyocytes 
properties.62,65 The wells had the treated culture aspirated and fresh medium added before being 
exposed for a minute to UV light from a transilluminator to bind the probe to the protein targets in 
the cell. The slides were washed with phosphate buffer solution, and then counter stained with cell 
dye known as 4,6-diamidino-2-phenylindole (DAPI). The slides are transferred to the confocal 
microscope and visualised with a UV laser at 312 nm, and a violet laser at 405 nm (Figure 79).  
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Figure 79. Confocal image of H9c2 cardiomyocyte cells fluorescing yellow with staining from the diazoxide probe 
and DAPI counterstain for nuclear visualisation (blue) of H9c2 cells. Scale bar = 75 μm, and 20x magnification 
(n=1). 
 
The DAPI fluoresced at 405 nm and allowed the cell nucleus to be clearly seen, as it became bound 
to adenine-thymine rich regions in DNA.209 The diazoxide probe emitted light at ca. 500 nm. What 
can be seen in this image is that the diazoxide probe had entered the cells, which was proven by 
visualising down the z-axis (not shown). The resolution of the camera and the brightness of the 
dansyl fluorophore are limiting factors in visualising the mitochondrion, so a large concentration of 
DZX-110 (100 µM), had to be used. Therefore, determination of where the probe targeted primarily 
(sarcolemma or mitochondria) was not possible. The high concentration may have caused the 
benzophenone to bind to nearby protein residues, not specifically the diazoxide targeted ones. 
With the knowledge of probe binding to mitochondrial proteins determined by previous work, the 
probe can visibly be seen in the cell from the confocal experimentation. Cell viability assays of 
diazoxide analogue 109 and DZX-110 were next investigated.  
4.1.2 Cell Viability Assays of Diazoxide Probe 
The viability of cells was measured by lactate dehydrogenase release and the metabolic reduction of 
MTT by living cells. When in the presence of ischaemic insult such as hydrogen peroxide (H2O2) the 
cardioprotective capabilities could be explored. The assay used hydrogen peroxide as the insult 
because it mimicked ischemia and reperfusion injury chemically.210 Some preliminary studies showed 
that the solubility of the dansylated diazoxide probe in water was limited to 100 µM; above this 
concentration the solution would saturate and precipitation of probe aggregates would occur. 
In initial MTT and LDH tests, the 800 µM concentration of H2O2 gave poor results with the scale of 
cell death being at a point where comparison of analogues was difficult. Better results were found 
with lower concentration of 600 µmol H2O2.  
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Figure 80. A). MTT test using treatment of diazoxide (DZX) 19 and analogue D-109. Effect of 1-hour pretreatment 
of each in µM, and 2 hour treatment of 600 µM H2O2 (MTT 15,000cell /well H9c2 n = 6, control normalised to 
100%) B). LDH test results. Effect of 1h pretreatment with parent DZX 19, and analogue D-109, and 2-hour 
treatment of 600 µM H2O2 (LDH 5000 cells/well n = 6, control normalised to 100%). The “*” represent the results 
of an ANOVA t-test comparing significance (p) against the control H2O2 response. *p<0.05, **p<0.01, 
***p<0.005, ****p<0.001. For the MTT tests, cardiomyocytes were seeded at 15,000 cells per well in 24-well 
plates. LDH tests were seeded with 5000 in 96-well plates.  
 
The results illustrated in Figure 80 show significant activity of analogue D-109. Although there was a 
decrease in activity between the parent DZX (19) and the active analogue D-109, this was further 
confirmation to the trend in activity of 105 and 106 reported by Galiñanes et al.  
LDH and MTT tests were then explored with the complete diazoxide probe DZX-110. The tests were 
performed via the same method as above. Confirmation of cardioprotective activity of DZX-110 can 
be seen by the comparison of the control insult via hydrogen peroxide and the residual activity of 
treated cells (Figure 81). 
The results of the MTT tests show a significant increase in the metabolism of the cells demonstrating 
a trend in viability when damage from H2O2 occurs. At the 20 µM concentration of DZX-110 
treatment the amount of MTT reduced improves by ca. 10% compared with the H2O2 control. The 
LDH tests are not displaying the same trend. Cells are not protected against necrotic damage 
through H2O2 use. However, statistically significant cardioprotection is only seen at 80 µM and 100 
µM. Further tests to determine exact efficacy include decreasing the amount of O2 in the 
atmosphere inducing hypoxia in the cells, where intracellular ROS would be generated.211 
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Figure 81. Effects of DZX-110 on MTT reduction and LDH release and 100 µM of parent DZX 19. A). MTT test 
using 1-hour pretreatment DZX-110 in µmol, and 2-hour treatment of 600 µM H2O2 (MTT 15,000cell /well H9c2 
n=6 control normalised to 100%) B). LDH test results. Effect of 1h pretreatment with DZX-110, and 2-hour 
treatment of 600 µM H2O2 (LDH 5000 cells /well n = 6, control normalised to 100%). The “*” represent the results 
of a t-test comparing significance (p) against the control H2O2 response. *p<0.05, **p<0.01, ***p<0.005, 
****p<0.001.  
 
Interestingly, the protective qualities of the complete probe DZX-110 were less than compound D-
109. This could be due to less of the active analogue being solubilised around the target protein, as it 
is already known that solubility of this compound is an issue, and there is a large increase in size (302 
vs 829 Da).  
Nevertheless, the probe should have been appropriate for the function of targeting the elusive KATP 
channel subunits, leading the investigation onto 2D gel electrophoresis tests. 
4.1.3 2D-Gel Electrophoresis Studies  
The mitochondrial extracts used for 2-dimensional SDS PAGE gel electrophoresis experiments on 
organophosphates were used again for the DZX-110 tests. This assay involved incubation of a DZX-
110 solution with the extract followed by centrifugation and irradiation. At this stage the 
benzophenone photoreactive component would covalently bind to free residues around the site(s) 
where the probe is located. Visualisation of the gels under 412 nm of blue light revealed spots where 
protein clusters containing the probe were likely to be found.  
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The spots revealed by the probe could have been very dense clusters of proteins which were auto-
fluorescing at this wave length.  However, this was unlikely, as other protein spots would have 
shown up. It had to be assumed that these spots were mitochondrial proteins bound to 
benzophenone after being targeted by DZX-110. (Figure 82). 
 
 
Figure 82. Gel displaying bound protein spots found via diazoxide probe DZX-110 with mitochondria. Probe DZX-
110 is incubated on ice with the extract in TRIS buffer. After 10 minutes they are transferred to a glass bottomed 
384 well plate to be irradiated at 360 nm for 10 minutes. The samples were added to acetone at 0 oC to 
precipitate the protein and wash off excess solution, this is dissolved in solubilisation buffer and continued the 
2D-gel protocol outlined in 5.3.9. The gels were visualised at 412 nm using a blue light laser (n=3). 
 
These spots are undergoing analysis by mass spectrometry by the John van Geest Cancer Research 
Centre to determine the identity of the proteins. Currently 228 peptide fragments with the increased 
mass associated with DZX-110 have been isolated from one protein spot and seven of the most 
confident results are displayed, (Table 4). The identities of the proteins that these peptides originate 
from, measured via comparisons with databases, have not revealed any known proteins.  
Peptide residues (+DZX-110) Tag length ALC 
KC(+828.24)ELLDYVGLDTTK 14 81 
T(+828.24)PVLEVDLAAFDK 13 81 
L(+828.24)LPALNVTLTDFAAGK 16 81 
N(+828.24)PQDYESEEQLEHR 14 76 
K(+828.24)YEDHLSGPVR 11 76 
T(+828.24)LPKRGNKVYVR 12 75 
T(+828.24)WLFFYSR 8 75 
Table 4. Table of peptide fragments modified by DZX-110, average local confidence (ALC) is a percentage given 
for de novo analysis relating to the percentage of correctly sequencing a peptide.  
A
 
B
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4.2 Synthesis of a Brighter, More Selective Diazoxide Probe 
The results of the confocal visualisation and the gel electrophoresis studies highlighted the 
weaknesses of the probe’s use of the dansyl fluorophore. Brightness at low concentrations and 
background autofluorescence are issues that can be circumvented by exciting bright photostable 
probes that respond at green – red-shifted wavelengths. A fluorophore which has a higher extinction 
coefficient than dansyl (ε = 4000) would increase the sensitivity of the probe, allowing for less 
populous protein units to be detected.  
The families of rhodamine, pyrene, and BODIPY have all been presented throughout this project. 
Each has a higher extinction coefficient than dansyl amide, and each would be more selective. There 
are problems with these choices however. The BODIPY family of fluorophores are not appropriate 
for investigation, due to difficulty with synthesis. Pyrenes have a narrow excitation and emission 
wavelength and an easily inhibited fluorescence due to aromatic amino acid residues. This would 
judge the synthesis of such a probe no better than the current tool.  
Rhodamines were explored and the issue of lactam closing can be circumvented by positioning the 
benzophenone photo affinity probe on the tertiary amide, as in probe DZX-110. Rhodamine B has 
high extinction coefficients and quantum yields, (ε =106,000, φ =0.95), and with rho-PSP probes 
used in SDS-PAGE gels, the severely fluorescently-diminished rhodamine organophosphate probes 
were brighter than the dansyl and pyrene probes. Adding to this rationale, being selective to green 
/yellow light considers the background fluorescence is insignificant.  
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4.2.1 Synthesis of Diazoxide Analogue D-109 
Fabrication commenced with synthesis of active analogue D-109. Which was achieved via a known 
procedure in four-steps starting with 1,2-dichloro-3-nitrobenzene 111.83 Benzyl thiol was generated 
in situ from refluxing benzyl chloride, thiourea, ethanol, water and catalytic ammonia, followed by 
addition of potassium hydroxide and refluxed with dichloronitrobenzene 111 for 2 hours. Upon 
cooling the precipitated 2-(benzylsulfanyl)-1-chloro-3-nitrobenzene 112 was collected as a yellow 
solid with a 77% yield (Scheme 36).  
 
Scheme 36. Synthesis of analogue D-109. (i). Benzyl chloride, thiourea, 1,2-chloro-3-nitrobenzene, NH3, 
CH3CH2OH, H2O reflux, 3h, KOH, CH3CH2OH, H2O, reflux, 2h (ii). Cl2, HCl, KMnO4, CH3COOH, H2O, rt, 30 min, 
dioxane, NH3.H2O, NaOH, HCl (iii). NH4Cl, iron powder, EtOH, H2O, reflux, 45 min. (iv). Glutaric acid monomethyl 
ester chloride, dioxane, rt, 1 h, NaOH, 1 h, HCl. 
 
The second step involved the generation of chlorine gas from reacting HCl on potassium 
permanganate and bubbling this through a solution of 2-(benzylsulfanyl)-1-chloro-3-nitrobenzene in 
acetic acid and water at room temperature for 30 minutes. This was then extracted with diethyl 
ether, and concentrated under reduced pressure. The resulting orange oil was then dissolved in 
dioxane and aqueous ammonia. A precipitate formed which was dissolved with NaOH. The mixture 
was treated with charcoal and filtered, and a precipitate was reformed using HCl. Product 113 was 
then filtered and collected in a 28% yield. 
After the formation of the sulphonamine 113, it was dissolved in hot ethanol and water mix with 
ammonium chloride and iron powder, then refluxed for 45 minutes. After work-up, addition of 
hexane caused the precipitate to form a brown powder of product 114 with a 50% yield.    
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2-Amino-6-chlorobenzenesulfonamide was dissolved in dioxane, and glutaric acid monomethyl ester 
chloride was added and the mixture stirred for 1 hour. Following this, the mix was concentrated and 
dissolved in 3% sodium hydroxide solution and stirred for 1 hour further. HCl was then added until a 
precipitate formed. It was left overnight for more to form. The product was then filtered and washed 
in ether to yield diazoxide D-109 with 42% yield. The 1H NMR data is consistent with data from the 
previously synthesised material.67 
4.2.2 Rhodamine Diazoxide Probe 
The next step in synthesis of a rhodamine B diazoxide probe was deciding which linker was to be 
used to connect the fluorophore to the benzophenone photoaffinity label and D-109. It was 
envisaged that a tertiary amide would be the simplest and most efficient method of joining the three 
components (Scheme 37). To this end, rho-alkyl 15, rho-PEG short 16 and rho-PEG long 17 were all 
considered. 
Rho-alkyl 15, rho-PEG short 16, and rho-PEG long 17 were dissolved in DMF at -78 oC, with potassium 
carbonate, in three separate reactions. 4-Bromomethyl benzophenone was then added dropwise 
and the mixture turned from pale pink to a black colour. This was then left for 12 hours to warm 
steadily to room temperature. Crude 1H NMR showed a mess of peaks, and column chromatography 
returned only starting material. 
This reaction was then repeated at 0 oC with sodium ethoxide to see if the reaction between the 
amide and the 4-bromomethyl benzophenone could be encouraged. This resulted in a mess of peaks 
that had no discernibly identifiable CH2 shifts between 3.5 and 4.5 ppm as an expected marker for 
the success of this reaction. Column chromatography returned starting rhodamine linker.  
A third set of conditions were trialled, using NaH as the base and refluxing in toluene and DMF. The 
mixture turned from a pale pink colour to a yellow with addition of the 4-bromomethyl 
benzophenone. This then disappeared and the mix turned colourless. It was assumed that the 
 153 
 
rhodamine was completely closing into its spirolactam form, hence the loss of colour. Only starting 
materials were returned after column chromatography.  
 
Scheme 37. The coupling of rhodamine B linkers 15, 16 and 17 with 4-bromomethyl benzophenone. (i). K2CO3, 
dry DMF, -78oC, 12 h. (ii). NaOEt, dry DMF, 0oC, 12 h. (iii) NaH, Toluene/DMF, reflux, 6 h.  
 
This led to synthesis of benzophenone coupled linkers 118 and 119, which began with 6-
aminohexanol, and TBDMS protected linker 40. Using DMF at -78oC and potassium carbonate, both 
products were achieved after column chromatography with ethyl acetate in yields of 23% for 118 
54% for 119. 
These two products would then be coupled to rhodamine B. HBTU was employed for this end due to 
the success with previous rhodamine compounds. Reaction Scheme 38 was planned to synthesise 
the final diazoxide probe. Regrettably, the tertiary amide was not formed from this reaction. DIPEA 
was trialled instead of TEA and starting materials were returned.   
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Scheme 38. Synthesis of diazoxide probe with rhodamine B. (i). K2CO3, DMF, -78 oC, 12 h. (ii). HBTU, rhodamine 
B, TEA, DCM, 0 oC, 12 h. (iii). TsCl, TEA, DMAP, 0 oC, 25 oC 12 h. (iv). TBAF, DCM, 25 oC. 
 
The failure of this coupling experiment led to the conclusion that creating a tertiary amide at this 
point of substitution on a rhodamine fluorophore is unlikely due to the bulk of the 
methylbenzophenone. Benzyl groups are the largest groups found bound to a tertiary amide in this 
fashion on a rhodamine fluorophore.212 The benzyl group acts as a blocking group for formation of 
the spirolactam ring, and the quenching of fluorescence. It was hoped that the benzophenone group 
would achieve the same effect. 
Attention then turned to rhodamine analogues with substitution in other positions about the 
benzene ring. The rhodamine 5 /6-carboxy-X-rhodamine had a free acid on either the 5 or 6 position 
of the aryl ring. Successful synthesis of 6-carboxy-X-rhodamine led us to explore whether a probe 
could be made with the linker already connected. The goal was to use trimellitic anhydride 93 or the 
trimelitic chloride 122 and methylbenzophenone aminohexanol 118, to synthesise the amide 123. 
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This then could be reacted with 8-hydroxyjulolidine to yield the rhodamine connected with affinity 
label and probe as in Scheme 39.  
Coupling the trimellitic chloride 122 was attempted by mixing 118 and TEA in dry DCM at 0 oC. The 
chloride was then added dropwise and an evolution of gas was given off. Crude 1H NMR gave an 
unclear spectrum, which even after purification gave indiscernible compounds.  The next two 
attempts were with trimellitic anhydride 93 and coupling agents HBTU and T3P. 1H NMR spectra of 
both crude products showed an array of peaks associated with 118 but with a mess of peaks around 
7 – 8 ppm. Attempts at returning purified product 123 from crude residues failed. One suggestion as 
to why the product did not form is that the trimellitic anhydride decomposed in the aqueous layer.  
 
Scheme 39. Proposed synthetic route for 5 /6-carboxy-X-rhodamine diazoxide probe 125. (i). 122, 118, TEA, dry 
DCM, 0 oC. (ii). 93, 118, HBTU, TEA, dry DCM 0 oC, 24 h. (iii). 93, 118, T3P, TEA, dry DCM, EtOAc, 0 oC, 24 h. (iv). 
8-hydroxyjulolidine, MeCOOH, dioxane, conc. HCl, reflux, 24 h. (v). TsCl, TEA, DMAP, 0 oC, 25 oC 12 h.  
 
With compound 123 unable to be synthesised, the attention turned to a final methodology of 
achieving a rhodamine diazoxide probe. 
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4.2.3 Sulphorhodamine B Probe via Click Chemistry 
With synthesis of a tertiary amide starting from rhodamine B proving difficult, a new scheme was 
formed relying on 1,2-cycloaddition to an azide to form a di-substituted cyclotriazide ring.  
This would couple together the rhodamine B fluorophore with either a protected linker, that would 
be deprotected and then coupled to a photoaffinity label and the selectivity function, or a linker with 
some of or all the functionality already present. 
In order to explore this methodology, two components needed to be fabricated. The synthesis of a 
terminal alkyne connected to benzophenone was investigated as the first component to the click 
chemistry (Scheme 40). TBDMS protected secondary amine 119 was dissolved in DMF and cooled to 
-78 oC. Potassium carbonate and then propargyl bromide was added. After work-up, crude 1H NMR 
illustrated the formation of the product. This however, has yet to be purified by column 
chromatography. 
 
Scheme 40. Synthesis of propargyl benzophenone TBDMS-protected amino hexanol. (i). K2CO3, propargyl 
bromide, DMF, -78oC, 6 h. 
 
The second component for click chemistry would deliver the azide moiety. Sulphorhodamine B 127 
could be bought commercially with little expense and contained a sulphonyl chloride substituent on 
the lower ring of the rhodamine. A substitution reaction with propanol azide in the presence of base 
would give one half of the click compound (Scheme 41).213 
This was potentially achieved by mixing sulphorhodamine B chloride 127 with 1-bromo-3-
propanolazide in dry DCM at 0 oC for 4 h. Workup in DCM gave a crude compound with a promising 
1H NMR spectra. Column chromatography returned a mixture of products. It is believed that the 
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desired product is in the mixture, but future purification steps need refining to isolate the product 
128 before click reactions can be explored, and probe 129 can be realised.  
 
Scheme 41. Synthesis of a sulphorhodamine B diazoxide probe utilising click chemistry. (i). 1-bromo-3-
propanolazide, dry DCM, TEA, 0oC, 4 h. (ii). 123, CuI, H2O, THF, heat, 24 h (iii). TBAF, dry DCM, 25oC, 4 h. (iv). TsCl, 
TEA, DMAP, 0oC, 25oC 12 h. 
4.3 Conclusions of Diazoxide Studies 
Diazoxide analogue D-109 has been shown to protect cells from H2O2 insult through maintaining 
metabolism at 20 µM in MTT tests, and the cells are protected from necrosis at 40 µM as seen in 
LDH tests. These results illustrated a potential cardioprotective quality, as the tests were performed 
in conditions mimicking ischaemia with insult coming from H2O2. When D-109 was incorporated into 
DZX-110 with the dansyl fluorophore and benzophenone photo affinity barb, the protective 
properties were retained and could be seen at concentrations of 20 µM in MTT and 80 µM in LDH 
assays (Figures 80, and 81).  
 158 
 
When DZX-110 was incubated with differentiated H9c2 cardiomyocytes at a concentration of 100 
µM, and exposed to UV light, the probe bound to proteins inside the cells. Visualisation of this relied 
on confocal microscopy (Figure 81). At a large concentration of 100 µM, DZX-110 is not specifically 
selective, and the benzophenone barb is likely binding to residues of proteins in close proximity. A 
brighter probe, in a lower concentration, imaged on a higher resolution confocal microscope, could 
reveal mitochondria fluorescing with the probes bound to the inner membrane. A suitable counter 
stain dye utilised in competition with DZX-110 would further confirm selectivity for mitochondria. 
2-Dimensional gel electrophoresis studies on mitochondrial extracts incubated with DZX-110, 
highlighted fluorescent proteins under 412 nm blue light laser. These clusters of fluorescent proteins 
indicated that probe DZX-110 had bound to the residues. These spots have been processed and are 
awaiting analysis by mass spectrometry. Preliminary analysis of one cluster of proteins had revealed 
tagged peptides. These have not been identified as of yet, but this work is ongoing. 
The synthesis of a brighter rhodamine based diazoxide probe that incorporated a tertiary amide – a 
moiety that forces the rhodamine to retain its open form, and therefore fluorescence, was met with 
difficulties. It was apparent from literature that the largest group successfully added to a rhodamine 
secondary amide was a phenyl.209 The attempts to synthesise an anhydride precursor 123 to 
rhodamine that incorporated a 5 /6 position tertiary amide with the 6-aminohexanol linker and 
benzophenone did not yield the desired product. Reaction stability of the trimellitic anhydride in 
basic or aqueous conditions was theorised to be the problem.  
To this end, the formation of rhodamine diazoxide probe 129 was planned. This integrated attractive 
click chemistry into the synthesis, by coupling the linker tertiary amide 126 to sulforhodamine 
propanyl azide 128. This chemistry needs to be further explored, as the current study was drawing to 
a close. Completion of synthesis of a brighter diazoxide probe leads into further mitochondrial 
protein fishing, and identification of target proteins. 
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5. Experimental Techniques 
5.1 Synthetic Reference 
5.1.1 3,5-Dimethyl-1H-pyrrole-2-carboxaldehyde 57 
 
Phosphorous oxychloride (1.88 g, 1.15 ml, 12.26 mmol) was added to DMF (0.9 g, 0.95 ml, 
12.31 mmol) over 20 minutes at 0 oC. The mixture was left to stir for 15 minutes at room 
temperature before being diluted with DCM (5 ml) and then cooled to 0 oC. A solution of 2,4-
dimethylpyrrole (1.0 g, 10.51 mmol) in DCM (5 ml) was then added drop wise. The mixture 
was refluxed for 30 minutes and cooled to room temperature followed by the addition of 
sodium acetate (8.30 g) in water (20 ml). The reaction was refluxed for a further 30 minutes. 
The cooled mixture was then separated and the aqueous layer, extracted with diethyl ether (3 
x 50 ml) and the organic layers were combined and dried with magnesium sulphate. Removal 
of the solvent in vacuo gave a brown oil. Purification by chromatography (silica, ethyl acetate) 
gave brown crystals, 0.08 g, (11%); IR (ATR, cm-1): 3235 (N-H), 1617 (C=O); δH (400 MHz, 
CDCl3): 2.27 (s, 3H, CH3), 2.29 (s, 3H, CH3), 5.78 (s, 1H, pyrrole-H), 9.38 (s, 1H, CHO), 12.28 (br.s 
1H, NH). Data consistent with the literature values.214 
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5.1.2 4-Methoxy-N-(prop-2-en-1-yl)benzamide 70 
 
 
To dry DCM (25 ml), p-anisoyl chloride (8 ml, 59.12 mmol) and TEA (16.7 ml, 120 mmol) 
were mixed and cooled to 0 oC. A solution of allyl amine (4.50 ml, 60 mmol) and) in DCM 
100 ml was then added dropwise to the amine solution. The reaction was then left to stir 
for 4 hours at RT. Water (75 ml) was added and the phases were then separated. Organic 
phase was then washed with a 1M HCl (100 ml) solution and brine (100 ml). The mixture 
was then dried over MgSO4, filtered and concentrated resulting in a pale-yellow oil, 8.11 g, 
(71%).  
 δH (CDCl3, 400MHz): 3.77 (s, 3H, OCH3), 4.05 (tt, 2H, J= (5.7, 1.5) x3, CH2), 5.19 (dq, 1H, J= 
10.3, 1.4, C=C), 5.28 (q, 1H, J= 1.6 x3, C=C), 5.92 (ddt, 1H, J= 17.1, 10.4, 5.6, 5.6, 1.1, C=C), 
7.05 -7.08 (m, 2H, Ar-H-OCH3), 7.46 -7.54 (m, 2H, Ar-H-amide), 8.00 (s, 1H, NH); Data is 
consistent with literature data.215 
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5.1.3 2-(4-Methoxyphenyl)-1H-pyrrole 72 
 
 
Compound 70 (2.10 g, 11.0 mmol) was placed into a dry RBF, purged with nitrogen and 
put in an ice bath. Phosgene (20% in toluene, 1.2 ml, 10.4 mmol) was injected into the 
system, and 8 drops of dry DMF added, then the reaction was then to left stir over night. 
The toluene was removed in vacuo and the residue dissolved in dry THF (40 ml). 
Potassium tert-butoxide (2.59 g, 38 mmol) was dissolved in dry DMF (20 ml), and cooled 
to 0 °C and this mixture was added dropwise to the butoxide solution, and the reaction 
was then left to stir for 30 minutes at 0 °C and was then poured over 60 ml of ice water, 
and separated. The aqueous phase was extracted using diethyl ether (3 x 60 ml). The 
combined organic phases were then washed with water (2 x 60 ml) and brine (60 ml). The 
organic phase was then dried over MgSO4 and concentrated to give a mustard yellow 
powder. Yield 1.10 g, (61%). δH (CDCl3, 300MHz): 3.81 (s, 3H, OCH3), 6.27 (q, 1H, J= 2.7 x3, 
CH2 pyrrole), 6.39 -6.41 (m, 1H, CH3 pyrrole), 6.80 -6.82 (m, 1H, CH4 pyrrole), 6.88 -6.92 (m, 
2H, Ar-H-OCH3), 7.38 -7.48 (m, 2H, Ar-H-pyrrole), 8.33 (br.s, 1H, NH). Data consistent with 
the literature values.216   
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5.1.4 2-Formyl-5-(4-methoxyphenyl)-pyrrole 74 
 
 
 
POCl3 (0.6 ml, 6.68 mmol) was added dropwise to dry DMF at 0 °C, and the solution was 
stirred for 15 minutes at room temperature. Dry DCM (40 ml) and compound 72 (1.0 g, 
5.76 mmol) was then added dropwise, at 0 °C. The reaction then refluxed for 30 minutes, 
before being cooled to room temperature and NaOAc (4.55 g, 33.48 mmol) in water (40 
ml) was added. This mixture was then refluxed for a further 30 minutes. The organic phase 
was then separated, and the aqueous phase was extracted using diethyl ether (3 x 100 
ml). The combined organic phases were washed with water (2 x 100 ml) and saturated 
Na2CO3 solution (1 x 100 ml), and then dried over Na2SO4. The resulting green powder 
required no further purification and was carried forward. (0.76 g, 65%); δH (CDCl3, 
300MHz): 3.78 (s, 3H, OCH3), 6.47 (d, 1H, J= 3.9, CH4 pyrrole), 6.83 -6.91 (m, 2H, Ar-H-
OCH3), 6.94 (d, 1H, J= 3.9, CH3 pyrrole), 7.47-7.52 (m, 2H, Ar-H-pyrrole), 9.40 (br.s, 1H, 
CHO), 9.52 (s, 1H, NH); Data consistent with the literature values.217   
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5.1.5 Pyrrole-2-(ethyl)propenoate 52 
 
 
Dry THF (150 ml) was added to triethyl phosphonoacetate (13.25 ml, 67 mmol) and n-BuLi 
(1.6 M in hexanes, 45.93 ml, 73 mmol) at -78 °C. The reaction was then stirred for 5 
minutes before warming to 0 °C, where it stirred for a further 40 minutes. Pyrrole-2-
carboxaldehyde (6.35 g, 67 mmol) was added, and stirred for 2 hours at 0 °C, then 
warmed to room temperature over 12 hours. This was concentrated in vacuo and the 
remaining residue was portioned between water (150 ml) and ethyl acetate (150 ml). The 
aqueous phase was extracted (3 x 150 ml EtOAc) and the combined organic phases were 
then washed with water (2 x 200 ml) and brine (1 x 200 ml). This was dried over MgSO4 
and concentrated. The resulting oil was purified by column chromatography (Silica, 70: 30 
cyclohexane: diethyl ether). The desired compound resulted as an off-white powder, 3.80 
g (34%). δH (CDCl3, 300MHz): 1.30 (t, 3H, J= 7.1 x2, CH3), 4.22 (q, 2H, J= 7.1 x3, CH2), 5.95 
(m, 1H, C=C), 5.99 (m, 1H, C=C), 6.25 -6.27 (m, 1H, ArH3), 6.53 -6.57 (m, 1H, ArH4), 6.90 -
6.92 (m, 1H, ArH5), 8.86 (br.s, 1H, NH); Data consistent with the literature values.218 
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5.1.6 Pyrrole-2-(ethyl)propanoate 53 
 
Compound 52 (2.0 g, 12.12 mmol) was dissolved in methanol (40 ml), and to this 
palladium on activated charcoal catalyst was added in good amounts. Hydrogen balloons 
were then fitted to the system for consumption and the reaction was left to run for 48 
hours. A celite column was packed (3 cm celite) and wetted with methanol, and the 
product was pushed through with nitrogen. The resulting dark yellow oil required no 
further purifying and yielded 1.86 g, (78%). δH (CDCl3, 300MHz): 1.30 (t, 3H, J= 7.1 x2, CH3), 
2.67 (t, 2H, J= 6.6 x2, CH2COO), 2.94 (t, 2H, J= 6.4 x2, CH2 pyrrole), 4.17 (q, 2H, J= 7.1 x3, 
CH2CH3), 5.94 -5.97 (m, 1H, CH3), 6.13 (q, 1H, J= 2.8 x3, CH4), 6.68 -6.70 (m, 1H, CH5), 8.65 
(br.s, 1H, NH); Data consistent with the literature values.175 
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5.1.7 2-Thiophene-allyl Amide 69 
 
Thiophene acyl chloride (3.0 g, 2.19 ml, 20.19 mmol) was added dropwise to a mixture of 
allyl amine (1.16 g, 1.45 ml, 18.17 mmol) in dry DCM (15 ml) at 0 oC. Pyridine then 
followed (1.45 ml, 18.17 mmol), and the reaction was left to stir for 4 hours at room 
temperature. The reaction was diluted with DCM (50 ml) and then separated with the 
addition of water and the organic phase was washed with water (3 x 50 ml), brine (50 ml), 
and the aqueous phase extracted with DCM (3 x 50 ml). The organics were then dried over 
MgSO4 and the mixture was concentrated to give an off white solid yielding 1.59 g, (57.2 
%); δH (CDCl3, 300 MHz): 3.95- 3.99 (m, 2H, CH2), 5.03- 5.19 (m, 2H, CH2), 5.77 -5.90 (m, 1H, 
CH), 6.99 (dd, 1H, J= 4.9, 3.7 CH3), 7.40 (dd, 1H, J= 4.9, 1.1, CH4), 7.68 (dd, 1H, J= 3.7, 1.1, 
CH5); δC (100 MHz, CDCl3): 42.3 (CH2), 116.9 (=CH2), 128.4, 129.9, 131.2, (3 x ArCH), 134.0 
(CH=), 137.5 (C), 161.7 (C=O). Data consistent with the literature values.177 
 
  
 166 
 
5.1.8 2-(2-Thienyl)-pyrrole 71 
 
 
 
N-2-propenyl-2-thiophenecarboxamide 69 (1.5 g, 9.79 mmol) was dissolved in phosgene 
solution (20% in toluene, 4.36 ml), 5 drops of anhydrous DMF were added, and the 
solution was stirred at room temperature for 16 hours before being concentrated to give 
a pale-yellow liquid. This was then dissolved in dry THF (4 ml), and added drop wise to a 
solution of sodium tert-butoxide (2.00 g, 29.4 mmol) dissolved in dry DMF (14 ml). The 
reaction was stirred at 0 oC for 10 minutes and the poured into ice water (50 ml). The 
reaction was extracted with diethyl ether (3 x 50 ml), dried with MgSO4 then concentrated 
to a residue, and after purification through flash column chromatography (silica, DCM) 1.0 
g (68%) of brown crystals were yielded. These crystals were used immediately as the 
product rapidly decomposes. δH (CDCl3, 300 MHz): 6.23 -6.26 (m, 1H, CH4 pyrrole), 6.40 -
6.42 (m, 1H, CH3 pyrrole), 6.79 -6.81 (m, 1H, CH5 pyrrole), 6.99 -7.01 (m, 1H, CH3 thienyl), 
7.04 -7.06 (m, 1H, CH4 thienyl), 7.13 (dd, 1H, J= 5.0, 1.2, 1.2, CH5 thienyl), 8.80 (br.s, 1H, 
NH); Data consistent with the literature values.177 
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5.1.9 2-Foryml-5-(2-thienyl)-pyrrole 73 
 
 
Phosphorus oxychloride (1.13 g, 0.69 ml, 7.32 mmol) was added drop wise to dry DMF 
(0.54 g, 0.56 ml, 7.32 mmol) at 0 oC, then warmed to room temperature over 15 minutes. 
The reaction was again cooled to 0 oC and dry DCE (13 ml) was added followed by a 
solution of thiophene pyrrole 72 (1.0 g, 6.7 mmol) in dry DCE (33 ml) drop wise. This 
mixture was refluxed for 1 hour, and upon cooling a solution of sodium acetate (5.0 g, 
12.3 mmol) in water (13 ml) was added. The reaction was refluxed for a further hour. The 
organic layer was washed with water (3 x 50 ml), brine (50 ml) and collected, and the 
aqueous layer extracted with DCM (3 x 100 ml). The combined organics were and dried 
with MgSO4. The desired product was recrystallized using hexane to give gold crystals. 
Yield 0.39 g, (30%); δH (CDCl3, 300 MHz): 6.52 (d, 1H, J= 3.9, CH3 pyrrole), 7.03 (d, 1H, J= 
3.8, CH4 pyrrole), 7.11 (dd, 1H, J= 5.1, 3.6, CH3 thienyl) 7.54 (dd, 1H, J= 5.1, 1.2, CH4 
thienyl), 7.68 (m, 1H, J= 3.6, 1.1, CH5 thienyl), 9.45 (s, 1H, CHO), 12.50 (br.s, 1H, NH); δC 
(100 MHz, CDCl3): 114.1 (CH pyrrole), 130.0 (CH pyrrole), 131.3, 131.9, 133.4 (3 x CH 
thienyl) 138.5, 139.0, 139.3, (3 x C3) 183.8 (C=O). Data consistent with the literature 
values. 214 
  
 168 
 
5.1.10 BODIPY TMR Ethyl Ester 76 
 
 
Compound 74 (300 mg, 1.49 mmol) and Compound 53 (231 mg, 1.49 mmol) were placed 
in a dry RBF with dry DCM (50 ml). POCl3 (0.15 ml, 1.64 mmol) was mixed with dry DCM (5 
ml) in a second RBF and the POCl3 solution was added to the pyrrole solution dropwise at 
0 °C, and left to stir for 30 minutes. The reaction warmed to room temperature and stirred 
for 2 hours. The solution was then cooled to 0 °C, and BF3 diethyl etherate (0.74 ml, 6 
mmol) and DIEA (1.09 ml, 6.3 mmol) was added, and the reaction was stirred overnight. 
To this 50 ml of DCM was added, the mixture separated, and the organic phase was 
washed with water (3 x 50 ml) and brine (1 x 100 ml). The aqueous phase was then 
extracted using DCM (50 ml) and the combined organic phases were dried over MgSO4 
and concentrated. The residue was purified by flash column chromatography (DCM), 
yielding 230 mg, (39%). δH (CDCl3, 400MHz): 1.23 (m, 6H, CH3), 2.65 (t, 2H, J= 7.4, CH2), 
3.22 (t, 2H, J= 7.7, CH2), 3.76 (m, 3H, OCH3), 4.15 (m, 2H, COOCH2), 6.24 (d, 1H, J= 4.1, CH3 
pyrrole), 6.54 (d, 1H, J= 4.4, CH7 pyrrole), 6.91 (d, 2H, J= 9.6, Ar-H-OCH3), 6.97 (d, 1H, J= 
4.4, CH4), 7.44, (dd, 1H, J= 5.7, 3.3, CH6 pyrrole) 7.62 (dd, 1H, J= 5.7, 3.2, CH5 pyrrole), 7.86 
(d, 2H, J= 8.0, Ar-H-pyrrole); Data consistent with the literature values.175 
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5.1.11 BODIPY 558/568 Ethyl Ester 75 
 
Compound 73 (200 mg, 1.20 mmol) and compound 53 (230 mg, 1.32 mmol) were 
dissolved in dry DCM (50 ml). POCl3 (200 mg, 0.12 ml, 1.32 mmol) in DCM (2 ml) was 
added at 0 oC. The mixture was stirred for 30 minutes at 0 oC then at room temperature 
for 2 hours. The solution was cooled to 0 oC, and boron trifluoride etherate (0.69 g, 0.6 ml, 
4.82 mmol) and DIEA (0.65 g, 0.88 ml, 5.04 mmol) were added. After stirring for 12 hours 
at room temperature, DCM (50 ml) was then added as well as water (100 ml) and the 
mixture was separated, washed with water (3 x 50 ml) and brine (100 ml), the aqueous 
later was extracted with DCM (2 x 50 ml) and the combined organic layers were dried 
(MgSO4) and concentrated in vacuo. The crude product was purified by flash 
chromatography (silica, DCM) to give the resulting product as a red oil yielding 0.13 g, 
(28%); δH (CDCl3, 400 MHz): 1.23 (m, 3H, CH3,), 2.86 (t, 2H, CH2, J= 7.55 Hz), 3.38 (t, 2H, 
CH2, J= 7.38), 4.14 (q, 2H, CH2), 6.39 (d, 1H, J= 4.12, CH7 pyrrole), 6.81 (d, 1H, J= 4, CH3 
pyrrole), 6.99, (d, 1H, J= 4.35, CH6 pyrrole), 7.04 (d, 1H, J= 4.35, CH4 pyrrole), 7.13 (m, 1H, 
CH5 pyrrole), 7.19 (dd, 1H, J= 4.97, 3.95 CH4 thienyl), 7.50 (d, 1H, J= 4.48, CH3 thienyl), 8.14 
(d, 1H, J= 3.56, CH5 thienyl); Data consistent with the literature values.177 
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5.1.12 BODIPY FL Ethyl Ester 58 
 
 
Compound 56 (200 mg, 1.20 mmol) and 3,5-dimethyl-1H-pyrrole-2-carboxaldehyde 74 
(160 mg, 1.3 mmol) was dissolved in dry DCM (50 ml). POCl3 (200 mg, 0.12 ml, 1.32 mmol) 
in DCM (2 ml) was added at 0 oC, the mixture was stirred for 30 minutes at 0 OC then at 
room temperature for 2 hours. Boron trifluoride etherate (0.69 g, 0.6 ml, 4.82 mmol) and 
DIEA (0.65 g, 0.88 ml, 5.04 mmol) were added at 0 oC and after 12 hours the mixture had 
warmed to room temperature. DCM (100 ml) was added and the mixture was washed 
with water (3 x 100 ml) then brine, (100 ml). The aqueous later was extracted with DCM (2 
x 50 ml) and the combined organic layers were dried (MgSO4) and concentrated in vacuo. 
The crude product was purified by flash chromatography (silica, DCM) to give the resulting 
product as red crystals, yielding 141 mg, (52%). δH (400 MHz, CDCl3): 1.17 (t, 3H, J= 7.1, 
CH3), 2.16 (s, 3H, CH3 pyrrole), 2.48 (s, 3H, CH3 pyrrole), 2.69 (t, 2H, J= 7.7, CH2 pyrrole), 
3.21 (t, 2H J=7.5, CH2COO), 4.04 (m, 2H, CH2), 6.01 (s, 1H, CH3), 6.17 (d, 1H, J= 3.9, CH7), 
6.77 (d, 1H, J= 3.7, CH6), 6.99 (s, 1H, CH5); Data consistent with the literature values.158 
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5.1.13 BODIPY FL 50 
 
 
Compound 58 (500 mg, 1.60 mmol) was dissolved in THF (30 ml) and conc. HCl (37%, 10 
ml) was added with water (30 ml). The reaction was left to stir for 48 hours and then DCM 
(100 ml) was added, and the organic phase was separated then washed with water (2 x 
100 ml) and brine (1 x 200 ml). The aqueous phase was then extracted using DCM (3 x 100 
ml). The combined organic phases were dried over MgSO4 then concentrated under 
vacuum. The product was purified by flash column chromatography (silica, DCM, 2% 
MeOH) yielding a red powder 160 mg, (34%). δH (400 MHz, CDCl3): 2.18 (s, 3H, CH3), 2.47 
(s, 3H, CH3), 2.76 (t, 2H, J= 7.5, CH2 pyrrole), 3.23 (t, 2H J= 7.5, CH2COOH), 6.05 (s, 1H, CH3), 
6.22 (d, 1H, J= 3.9, CH7), 6.81 (d, 1H, J= 3.7, CH6), 7.02 (s, 1H, CH5); δF (376 MHz, CDCl3): -
145.26 (q, JB-F 33.2). Data consistent with the literature values.158 
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5.1.14 BODIPY 558/568 52 
 
 
Compound 75 (550 mg, 1.38 mmol) was dissolved in THF (30 ml) and conc. HCl (37%, 10 
ml) was added with water (30 ml). The reaction was left to stir for 48 hours then DCM 
(100 ml) was added, and the organic phase was separated and washed with water (2 x 100 
ml) and brine (1 x 100 ml). The aqueous phase was then extracted using DCM (3 x 100 ml).  
The concentrated crude residue was purified by flash column chromatography (silica, DCM 
2% MeOH) yielding the resulting product as purple crystals 170 mg, (35%); δH (CDCl3, 400 
MHz): 2.85 (t, 2H, J= 7.5, CH2 pyrrole), 3.38 (t, 2H, J= 7.5, CH2COOH), 6.39 (d, 1H, J= 4.1, 
CH7 pyrrole), 6.79 (d, 1H, J= 4.3, CH3 pyrrole), 6.96, (d, 1H, J= 4.1, CH6 pyrrole), 7.02 (d, 1H, 
J= 4.1, CH4 pyrrole), 7.11 (m, 1H, CH5 pyrrole), 7.19 (dd, 1H, J= 4.9, 3.9, CH4 thienyl), 7.50 
(dd, 1H, J= 5.1, 0.9, CH3 thienyl), 8.14 (d, 1H, J= 3.8, CH5 thienyl); Data consistent with the 
literature values.177 
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5.1.15 BODIPY TMR 51 
 
 
Compound 76 (550 mg, 1.38 mmol) was dissolved into THF (30 ml). To this conc. HCl (37%, 
10 ml) was added with water (30 ml) and the reaction was left to stir. After 48 hours, DCM 
(100 ml) was added, and the organic phase was separated. This was washed with water (2 
x 100 ml) and brine (1 x 200 ml), and the aqueous phase was then extracted using DCM (3 
x 100 ml). The organics were concentrated and purified by column chromatography (silica, 
DCM 2% MeOH) yielding 80 mg, (28.84%). δH (CDCl3, 400MHz): 2.74 (t, 2H, J= 7.4, CH2 
pyrrole), 3.29 (t, 2H, J= 7.5, CH2COOH), 3.86 (s, 3H, OCH3), 6.35 (d, 1H, J= 4.1, CH3 pyrrole), 
6.63 (d, 1H, J= 4.4, CH7 pyrrole), 6.94 (d, 1H, J= 4.1, CH4 pyrrole), 6.99 (m, 2H, Ar-H-
pyrrole), 7.06 (d, 1H, J= 4.0, CH6 pyrrole), 7.13 (m, 1H, CH5 pyrrole), 7.93 (m, 2H, Ar-H-
OCH3); Data consistent with the literature values.175 
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5.1.16 (6-Hydroxyhexyl)carbamoyl BODIPY TMR 77 
 
In an RBF, BODIPY TMR (100 mg, 0.27 mmol) was placed, and dry DCM (20 ml) was added.  
T3P solution (0.2 ml, 50% in DMF, 0.54 mmol) was added along with TEA (0.1 ml), and 6-
aminohexan-1-ol (31 mg, 0.26 mmol). This was left stirring at room temperature for 12h 
and then separated with water (20 ml), and the organic phase was washed with water (2 x 
20 ml), brine (50 ml) and extracted with DCM (2 x 20 ml). The compound was put through 
a plug of silica and several fractions collected. The first fractions contained the desired 
product with 20 mg yield (20%). δH (CDCl3 300MHz): 1.15 -1.45 (m, 8H, CH2), 2.49 (t, 2H, J= 
6, CH2 pyrrole), 3.09 (t, 2H, J= 6, CH2NH), 3.18 (t, 2H, J= 6, CH2CO), 3.51 (t, 2H, J= CH2OH), 
3.80 (s, 3H, OCH3), 5.80 (s, 1H, NH), 6.29 (d, 1H, J= 3, CH3 pyrrole), 6.56 (d, 1H, J= 6 CH7 
pyrrole), 6.90 (d, 1H, CH4 pyrrole), 6.93 (d, 2H, J= 9, Ar-H-pyrrole), 7.02 (d, 1H, J= 3, CH6 
pyrrole), 7.10 (d, 1H, J= 3, CH5 pyrrole), 7.84 (d, 2H, J= 9, Ar-H-OCH3).   
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5.1.17 Saligenin Chlorophosphinine-2-oxide 45 
 
 
2-Hydroxybenzyl alcohol (1.00 g, 8.05 mmol) and TEA (2.50 ml, 2.15 mmol) in dry DCM 
(200 ml), had a solution of POCl3 (0.83 ml, 8.83 mmol) in dry DCM (4 ml) added dropwise 
at -78 oC. The mixture was stirred for 45 minutes, allowed to warm to room temperature 
and then concentrated under a vacuum. Dry toluene (30 ml) was added and the mixture 
stood in a fridge for 1 hour and then filtered, the solvent was removed in vacuo. The 
product was dried to obtain the desired compound 45 (1.50 g, 91%) which can be brought 
forward with no further purification. δH (400 MHz, CDCl3): 5.50- 5.59 (m, 2H, CH2), 7.08 (d, 
1H, J= 8.2, ArH1), 7.18 (d, 1H, J= 7.2, ArH4), 7.25 (t, 1H, J= 7.4, ArH2), 7.38 (t, 1H, J= 7.8 
ArH3); δP (162 MHz, CDCl3): (s, -5.38 ppm). Data consistent with the literature values.219 
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5.1.18 Phenyl Saligenin Phosphate 7 
 
Phenyl phosphorodichloridate (1 g, 4.73 mmol), 2-hydroxybenzyl alcohol (0.5 g, 4.02 
mmol) and TEA (2 ml, 26 mmol) were placed into a RBF and dissolved in dry THF (50 ml) 
then stirred at 0 oC for 30 minutes. Refluxing for 12 hours then followed, and the reaction 
solution was then diluted with water (50 ml) and extracted with CHCl3 (3 x 50 ml). The 
combined organic layers were dried over MgSO4 and concentrated in vacuo. This gave the 
product in a yield of 70% (700 mg). δH (400 MHz, CDCl3): 5.40-5.47 (m, 2H, CH2), 7.11-7.21 
(m, 9H, Ar-H); δP (CDCl3, 162 MHz): -15.08 ppm. Data consistent with the literature 
values.220 
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5.1.19 2-Hydroxy-dioxaphosphinine-2-oxide 47 
 
 
After formation of compound 45 (7.33 mmol), water (2 ml) is added to the RBF and the 
mixture is left overnight. All the solvent is removed and the compound recrystalised from 
chloroform to leave a white amorphous solid, 1.00 g (73%). δH (400 MHz, CDCl3): 5.37-5.40 
(d, 2H, J= 13.5 CH2), 7.03 (d, 1H, J= 8.2, ArH1), 7.12 (m, 1H, ArH4), 7.21 (m, 1H, ArH2), 7.33 
(t, 1H, J= 7.83, ArH3), 9.71 (s, 1H, OH); δC (100 MHz, CDCl3): 67.9 (JPC= 6, CH2), 118.3 (JPC= 9, 
CH1), 118.4 (JPC= 9.5, CH4), 123.9 (CH2), 125.8 (JPC = 77, CH3), 129.5 (JPC= 49, C6), 150.5 (JPC= 
6, CO5); δP (162 MHz, CDCl3): (s, -8.62ppm). 
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5.1.20 (6-Hydroxyhexyl)carbamoyl Rhodamine B 15 
 
Rhodamine B 1 g (2.08 mmol), and HBTU 0.79 g (2.08 mmol) was dissolved in dry DCM (250 
ml) and TEA 2 ml (26 mmol) then followed. 365 mg (3.12 mmol) of 6-aminohexan-1-ol 
dissolved in dry DCM (10 ml) is then injected into the system. The reaction was left stirring for 
12 hours after this work-up proceeded by washing with water (2 x 100 ml), brine (100 ml) and 
then extracted with DCM (3 x 100 ml). After drying with magnesium sulphate and filtering, the 
resulting solution was then purified on silica with 49% acetone, 50% toluene and 1% TEA 
returning the product 300 mg (26.6 %). IR (ATR, cm-1): 3352 (OH), 2970, 2929, 2862 (CH, 
rhodamine), 1665 (C=O, amide), 1613 (C=C) 1513 (NH bending); δH (400 MHz, CDCl3): 1.16 (m, 
18H, 12CH3, 6CH2), 1.35 (m, 2H, CH2), 3.11 (t, 2H, J= 6.8 CH2NH), 3.34 (q, 8H, J= 6.9 N(CH2)2), 
3.52 (t, 2H, J= 6.6 CH2OH), 6.27 (d, 2H, J= xantheneH4,5), 6.48 (m, 4H, xantheneH1,2,7,8), 7.07 (m, 
1H, ArH6), 7.40 -7.44 (m, 2H, ArH4,5), 7.88 -7.97 (m, 1H, ArH3); δC (100 MHz, CDCl3): 12.5 (CH3 
xanthene), 24.7 (CH2), 26.3 (CH2), 27.9 (CH2), 32.3 (CH2), 39.9 (CH2NH), 44.3 (CH2 xanthene), 
62.6 (CH2OH), 64.7 (C9 lactam), 97.5 (4/ 5 xanthene), 105.7 (2/ 7 xanthene), 107.8 (8a/ 9a 
xanthene), 122.4 (Ar 3), 123.5 (Ar 6), 128.7 (Ar 4), 128.8 (Ar 2), 131.9 (Ar 1), 132.3 (Ar 5), 148.5 
(3/ 6 xanthene), 153.1 (4a/ 5a xanthene), 153.3 (1/ 8 xanthene), 167.8 (C=O); HRMS (NSI) 
(m/z), [M+H] calcd, for C34H44N3O3+ 542.3377 found 542.3364.  
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5.1.23 (6-TBDMShydroxyhexyl)carbamoyl Rhodamine B 41 
 
Rhodamine B (305 mg, 0.7 mmol), compound 15 (160 mg, 0.7 mmol) and HBTU (262 mg, 0.7 mmol) 
were dissolved in dry DCM (100 ml), cooled to 0 oC and 1 ml (13 mmol) of TEA then followed. The 
reaction warmed to room temperature and left for the next 24 hours. Work-up then followed by 
washes with water (2 x 100 ml), brine (100 ml) and extracted with DCM (2 x 100 ml). Column 
chromatography with 98 % DCM and 2 % TEA yielded 61 mg of a clear pink oil (13 %).  
IR (ATR, cm-1): 2950, 2929, 2856 (rhodamine), 1689 (amide), 1614, 1513 (NH bending), 1467 1219 
(xanthene) 1256 (Si-CH3), 1092 (Si-O-C(CH3)) δH (400 MHz, CDCl3): 0.04 (m, 6H, CH2Si), 0.87 (m, 9H, 
SiC(CH3)) 1.08- 1.16 (m, 18H, 12CH3, 6CH2), 1.33 (m, 2H, CH2), 3.09 (t, 2H, J= 7.3, CH2NH), 3.34 (q, 8H, 
J= 7.0, N(CH2)2) 3.48 (t, 2H, J= 6.6, CH2O), 6.26 (dd, 2H, J= 8.9, 2.6, xantheneH4,5), 6.38- 6.44 (m, 4H, 
xantheneH1,2,7,8), 7.06 (m, 1H, ArH6), 7.42 (m, 2H, ArH4,5), 7.89 (m, 1H, ArH3); δC (100 MHz, CDCl3): -
5.3 (CH3Si), 12.5 (CH3 xanthene), 25.3 (CH2), 25.9 (CH3), 26.9 (CH2), 28.1 (CH2), 32.6 (CH2), 40.3 
(CH2NH), 44.3 (CH2 xanthene), 63.2 (CH2O), 64.7 (C9 lactam), 97.5 (4/ 5 xanthene), 105.9 (2/7 
xanthene), 107.8 (8a/ 9a xanthene), 122.6 (Ar 3), 123.6 (Ar 6), 127.8 (Ar 4), 128.9 (Ar 2), 131.5 (Ar 1), 
132.0 (Ar 5), 148.6 (3/ 6 xanthene), 153.2 (4a/ 5a xanthene), 153.5 (1/ 8 xanthene), 167.9 (C=O); 
HRMS (NSI) (m/z), [M+H] calcd, for C40H58N3O3Si+ 656.4242 found 656.4230. 
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5.1.24 (6-Saligeninhexyl)carbamoyl Rhodamine B Phosphate 18 
 
To a stirring solution of rhodamine amidohexanol 15 (260 mg 0.44 mmol), and TEA (1 ml, 
13 mmol) in dry DCM (250 ml) at 0 oC, saligenin chlorophosphate 45 (270 mg, 1.32 mmol) 
dissolved in dry DCM (10 ml) was added dropwise. This was then left to stir for 24 hours. 
Upon completion, work-up proceeded with washes of water (2 x 100 ml) and brine (100 
ml), extraction with DCM (3 x 100 ml). The purified pink oil compound was achieved by 
chromatography on silica with toluene: acetone: TEA (1:1.9:0.1) and yielded with 34% 
(106 mg). IR (ATR, cm-1): 2970, 2934, 2929 (CH, rhodamine), 1682 (C=O, amide), 1613 
(C=C) 1513 (NH bending), 1017, 932 (P=O); δH (400 MHz, CDCl3): 1.06 -1.08 (m, 6H, CH2), 
1.16 (t, 12H, J= 7.0, CH3), 1.52 (m, 2H, CH2), 3.05 (t, 2H, J= 6.9, CH2NH), 3.33 (q, 8H, J= 6.9, 
CH2), 4.03- 4.10 (m, 2H, CH2OP), 5.29- 5.33 (m, 2H, CH2OP), 6.26 (dd, 2H, J= 8.8, 2.5, 
xanthene H4,5),  6.37 -6.42 (m, 4H, xanthene H1,2,7,8), 7.01 -7.12 (m, 4H, ArH6), 7.29 (m, 1H, 
OPArH), 7.41- 7.48 (m, 3H, ArH4,5), 7.89 (m, 1H, ArH3); δC (100 MHz, CDCl3): 12.5 (CH3 
xanthene), 24.7 (CH2), 26.3 (CH2), 27.8 (CH2), 29.7 (CH2, JAC= 7), 40.0 (CH2NH), 44.3 (CH2 
xanthene), 64.7 (C9 lactam), 68.4 (CH2O, JAC= 5), 68.8 (CH2O, JAC= 6), 97.5 (4/ 5 xanthene), 
105.8 (2/ 7 xanthene), 107.8 (8a/ 9a xanthene), 118.6 (CH1, JAC= 10), 122.6 (Ar 3), 123.7 (Ar 
6), 124.0 (CH2), 125.2 (CH3, JAC=) , 127.9 (Ar 4), 128.9 (Ar 2), 129.6 (C6), 131.5 (Ar 1), 132.1 
(Ar 5), 148.6 (3/ 6 xanthene), 153.3 (4a/ 5a xanthene), 153.4 (1/ 8 xanthene), 167.9 (C=O): 
δP (162 MHz, CDCl3): (s, -8.90ppm); HRMS (NSI) (m/z), [M+H] calcd, for C41H49N3O6P+ 
710.3353 found 710.3343. 
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5.1.25 (2-(2-Hydroxyethoxy)ethyl)carbamoyl) Rhodamine B 16 
 
Rhodamine B (1 g, 2.08 mmol), was added to a RBF with HBTU (0.79 g, 2.08 mmol) in dry 
DCM (250 ml), 2 ml (26 mmol) of TEA then follows. 2-(2-Aminoethoxy) ethanol (309 mg 
2.08 mmol) dissolved in dry DCM (10 ml) is then injected into the system and the reaction 
left for 12 hours. Water (100 ml) was then added and the phases separated. The organic 
phase was washed with water (2 x 100 ml), and brine (100 ml), and the aqueous phases 
were extracted with DCM (3 x 100 ml). After drying with MgSO4 and filtering, the resulting 
solution is purified with silica column chromatography with 49% acetone, 50% toluene 
and 1% TEA. The yield returned is 384 mg (35 %). 
IR (ATR, cm-1): 3374 (OH), 2967, 2924, 2870 (CH, rhodamine), 1686 (C=O, amide), 1613 
(C=C) 1513 (NH bending), 1116 (C-O); δH (400 MHz, CDCl3): 1.16 (t, 12H, J= 7.1, CH3), 3.18 
(t, 2H, J= 6.1, CH2NH), 3.32-3.36 (m, 12H, CH2), 3.58 (t, 2H, J= 4.5, CH2OH), 6.26 (dd, 2H, J= 
8.9, 2.4, xanthene H4,5),  6.37 -6.46 (m, 4H, xanthene H1,2,7,8), 7.05 -7.09 (m, 2H, ArH3), 
7.41- 7.45 (m, 2H, ArH4,5), 7.89 (m, 1H, ArH6); δC (100 MHz, CDCl3): 12.6 (CH3 xanthene), 
39.8 (CH2NH), 44.4 (CH2 xanthene), 47.0 (CH2OH), 61.6 (CH2O), 65.1 (C9 lactam), 72.1 
(CH2OH), 97.7 (4/ 5 xanthene), 105.4 (2/ 7 xanthene), 108.1 (8a/ 9a xanthene) 122.8 (Ar 
3), 123.8 (Ar 6), 128.1 (Ar 4), 128.9 (Ar 2), 131.0 (Ar 1) 132.6 (Ar 5), 148.8 (3/ 6 xanthene), 
153.3 (1/ 8 xanthene), 153.7 (4a/ 5a xanthene), 168.7 (C=O); HRMS (NSI) (m/z), [M+H] 
calcd, for C32H40N3O4+ 530.3013 found 530.2999. 
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5.1.26 (2-(2-Saligeninethoxy)ethyl)carbamoyl) Rhodamine B 48 
 
 
Compound 16 (384 mg, 0.72 mmol) was mixed in dry conditions with TEA (2 ml, 26 mmol), 
and dry DCM (250 ml). This synthesis follows the same technique as 5.1.24, with saligenin 
chlorophosphate being added dropwise (444 mg, 2.17 mmol). Work-up proceeded by the 
standard technique (2 x H2O, 1 x brine) and extracted with DCM. Acetone, toluene and 
TEA column yielded a very pale pink oil of about 151 mg (30%). IR (ATR, cm-1): 2970, 2925, 
2871 (CH, rhodamine), 1686 (C=O, amide), 1613 (C=C), 1513 (NH bending), 1116 (C-O), 
1018, 935 (P=O); δH (400 MHz, CDCl3): 1.14 (t, 12H, J= 7.0, CH3), 3.12 (t, 2H, J= 7.0, CH2NH), 
3.19-3.37 (m, 12H, CH2), 4.10 (m, 2H, CH2OP), 5.18- 5.39 (m, 2H, CH2OP), 6.22 (ddd, 2H, J= 
17.7, 8.9, 2.5, xanthene H4,5),  6.33 -6.41 (m, 4H, xanthene H1,2,7,8), 6.95- 7.05 (m, 3H, ArH3, 
OPCH1,2), 7.14- 7.26 (m, 2H, OPCH3,4), 7.40- 7.44 (m, 2H, ArH4,5), 7.87 (m, 1H, ArH6); δC (100 
MHz, CDCl3): 12.5 (CH3 xanthene), 39.1 (CH2NH), 44.3 (CH2 xanthene), 64.3 (C9 lactam), 
67.5 (CH2OP, JPC= 5), 68.5 (CH2O, JPC= 8), 69.03 (CH2OP, JPC= 6), 97.5 (4/ 5 xanthene), 105.3 
(2/ 7 xanthene), 107.9 (8a/ 9a xanthene), 118.6 (CH1, JPC= 9), 120.5 (CH4, JPC= 10), 122.6 (Ar 
3), 123.7(CH2), 123.9 (Ar 6), 125.2 (CH3), 127.9 (Ar 4), 128.8 (Ar 2), 129.4 (C6), 130.7 (Ar 1), 
132.3 (Ar 5), 148.6 (3/ 6 xanthene), 150.1 (JPC= 6, CO5), 153.2 (1/ 8 xanthene), 153.7 (4a/ 
5a xanthene), 168.2 (C CONH). δP (162 MHz, CDCl3): (s, -9.01ppm); HRMS (NSI) (m/z), 
[M+H] calcd, for C39H45N3O7P+ 698.2990 found 698.2987. 
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5.1.27 (2-(2-(2-Hydroxyethoxy)ethoxy)ethyl)carbamoyl) Rhodamine B 17 
 
Rhodamine B (1 g, 2.08 mmol), was added to a RBF with HBTU (0.79 g, 2.08 mmol), and 
dissolved in dry DCM (250 ml). TEA (2 ml, 26 mmol) was added and a solution of 2-[2-(2-
aminoethoxy) ethoxy] ethanol (309 mg, 2.70 mmol) dissolved in dry DCM (10 ml) was also 
injected into the system. The reaction was left for 12 hours before the phases were 
separated on addition of water (100 ml). Washes followed with water (2 x 100 ml), brine 
(100 ml) and then extraction with DCM (3 x 100 ml). After drying with MgSO4 and filtering, 
the resulting residue is purified via silica column chromatography with 49% acetone, 50% 
toluene and 1% TEA and returned the product 800 mg (67%). 
IR (ATR, cm-1): 3362 (OH), 2969, 2926, 2871 (CH, rhodamine), 1685 (C=O, amide), 1613 
(C=C) 1513 (NH bending), 1116 (C-O); δH (400 MHz, CDCl3): 1.14-1.16 (t, 12H, J= 7.03, 
CH3), 3.15 (t, 2H, J= 7.1, CH2NH), 3.28- 3.39 (m, 8H, CH2), 3.48- 3.52 (m, 8H, CH2), 
3.69-3.73 (t, 2H, CH2OH), 6.24 (dd, 2H, J= 8.8, 2.1, xanthene H4,5), 6.31- 6.42 (m, 
4H, xanthene H1,2,7,8), 7.01- 7.06 (m, 1H, ArH3), 7.37-7.42 (m, 2H, ArH4,5), 7.85-7.88 
(m, 1H, ArH6) ; δC (100 MHz, CDCl3): 12.6 (CH3 xanthene), 39.1 (CH2NH), 44.4 (CH2 
xanthene), 61.8 (CH2OH), 64.9 (C9 lactam), 67.8 (CH2O), 70.0 (CH2O), 70.4 (CH2O), 
72.5 (CH2O), 97.8 (4/ 5 xanthene), 105.8 (2/ 7 xanthene), 108.1 (8a/ 9a xanthene) 
122.8 (Ar 3), 123.8 (Ar 6), 128.0 (Ar 2), 128.9 (Ar 4), 131.0 (Ar 1) 132.4 (Ar 5), 148.8 
(3/ 6 xanthene), 153.3 (1/ 8 xanthene), 153.7 (4a, 5a xanthene), 168.4 (C=O); HRMS 
(NSI) (m/z), [M+H] calcd, for C34H44N3O5+ 574.3275 found 574.3267. 
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5.1.28 (2-(2-(2-Saligeninethoxy)ethoxy)ethyl)carbamoyl Rhodamine B 49 
 
Compound 17 (300 mg, 0.52 mmol) was dissolved in dry DCM (250 ml), with TEA (1 ml, 13 
mmol) also being added. Saligenin chlorophosphite solution 45 was added dropwise (80 
mg, 0.40 mmol) in dry DCM (10 ml) at -78 oC. The organic phase was washed with water (2 
x 50 ml), and brine (50 ml) and then extracted with DCM (3 x 50 ml). After drying, the 
compound was purified through a column of silica, 50% acetone in toluene, yielding 80 mg 
(27%). IR (ATR, cm-1): 2970, 2925, 2871 (CH, rhodamine), 1686 (C=O, amide), 1613 (C=C) 
1514 (NH bending), 1116 (C-O), ), 1019, 934 (P=O); δH (400 MHz, CDCl3): 1.15 (t, 12H, J= 
6.9, CH3), 3.15 (t, 2H, J= 7.3, CH2NH), 3.31-3.51 (m, 12H, CH2), 3.43 -3.46 (m, 2H, 
CH2), 3.63 (bt, 2H, J= 4.69, CH2), 4.19- 4.34 (m, 2H CH2OP), 5.21-5.44 (m, 2H, 
CH2OP), 6.26 (bt, 2H, J= 8.9, 2.5, xanthene H4,5), 6.37- 6.44 (m, 4H, xanthene 
H1,2,7,8), 6.99- 7.09 (m, 4H, ArH3, OPCH1,2,3), 7.24- 7.30 (m, 1H, OPCH3), 7.40- 7.44 
(m, 2H, ArH4,5), 7.87- 7.89 (m, 1H, ArH6) ; δC (100 MHz, CDCl3): 12.5 (CH3 xanthene), 
39.1 (CH2NH), 44.2 (CH2 xanthene), 64.7 (C9 lactam), 67.3 (CH2OP, JAC= 6), 67.7 
(CH2O), 68.6 (CH2OP, JAC= 7), 69.6 (CH2O), 69.8 (CH2O), 70.3 (CH2O), 97.6 (4/ 5 
xanthene), 105.4 (2/ 7 xanthene), 107.9 (8a/ 9a xanthene), 118.5 (CH1, JAC= 8), 
120.4 (CH4, JPC= 9), 122.5 (Ar 3), 123.7 (Ar 6), 124.0 (CH2), 125.2 (CH3, JAC= 3), 127.8 
(1/ 8 xanthene), 128.6 (Ar 2), 128.9 (Ar 4), 129.4 (C6), 130.8 (Ar 1) 132.3 (Ar 5), 
148.6 (3/ 6 xanthene), 149.9 (CO5, JPC= 9), 153.1 (4a/ 5a xanthene), 153.6 (1/ 8 
xanthene), 168.1 (C=O); δP (162 MHz, CDCl3): (s, -9.02ppm); HRMS (NSI) (m/z), [M+H] 
calcd, for C41H49N3O8P+ 742.3252 found 742.3246. 
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5.1.29 1,2,3,4-Tetrahydroquinolin-7-ol 87 
 
7-Hydroxy-3,4-dihydro-2-quinolinone (200 mg, 1.2 mmol), was dissolved in THF (20 ml), 
borane dimethylsulfide (9.8 ml, 2M in THF, 19.6 mmol) was then added and heated to 
reflux for 30 minutes. After this methanolic HCl (20 ml) was added and refluxed for a 
further 30 minutes. The solvent was evaporated, and residue washed with MeOH (3 x 10 
ml) to remove boric acid. Work-up then proceeded by dissolving the crude green oil in 
DCM (20 ml), water washes (2 x 20 ml) and brine (20 ml). Column chromatography with 
3:1 hexane and ethyl acetate yielded 100 mg (55%) of a clear oil. 
δH (400 MHz, CDCl3): 1.69 (m, 2H, CH2), 2.46 (t, 2H, J= 6.35, CH2NH), 3.09 (t, 2H, J= 
5.49, CH2Ar), 5.42 (br.s, 2H, OH, NH), 5.92 (m, 1H, ArH5), 5.99 (d, 1H, J= 2.4, ArH6), 
6.5 (d, 1H, J= 7.76, ArH8); Data consistent with the literature values. 143 
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5.1.30 (6-Hydroxyhexyl)-4-(pyren-2-yl)butanamide 83 
 
Pyrene butyric acid (200 mg, 0.7 mmol) was added to a RBF with HBTU (263 mg, 0.7 
mmol) and 6-aminohexanol (164 mg, 1.4 mmol), in dry DCM (200 ml). The reaction was 
cooled to 0 oC and TEA (2 ml, 26 mmol) was then added and the mixture allowed to stir for 
12 hours, warming to room temperature. Work-up followed with water (2 x 100 ml) and 
brine (100 ml), and extraction with ethyl acetate (3 x 100 ml). Column purification with 
ethyl acetate resulted in 210 mg (78.12 %) yield of a clear, pale orange waxy, crystalline 
solid. M.p. 143 -145 oC. IR (ATR, cm-1): 3379 (CH aromatic), 3308 (OH), 3040 (NH), 2931 
(CH alkane), 1638 (C=O), 1537 (C=C aromatic); δH (400 MHz, CDCl3): 1.24 -1.39 (m, 4H, 
CH2), 1.42 -1.56 (m, 4H, CH2), 2.19 -2.26 (m, 4H, CH2), 3.22 (q, 2H, J= 6.8 x3, CH2NH), 3.40 
(t, 2H, J= 7.3, CH2CO), 3.60 (t, 2H, J= 6.6, CH2OH), 5.36 (br.s, 1H, NH), 7.86 (d, 1H, J= 7.8, 
ArH), 7.97 -8.03 (m, 3H ArH), 8.10 -8.12 (m, 2H, ArH), 8.17 (dd, 2H, J= 8.0, 2.29, ArH), 8.30 
(d, 1H, J= 8.0, ArH); δC (CDCl3 100 MHz): 25.3, 26.5, 27.5, 29.7, 32.9, 32.6, 32.8 (CH2CO), 
36.1 (CH2 pyrene), 39.4 (CH2NH), 62.8 (CH2OH), 123.4 (C3a1), 124.8 (C5a1), 124.9 (C3), 
125.0 (C6), 125.1 (C8), 125.2 (C2), 125.9 (C7), 126.7 (C4), 127.4 (C5), 127.5 (C9), 128.8 
(C10), 129.9 (C3a), 130.9 (C5a), 131.4 (C8a), 134.5 (C10a), 135.8 (C1), 172.6 (CO); HRMS 
(NSI) (m/z), [M+H] calcd, for C26H30NO2+ 388.2271 found 388.2269. 
 
   
 187 
 
5.1.31 (6-Saligeninhexyl)-4-(pyren-2-yl)butanamide Phosphate 84   
 
 
(6-hydroxyhexyl)-4-(pyren-2-yl)butanamide 83 (200 mg, 0.51 mmol) is dissolved in THF 
and dry DCM (1:3) and cooled to -78 oC. Then TEA (2 ml, 26 mmol) was added followed by 
the dropwise addition of saligenin chlorophosphate 45 (350 mg, 1.71 mmol). The product 
was yielded after work-up with water, brine and extraction with DCM, proceeded by 
column chromatography with ethyl acetate. The resulting pale orange oil weighed 120 mg 
(42%). IR (ATR, cm-1): 3314 (CH aromatic), 3308 (OH), 3040 (NH), 2931 (CH alkane), 1644 
(C=O), 1542 (C=C aromatic) 1289 (P=O), 1014 (POC), 932 (P=O); δH (400 MHz, CDCl3): 1.23 -
1.42 (m, 6H, CH2), 1.59 -1.64 (m, 2H, CH2), 2.15 -2.25 (m, 4H, CH2), 3.15 (q, 2H, J= 6.8 x3, 
CH2NH), 3.34 (t, 2H, J= 7.3 x2, CH2CO), 4.12 (m, 2H, CH2OP), 5.24 -5.27 (mABX, 2H, POCH2), 
5.73 (br.s, 1H, NH), 6.97 -7.01 (m, 2H, ArH), 7.05 (td, 1H, J= 7.5, 0.9, ArH4), 7.25 (m, 1H, 
ArH5), 7.81 (d, 1H, J= 7.78, pyrene), 7.94 -7.99 (m, 3H, pyrene), 8.06 (m, 2H, ArH3), 8.13 (d, 
2H, J= 7.78, pyrene), 8.28 (d, 1H, J= 9.15, pyrene);  
δC (CDCl3 100 MHz): 24.8, 26.1, 27.6, 29.4, 30.1 (CH2, JPC= 7) 32.8 (CH2CO), 36.1 (CH2), 39.2 
(CH2NH), 68.6 (CH2OP, JPC= 8), 68.7 (POCH2, JPC= 6), 118.7 (CH1, JPC= 8), 120.7 (CH4, 10), 
123.5 (C3a1), 124.2 (C5a1), 124.8 (CH2 JPC= 4), 124.9 (C3), 125.0 (C6), 125.1 (C8), 125.3 (C2), 
125.9 (C7), 126.7 (C4), 127.4 (C5), 127.5 (C9), 128.8 (C10), 129.8 (C6), 129.9 (C3a), 130.9 
(C5a), 131.5 (C8a), 136.1 (C1), 150.2 (CO5, JPC= 6.7), 172.8 (CO);  
δP (CDCl3, 162 MHz): -8.79 ppm; HRMS (NSI) (m/z), [M+H] calcd, for C33H35NO5P+ 556.2247 
found 556.2235. 
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5.1.32 2-(4-(Pyren-2-yl)butoxy)saligenin Phosphate 85 
 
Pyrene butanol (200 mg, 0.73 mmol), was dissolved in dry DCM (200 ml), and (1 ml, 13 
mmol) TEA. At 0 oC, saligenin chlorophosphate 45 was added (300 mg, 1.46 mmol). After 
warming to room temperature over 12 hours, water (100 ml) was added and the phases 
separated then the organic phase is washed with water (2 x 100 ml) and brine (100 ml). 
Extraction of the aqueous fraction with ethyl acetate (3 x 100 ml), drying with MgSO4 and 
filtering gives the yellow crude oil. This is purified with ethyl acetate on a silica column 
giving a pale-yellow oil, 76 mg (24%). IR (ATR, cm-1): 3673 (CH aromatic), 2936 (CH alkane), 
1457 (C=C aromatic), 1294 (P=O), 1016 (POC), 932 (P=O); δH (400 MHz, CDCl3): 1.84 -1.88 
(m, 4H, CH2), 3.33 (t, 2H, J= 7.2, CH2NH), 4.27 (m, 2H, CH2OP), 5.21 -5.29 (m, 2H, POCH2), 
6.91 -7.03 (m, 2H, ArH), 7.17 -7.26 (m, 1H ArH), 7.79 (d, 2H, J= 7.8, pyrene), 7.97 -8.21 (m, 
7H, pyrene); δC (CDCl3 100 MHz): 27.6 (CH2), 30.2 (CH2, JPC =6), 32.9 (CH2pyrene), 68.6 
(POCH2, JPC= 7), 68.8 (CH2OP, JPC= 6), 118.8 (CH1, JPC =8), 120.6 (CH, JPC =10), 123.3 (C3a1), 
124.2 (CH2), 124.8 (C5a1), 124.9 (C3), 125.0 (C6), 125.1 (C2), 125.3 (CH3), 125.9 (C7), 126.8 
(C4), 127.3 (C5), 127.4 (C9), 127.6 (C10), 128.6 (C6 JPC =5), 129.7 (C3a), 129.9 (C5a), 130.9 
(C8a), 131.5 (C10a), 136.1 (C1), 150.2 (CO5, JPC =7), 187.4 (C=O); δP (CDCl3, 162 MHz): -8.76 
ppm; HRMS (NSI) (m/z), [M+H] calcd, for C27H24NO4P+ 443.1407 found 443.1399. 
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5.1.31 6-Hydroxyhexylamino-4-benzophenone 118 
 
6-Aminohexan-1-ol (250 mg 2.16 mmol) was dissolved in dry DMF (50 ml) and cooled to -
78 oC. Into this RBF, potassium tert-butoxide followed (242 mg, 2.16 mmol). A solution of 
4-bromomethylbenzophenone (594 mg, 2.16 mmol) was then added dropwise. The 
mixture turned black rapidly and was left to warm to room temperature over 6 hours. The 
solution was then diluted with ethyl acetate, worked-up with washes of water (6 x 100 
ml), LiCl (3 x 100 ml), and brine (3 x 100 ml). The aqueous phase was extracted with ethyl 
acetate (3 x 100 ml), dried and concentrated. Column chromatography with 1% TEA in 
ethyl acetate yielded the product, 200 mg (30%). δH (400 MHz, CDCl3): 1.26- 1.39 (m, 4H, 
CH2), 1.43- 1.53 (m, 4H, CH2), 2.57 (t, 2H, J= 7.2, CH2NH), 3.55 (t, 2H, J= 6.5, CH2OH), 3.79 
(s, 2H, CH2Ar), 7.35- 7.43 (m, 4H, ArH), 7.49- 7.53 (dt, 1H, J= 7.4, 1.26, ArH), 7.69- 7.73 (m, 
4H, ArH); δc (100 MHz, CDCl3): 25.7, 27.1, 30.0, 32.7 (4 x CH2), 49.5 (CH2NH), 53.7 (CH2Ar), 
62.8 (CH2OH), 127.9, 128.35, 130.0, 130.4, 132.4 (5 x CH), 136.3 (C, Ar-Me), 137.8, 145.4 (2 
x CCO ), 196.4 (C=O); HRMS (NSI) (m/z), [M+H] calcd, for C20H26NO2+ 312.1958 found 
312.1959. 
  
 190 
 
5.1.32 TBDMS-6-hydroxyhexylamine 40 
 
6-Aminohexanol (100 mg, 0.85 mmol) was dissolved in dry DMF (15 ml). Into it a small amount of 
catalytic DMAP and TBDMSiCl (150 mg, 0.99 mmol) was also added. TEA (1 ml, 13 mmol) was then 
injected and the reaction was left for 72 hours. Ethyl acetate was added, and the reaction mixture 
was washed with water (6 x 100 ml), LiCl (3 x 100 ml), and brine (3 x 100 ml). The aqueous phase was 
extracted with ethyl acetate (3 x 100 ml), dried and concentrated. This was purified by silica column 
in 1% TEA /ethyl acetate mix, yielding 100 mg (51%). δH (400 MHz, CDCl3): 0.02 (s, 6H, (CH3)2Si), 0.86 
(s, 9H, CH3), 1.29- 1.49 (m, 8H, CH2), 3.17 (t, 2H, J= 5.9, CH2NH), 3.55 (t, 2H, J= 6.6, CH2OH); Data 
consistent with the literature values.221 
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5.1.33 4-Methylbenzophenone-6-O-TBDMS-hexylamine 119 
 
TBDMS-6-hydroxyhexylamine (500 mg, 2.1 mmol), and potassium tert-butoxide (360 mg, 3.2 mmol) 
were dissolved in dry DMF (50 ml) and cooled to -78 oC. 4-bromomethylbenzophenone (594 mg, 2.1 
mmol), solution was then added dropwise and the solution turned black, then allowed to warm to 
room temperature over 12 hours. The solution was then diluted with ethyl acetate, worked-up with 
washes of water (6 x 100 ml), LiCl (3 x 100 ml), and brine (3 x 100 ml). Column chromatography with 
ethyl acetate and 1% TEA awarded 265 mg (30%) oily product. δH (400 MHz, CDCl3): 0.00 (s, 6H, 
(CH3)2Si), 0.84 (s, 9H, CH3), 1.25- 1.28 (m, 4H, CH2), 1.42- 1.54 (m, 4H, CH2), 2.61 (t, 2H, J= 7.3, 
CH2NH), 3.55 (t, 2H, J= 6.3, CH2OH), 3.85 (s, 2H, CH2Ar), 7.38- 7.43 (m, 4H, ArH), 7.48- 7.52 (m, 1H, 
ArH), 7.70 (d, 4H, J= 8.3, ArH); δc (100 MHz, CDCl3): -5.2 (CH3),  25.7, 26.3 (CH3) 27.1, 29.4, 32.8 (4 x 
CH2), 49.1 (CH2NH), 53.2 (CH2Ar), 63.1 (CH2OH), 128.3, 130.0, 130.4, 132.4 (5 x CH), 136.5 (C, Ar-Me), 
137.6, 143.9 (2 x CCO), 170.3 (CCH3), 196.4 (C=O). 
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5.1.34 TBDPS-6-hydroxyhexylamine 39 
 
6-Aminohexanol (1 g, 8.53 mmol) of was dissolved in of dry DMF (50 ml), and a small amount of 
catalytic DMAP was added along with TBDPSiCl (2.35 g, 8.53 mmol). TEA was then added (2 ml, 26 
mmol) and then left for 72 hours. The mixture was then diluted with ethyl acetate, worked-up with 
washes of water (6 x 100 ml), LiCl (3 x 100 ml), and brine (3 x 100 ml). An ethyl acetate column 
doped with 1% TEA achieved the purified product. 1.36 g (45%). δH (400 MHz, CDCl3): 1.04 (s, 9H, 
CH3), 1.26- 1.59 (m, 8H, CH2), 2.67 (t, 2H, J= 7.2, CH2NH), 3.55 (t, 2H, J= 6.5, CH2OH), 7.35- 7.43 (m, 
6H, ArH3,4,5), 7.65- 7.67 (m, 4H, ArH2,4). Data consistent with the literature values.222 
 
 
  
 193 
 
5.1.35 N-(6-hydroxy-hexyl)-5-dimethylamino-naphthalene-1-sulfonamide 46 
 
A flask was charged with dansyl chloride (1 g, 3.71 mmol), and dissolved in dry DCM (250 ml). 
Cooling to 0 oC proceeded the addition of DMAP (cat), and TEA (2 ml, 26 mmol). After 15 minutes, 6-
aminohexanol (500 mg, 4.3 mmol) was added. The whole mixture then returned to room 
temperature over 4 hours. Work-up procedure consisted of washes with water (3 x 100 ml) and 
brine (100 ml), followed by extraction with DCM (3 x 100 ml). After drying with MgSO4 and filtering, 
the crude residue was analysed by 1H NMR and found to be of an acceptable purity for the next 
reaction. (1.2 g, 92%). δH (CDCl3, 400 MHz): 1.10 -1.13 (m, 4H, CH2), 1.30 -1.37 (m, 4H, CH2), 2.33 
(br.s, 1H, OH), 2.84 -2.89 (m, 9H, N(CH3)2), 3.46 (t, 2H, J= 6.5, CH2OH), 5.51 (t, 1H, J= 6.1, SO2NH), 
7.14 (d, 1H, J= 7.3, ArH6), 7.49 (q, 2H, J= 7.8, ArH7,8), 8.21 (dd, 1H, J= 7.3, 1.14, ArH3), 8.33 (d, 1H, J= 
8.7, ArH2), 8.52 (d, 1H, J= 8.5, ArH4); Data is consistent with previous work.67 
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5.1.36 N-(6-hydroxysaligeninposphate-hexyl)-5-dansyl-sulfonamide 10 
 
A solution of N-(6-hydroxy-hexyl)-5-dimethylamino-naphthalene-1-sulfonamide (200 mg, 0.57 mmol) 
in dry DCM (100 ml) was added (1 ml, 13 mmol) TEA and cooled to -78 oC. Saligenin chlorophosphite 
solution 45 (174 mg, 0.85 mmol) in dry DCM (10 ml) was added dropwise, this was left stirring to 
warm to room temperature for 24 hours. The mixture was concentrated in vacuo, and then 
dissolved in cold toluene (0 oC). This was left at 4 oC for 1 hour before being filtered and 
concentrated. Column chromatography on silica with ethyl acetate yielded the resultant orange oil 
110 mg (22%). δH (400 MHz, CDCl3): 1.08 (m, 4H, CH2), 1.27 (t, 2H, J= 7.2, CH2), 1.46 (t, 2H, J= 7.2, 
CH2), 2.78 (t, 2H, J= 6.8, CH2NH), 2.85 (s, 9H, N(CH3)2), 4.10 (m, 2H, CH2OP), 5.34 (m, 2H, POCH2), 6.97 
(d, 1H, J= 8.2, ArH1), 7.01- 7.07 (m, 2H, ArH2,3), 7.17 (d, 1H, J= 7.5, CH6 dansyl), 7.22 -7.26 (m, 1H, 
ArH4), 7.44 -7.51 (m, 2H, CH7,8 dansyl), 8.18 (d, 1H, J= 7.3, CH3 dansyl), 8.28 (d, 1H, J= 8.7, CH2 
dansyl), 8.48 (d, 1H, J= 8.5, CH4 dansyl); δP (162 MHz, CDCl3): -8.9. Data is consistent with previous 
work.67 
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5.1.37 Benzyl(2-chloro-6-nitrophenyl)sulfane 112 
 
1,2-Chloro-3-nitrobenzene (10 g, 52 mmol) was dissolved in ethanol (100 ml). After 3 hours of 
refluxing this mixture was added to a solution of benzyl chloride (6 ml, 50 mmol), thiourea (4 g, 50 
mmol), ethanol (10 ml) and water (10 ml) and some catalytic ammonia. Potassium hydroxide 
solution (7.0 g/ 50 ml H2O) was added dropwise then refluxed for further 2 hours. The mixture was 
then cooled in an ice bath and the precipitate containing the 2-(benzylsulfanyl)-1-chloro-3-
nitrobenzene then collected as a yellow solid with a 77% yield. This was brought forward to the next 
step in a crude state. 
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5.1.38 2-Chloro-6-nitrobenzenesulfonamide 112 
 
Gaseous chlorine gas was generated from HCl (10 g, 0.27 mol) dropped onto potassium 
permanganate (2 g, 0.01 mmol) in a twin-necked flask. The chlorine was bubbled through a solution 
of 2-(benzylsulfanyl)-1-chloro-3-nitrobenzene (600 mg, 1.8 mmol) in acetic acid (12 ml) and water (3 
ml) at room temperature for 30 minutes. This was then poured onto ice (ca. 50 g), extracted with 
diethyl ether, dried with MgSO4 and concentrated under reduced pressure. The resulting orange oil 
was then dissolved in dioxane (5 ml) and a volume of 30% solution of aqueous ammonia (10 ml) until 
completely dissolved. This solution was then treated with charcoal, filtered, and using 6M HCl, 
adjusted to pH 3. A precipitate then forms which was collected in a 28% yield. M.p. = 127 – 132 oC 
Data consistent with the literature values. 120 
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5.1.39 2-Amino-6-chlorobenzenesulfonamide 114 
 
The 2-chloro-6-nitrobenzenesulfonamide 113 (100 mg, 0.42 mmol) was dissolved in 1:1 mix of hot 
ethanol and water (5 ml), with ammonium chloride (80 mg, 1.5 mmol) and a spatula full of iron 
powder (ca. 200 mg), and refluxed for 45 minutes. This was filtered and concentrated, then 
extracted with DCM (3 x 50 ml), then dried and concentrated once more. Addition of hexane (10 ml) 
causes precipitation which is collected under gravity and washed with ice cold hexane, to yield 43 
mg of light brown powder with a 50% yield. δH (CDCl3, 400 MHz): 6.72 (m, 1H, Ar-H), 7.06 (d, 1H, Ar-
H), 7.41 (m, 1H, J= 7.9,  Ar-H), Data consistent with the literature values.120 
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5.1.40 4-(8-Chloro-1,1-dioxido-4H-benzo[e][1,2,4]thiadiazin-3-yl)butanoic Acid  109 
 
2-Amino-6-chlorobenzenesulfonamide (1 g, 4.84 mmol) was dissolved in dioxane (10 ml). Glutaric 
acid monomethyl ester chloride (1.2 ml, 8.64 mmol) was then added and allowed to stir at room 
temperature for 1 hour. The mixture was concentrated in vacuo, and dissolved in a 3% sodium 
hydroxide solution (10 ml) and stirred for 1 hour further. Precipitate forms when acidified with 2 M 
HCl and continues forming when it is left overnight. The product is then filtered and washed in 
diethylether to yield 614 mg (42%) diazoxide 109. M.p. 208-210 oC; δH (CDCl3, 400 MHz): 2.01 (m, 2H, 
CH2) 2.42 (t, 2H, J= 7.2, CH2), 2.65 (t, 2H, J= 7.5, CH2), 7.24 (d, 1H, J= 8.2, ArH), 7.39 (d, 1H, J= 7.8, 
ArH), 7.55 (t, 1H, J= 8, ArH), 11.04 (br.s, 1H, NH); Data is consistent with data from the previous 
work.67 
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5.1.41 5 /6-Carboxy-X-rhodamine 91 /92 
 
Trimellitic anhydride (230 mg, 1.2 mmol) was dissolved in ethanoic acid (20 ml). 8-hydroxyjulolidene 
(450 mg, 2.4 mmol) was subsequently dissolved in dioxane (10 ml). Both solutions were added to a 
RBF with 2 drops of catalytic, concentrated HCl. This was refluxed for 12 hours and the solution 
turned from an orange colour to a dark red. Mixture was diluted with DCM (50 ml), followed by 
washing with water (2 x 100 ml) and brine (100 ml). The resultant blue residue from drying with 
MgSO4 and concentrating was purified. The product of the column was then further refluxed for 6 
hours with 8-hydroxyjulolidene (400 mg, 2.1 mmol), in dioxane /ethanoic acid (20 ml) with 2 more 
drops of conc. HCl. After work-up by the same technique the black residue was purified by column 
chromatography (DCM 1% MeOH) to yield both the 5, and 6-carboxy-X-rhodamine as dark purple 
oils 155 mg (24%) yield and 218 mg (33%).  
5-Carboxy-X-rhodamine δH (MeOD, 400 MHz): 1.74- 1.80 (m, 4H, CH2), 1.84- 1.88 (m, 4H, CH2), 2.35 
(m, 4H, CH2) 2.57 (m, 4H, CH2), 3.16 (m, 4H, CH2), 3.26 (dt, 4H, J= 3.26, 1.69, CH2), 6.34 (s, 2H, CH),  
7.26 (m, 1H, Ar-H), 8.08 (dd, 1H, J= 7.8, 1.72,  Ar-H), 8.52 (s, 1H, Ar-H);  
6-Carboxy-X-rhodamine δH ((CD3)2CO, 400 MHz): 1.89- 1.90 (m, 4H, CH2), 2.05 (m, 4H, CH2), 2.65 (m, 
4H, CH2) 2.99 (m, 4H, CH2), 3.30 (m, 4H, CH2), 3.49 (m, 4H, CH2), 6.69 (s, 2H, CH), 7.79 (s, 1H, Ar-H), 
8.20 (d, 1H, J= 7.9, Ar-H), 8.69 (d, 1H, J= 6.4, Ar-H); Data consistent with the literature values. 156 
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5.1.42 1,3,7,9-Tetramethyl BODIPY 60 
 
 
As a by-product of the synthesis of BODIPY FL ethyl ester 58 the reaction technique is the 
same as 5.1.12. 3-(1H-pyrrol-2-yl)propanoate (200 mg, 1.20 mmol) and 3,5-dimethyl-1H-
pyrrole-2-carboxaldehyde (160 mg, 1.3 mmol) then phosphorus oxychloride (200 mg, 0.12 
ml, 1.32 mmol) in DCM (2 ml) was added at 0 oC and stirred for 2 hours. Boron trifluoride 
etherate (0.6 ml, 4.82 mmol) and DIEA (0.88 ml, 5.04 mmol) follows and left stirring for 12 
hours. After the standard work-up procedure the crude product was purified by flash 
chromatography (silica, DCM) to give the resulting product as bright red crystals, yielding 
35 mg, (7%). δH (400 MHz, CDCl3): 2.35 (s, 3H, CH3), 2.65 (s, 3H, CH3), 6.16 (s, 2H, CH2,6), 
7.06 (s, 1H, CH4).  
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5.2 Synthetic Techniques 
5.2.1 General Techniques 
The glassware for reactions performed under anhydrous conditions was dried in an oven at ca. 
100oC. When needed, nitrogen gas is introduced and the glassware allowed to cool to room 
temperature before addition of reagents. All needles and syringes were used either fresh out of the 
plastic package, or dried glass syringes and metal needles were utilised. Reagents sensitive to air and 
moisture were transferred via syringe. Solutions in organic solvents were concentrated on a rotary 
evaporator and vacuum pump.  
All solvents were bought as analytical grade from either Fisher Scientific, or Sigma Aldrich and 
required no further purification. Solvents were kept dry in an MBraun MB SPS-800 solvent drier or 
distilled over MgSO4 and stored on drying beads (heated overnight >100oC in oven) in a sealed 
bottle.  
5.2.2 Column Chromatography 
Column chromatography was performed using Fluorochem silica gel (60A, 40 ± 63 micron). The silica 
gel was mixed in solvent to a slurry then poured into a glass column. The samples were then 
dissolved in solution and pipetted onto the surface of the silica, or absorbed onto dry silica, dried in 
vacuo, then the powder poured onto the top of the slurry in column. An electric pump was then 
used to apply pressure.  
For purification utilising warm glassware and solvents care is needed when heating flammable 
solvent. The mix was warmed gently on a low setting heat gun until evaporation of solvent started. 
Glassware only needed to be at > 50 oC, and the technique was performed in a fume hood to vent 
solvent vapour. 
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5.2.3 NMR Spectroscopy 
Hydrogen, carbon, fluorine and phosphorous, (1H NMR, 13C NMR, 19F NMR, 31P NMR), NMR spectra 
were measured on a Jeol ECX 400 spectrometer at 400 MHz, 100 MHz, 376 MHz and 162 MHz 
respectively. Results of the chemical shifts corresponding to each species are reported in parts per 
million (ppm), and coupling constants (J) are given in Hertz (Hz). Abbreviations for the multiplicity of 
proton data are as follows: s = singlet, d = doublet, dd = doublet of doublets, dt = doublet of triplets, 
t = triplet, tt = triplet of triplets, q = quintet, m = multiplet, br = broad. Assignments were based on 
HMQC, COSY and HMBC experiments. Phosphorous NMR’s determined with aid from Olaf Kühl 
Phosphorous-31 NMR spectroscopy.223 
 Solvent peaks listed are used as a reference value:  
Solvent 1H NMR 13C NMR 
CDCl3 7.27 ppm 77.00 ppm 
CD3OD 3.31 ppm 49.0 ppm 
(CD3)2SO 2.50 ppm 39.5 ppm 
 
5.2.4 Mass Spectrometry 
Mass spectrometry (MS) spectra were recorded at high resolution by the EPSRC National Mass 
Spectrometry Service Centre, School of Medicine, Swansea University.   
5.2.5 IR Spectrometry 
Infrared (IR) absorption spectra were measured with a Perkin Elmer Spectrum 100 FT-IR 
Spectrometer using an ATR attachment, and are reported in cm1. 
5.2.6 Fluorimetry 
All fluorimetry experiments occurred on a Cary Eclipse 3, with a scan rate of 600 nm/min, a data 
interval of 1.0000 nm, and average time of 0.1000 s. PMT voltage was medium, excitation filter on 
auto and emission filter auto. Excitation and emission slits width was set to at 5 nm, unless 
otherwise stated. The machine was controlled between each reading using a sample of distilled 
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water. All samples were measured in triplicate in a quartz fluorimetry cuvette with a path length of 1 
cm. the volume of all samples in cuvette was 3.5 cm3.  
5.2.7 UV-Vis Spectrometry 
The UV absorptions and emissions were measured by using an Agilent Technologies Cary 8454 UV-
Vis, at a range of wavelength from 150-1150 nm. All samples were measured in triplicate in a quartz 
cuvette with a path length of 1 cm. 
5.2.8 Thin Layer Chromatography 
Thin-layer chromatography (TLC) was carried out using silica plates in duran jars with various solvent 
mixes contained. The plates are UV-active and substances were detected with either short wave or 
long wave UV light. They are then made visible (if not already), by dipping into a container with 
iodine on silica, ninhydrin solution, phosphomolybdic acid (PMA) or potassium permanganate 
solution. 
5.3 Biological Techniques 
5.3.1 H9c2 Cell Culture 
H9c2 (rat embryonic cardiomyoblast-derived) cells were obtained from the European Collection of 
Animal Cell Cultures (Porton Down, Salisbury, UK). Mitotic cells were cultured in 25 cm2 cell culture 
flasks in Dulbecco’s modified Eagle’s Medium (DMEM) containing 10 % (v/v) foetal bovine serum 
(FBS), 2 mM L-glutamine, penicillin (100 U/ml) and streptomycin (100 µg/ml). These cultures were 
maintained in an incubator at 37°C with a controlled atmosphere of 95 % air/5 % CO2 until 80% 
confluent. Cells were then detached using trypsin (0.05 % w/v)/EDTA (0.02 % w/v) in sterile 
phosphate buffered saline (PBS). They were distributed into n-well plates appropriate for further 
testing. Remaining cells then re-cultured in 25 cm2 flasks. 
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5.3.2 H9c2 Cell Differentiation 
Differentiation of H9c2 cells was induced by culturing the cells for 7 days in the continued presence 
of 10 nM retinoic acid in DMEM growth medium with 1 % (v/v) FBS. The differentiation medium was 
replaced every 48 h. The cells were observed to form multinucleated elongated myotubes, 
consistent with the structure of a cardiomyocyte.  
5.3.3 Cell Lysis 
After the cell culture and differentiation period as described above the cells were ready to be lysed. 
Cells were lysed using boiling lysis solution (300 µl 0.5 % (w/v) SDS solution in TBS (20 mM Tris base, 
150 mM NaCl). To gather the cells and ensure complete lysis the surface of the T25 flasks were 
scraped using a scraper. Eppendorf tubes (2 ml), were then filled with the lysate and boiled for 10 
min. The samples were then stored for future use at -20oC.  
5.3.4 Protein Estimation 
The protein content of the lysates was calculated using 2 different techniques. The first, is a 
modification of the Lowry method224 by Bio-Rad called DC Protein assay. Samples of cell lysates (5 μl) 
were added to a 96 well plate, 25 µl of assay reagent A’ (20 µl of reagent S and 1 ml of reagent A), 
and 200 µl assay reagent B were then added to the wells. The samples were incubated in the dark 
with gentle agitation for 30 minutes at room temperature. Then the absorbance was read at 620 nm 
using a standard 96 well plate reader CLARIOstar (BMG Labtech). To calculate the protein content of 
the samples, the results were compared to the absorbance reading with a standard curve plotted 
from the results of BSA standards.  
The second technique employed to estimate protein concentration was the bicinchoninic acid 
protein assay (BCA).225 Firstly the BCA working reagent was per the manufacturer’s instructions by 
mixing 50 parts reagent A with 1-part reagent B (6 ml of A and 0.12 ml B). Unknown samples were 
diluted 1:10, 1:50 and 1:250 and loaded into a 96 well plate in triplicate. 200 µl of BCA standard 
working reagent was then added and in the dark at 37oC the plate was incubated. 30 minutes later 
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the plate was read at 570 nm and the absorbance values plotted against the standard curve. As in 
the Lowry method BSA standards are used for a standard curve. 
5.3.5 MTT Reduction Assay 
Differentiated H9c2 cells in culture were assessed for viability proportional to metabolism using the 
MTT assay. Addition of 15,000 cells per well of undifferentiated H9c2 cells were seeded in 24-well 
cell culture plates. This was incubated overnight at 37°C in complete DMEM growth medium. Cells 
were then induced to differentiate for several days using the differentiation method in 5.3.2. They 
were treated in accordance to the particular experiment being undertaken. The cell plates were 
incubated for 1 h in 0.5 mg/ml MTT solution in DMEM at 37°C.  The medium was aspirated from 
each well, leaving blue, insoluble formazan crystals at the bottom of each well. 500 μl of DMSO 
(dimethyl sulphoxide) was added to dissolve formazan crystals. 200 μl of the resulting solution was 
transferred into a 96-well plate and the absorbance was read at 570 nm using a standard 96-well 
plate reader CLARIOstar (BMG Labtech). After subtracting the blank absorbance from each assay, the 
magnitude of the MTT reduction determined by the absorbance at 570 nm is proportional to cell 
viability. 
5.3.6 Lactate Dehydrogenase Assay 
LDH (lactate dehydrogenase) assay was performed using the CytoTox 96® non-radioactive cytotoxic 
assay kit (Promega). This kit allows LDH release to be measured via production of a coloured 
formazan product. The first reaction allows released LDH from cells to catalyse the formation of 
pyruvate and NADH from lactate and NAD+. The second reaction occurring, is the catalyses of NAD+ 
(from NADH) and a red coloured, formazan product (from a tetrazolium salt) by the dehydrogenase 
enzyme diaphorase (present in the substrate mix in kit). A standard plate reader measuring 
absorbance at 490 nm, shows that LDH release is proportional to the red formazan product.  
H9c2 cells were cultured for 24h in complete DMEM growth medium with 5000 cells/well, in a 96 
well plate. The cells were then allowed to differentiate over several days in differentiation medium 
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as described above. Treatment was then performed in 200 μl of complete medium with appropriate 
concentrations of treatment. The well plate was centrifuged to compact cellular debris and 50 μl of 
supernatant was then transferred to a non-sterile 96 well plate. Reconstituted assay buffer (50 µl, 
from kit, 10 ml assay buffer added to one bottle of substrate mix) was added to each well, then 
incubated in the dark for 30 min at room temperature with gentle agitation. The reaction was 
quenched with 50 μl of assay stop solution (1M acetic acid).  
5.3.7 SDS-PAGE 
A protein solution containing 75 μl of each sample suspended in 25 μl of 4x Laemmli buffer226 is 
boiled for 10 min. 10% (w/v) polyacrylamide gels of 0.75 mm thickness (Resolving gel; 5.9 ml 
deionised water, 5ml ProtoGel® 30% acrylamide mix, 3.8ml of 1.5 M TRIS-HCL pH 8.8, 0.15ml SDS 
solution ( 10 % (w/v) sodium dodecyl sulphate in deionised water) 0.15ml APS solution ( 10 % (w/v) 
ammonium persulfate in deionised water), 1 µl/ml TEMED) were cast using a Bio-Rad Mini-Protean 
III system with a layer of stacking gel on top, (Stacking gel; 3.4ml deionised water, 0.83 ml ProtoGel® 
acrylamide mix, 0.63 ml 1.0 M TRIS-HCL pH 6.8, 0.05 SDS solution, 0.05 APS solution and 0.005ml 
TEMED). Loaded into the wells on the gel was 40 µg of each sample dissolved in buffer, and 5 μl of 
protein ladder (Precision Plus Protein™ dual standards, BioRad). Electrophoresis was then performed 
at 200 V for 45 min, with the gels submerged in 1x electrophoresis buffer (2.5 mM TRIS, 19.2 mM 
glycine, 0.01 % (w/v) SDS, pH 8.3). The migration of the proteins could be observed due to the dye 
movement. Once protein separation was achieved the gels were removed from the electrophoresis 
tank and from the glass casting frames. They were then fixed for visualisation by incubating with 20 
ml of a solution of 40% (v/v) methanol, 10% (v/v) acetic acid and 50% (v/v) distilled water at room 
temperature for 15 minutes with gentle agitation. 
5.3.8 Irradiation of Samples 
Mitochondrial extracts (50 µl) were added to 49 µl of tris-buffered saline (TBS) (50 mM Tris-Cl, pH 
7.6; 150 mM NaCl), and 1 µl of desired concentration of diazoxide analogue. This was incubated for 
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ca. 30 minutes, then divided into two 50 µl aliquots. One aliquot is then centrifuged for 14,000g/20 
minutes and re-suspended in 50 µl TBS. The samples are then pipetted into an optical 384 well plate 
(nunc), and irradiated on a transilluminator at ca. 360 nm for 10 minutes. The samples were then 
added to 3.6 µl of 4x Laemmli buffer for SDS-PAGE processing. 
5.3.9 2D Gel Electrophoresis 
Protein samples can be identified using MALDI-TOF MS/MS with a greater level of accuracy after 
running samples through 2D gel electrophoresis. This separates cellular proteins by two parameters, 
molecular weight and isoelectric point (pH). After irradiation, the sample was re-suspended 300 µl 
urea lysis buffer (8 M urea, 50 mM DTT, 4 % (w/v) CHAPS, 0.2 % (v/v) Biolite® ampholytes (pH 3-10) 
(Biorad®), in deionised water). Acetone was then added (1800ul) to allow the protein to precipitate, 
this was incubated at -20 °C for 15 hours. The lysate-acetone mixture forms a visible precipitate, this 
was then centrifuged at 10,000 RCF for 10 minutes at 4 °C to gather the proteins into a pellet. The 
pellet was then covered and left to dry out for 1 h in a fume cupboard. 300 µg of protein was 
suspended in 120 µL rehydration buffer (pH 3-10). The 120 µl sample was transferred into an IEF 
focusing tray, ensuring an even spread on the bottom of the tray with the liquid making contact with 
both anode and cathode wires. A 7 cm 3-10 pH IGP ReadyStrip™ (Biorad) was positioned on top of 
the protein sample, ensuring correct orientation and full contact with the protein sample without 
bubbles. The samples were left for one hour so it could be absorbed into the IPG gel. Active 
rehydration at 50 V for 16 h then occurs using a Protean IEF Cell (Biorad). A layer of mineral oil was 
poured on top of the IPG strip to prevent buffer evaporation. After rehydration IEF system electrode 
wicks (Biorad) were inserted in-between the IPG strip and the top of the electrodes in the focusing 
tray, these function to remove excess salts and ensure an effective focusing. The IPG strips were 
focused with the following protocol, which separates the proteins in the 1st dimension; a linear 
voltage slope, up to 250 V was utilised for 20 min. Following this, a second linear voltage slope 
increasing to 4000 V was applied for 2 h. A rapid voltage slope to 4000 V for 10,000 Volt hours was 
then employed, before a final rapid voltage slope down to 500 V was applied to the gel for 25 h. 
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After focusing, the IPG strips were prepared for running in the second dimension. The IPG strips 
were placed in an equilibration tray and 2500 µl of equilibration buffer 1 was added for 10 min at 
room temperature with gentle agitation. Buffer 1 was then substituted with 2500 µl equilibration 
buffer 2 and incubated at room temperature for 10 min with gentle agitation.  
The strips were then positioned on top of a 15 % SDS acrylamide gel. A small piece of filter paper 
was soaked in a mixture of 10 % protein ladder (Precision Plus Protein™ dual standards, BioRad) and 
90% 4x Laemmli buffer and placed at the side of the IPG strip to allow for molecular weight 
comparison. The second-dimension separation was then carried out by electrophoresing the gel at 
200 V for 45 min, in an electrophoresis tank containing 1 x electrophoresis buffer. The bromophenol 
blue present in the IPG strips allowed for visible tracking of the dye to ensure optimal separation of 
protein.  After electrophoresis the gels were removed and washed for 5 min three times in deionised 
water. The gels could then be fixed and visualised. 
5.3.10 Visualisation of Gels 
Imaging of gels utilised three different imagers. The Syngene U:Genius3 was used for any gels 
requiring UV light to excite bands. Fujifilm FLA-4000 was used for green / blue LED side lamps and 
white light imaging. Fujifilm 5000 contains the 473 nm (blue light), 532 nm (green light) and 685 nm 
(red light) lasers. The gels were placed onto the sample platforms, and then scanned according to 
manufacturer’s guidelines. 
5.3.11 Extraction of Mitochondria from Rat Liver 
Rat livers were harvested from freshly slaughtered rats and kept on ice until ready for fractionating. 
These were divided into chunks using scissors and forceps in extraction medium, (0.25M sucrose, 5 
mM HEPES buffer, and 1 mM EDTA, pH 7.2) on ice and washed and drained until the extraction 
medium was clear. The solution was poured into a Pyrex homogenisation flask, a Teflon mortar 
(Potter-Elvehjem) was attached to the tissuemiser (RW20, Janke & Kunkel, IKA-Labortechnik). The 
machine was used in bursts to prevent prolonged or overly vigorous homogenization, as this can 
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damage the mitochondria. This process occurs at ca. 1,600 rpm at no warmer then 4oC to prevent 
activation of proteases and phospholipases. 
This solution was then transferred to a precooled centrifuge cartridge and placed into a cold 
centrifuge (Beckman Avanti J-30 I) to form a nuclear pellet, the homogenate was centrifuged at 500 
g for 10 minutes. The supernatant fluid was then removed from the large cellular fragments that 
gathered. The supernatant was then added to a clean centrifuge tube and spun at 9400 g for 10 
minutes at 4 oC.  
The supernatant was then discarded and fresh extraction buffer added to the formed mitochondrial 
pellet. Damaged uncoupled mitochondria break off during this process and can be lost with the 
discarded supernatant as the more intact mitochondria sediment more quickly. This was centrifuged 
again at 9400 g for 10 minutes at 4 oC and the supernatant discarded. This process can be repeated 
until the pellet retains its creamy yellow colour and all the large red extracellular components have 
been removed. 
A white foamy material at the top of the centrifuge tubes was removed by wiping with a cotton bud. 
This material contains lipids and can uncouple the mitochondria causing damage. When the process 
of centrifugation and washing was completed the supernatant was discarded with care not to 
disturb the pellet. Remaining fluid was removed with a Pasteur pipette. A glass rod was then used to 
stirs the pellet into a smooth paste, trying not to introduce air into the suspension. The 
mitochondrial paste was kept concentrated at -80 oC to minimise exposure to oxygen, and to retain 
dormancy. A small amount of the paste was diluted and used for protein concentration estimation. 
5.3.12 Visualisation of Cells by Confocal Microscopy 
H9c2 cells were seeded into an 8 well BD Falcon™ CultureSlide at a density of 15,000 cells/well. The 
chamber slide was incubated for 24 hours in fully supplemented DMEM growth medium. 
Differentiation of the cells was then induced as described above with 7 days of culturing in serum 
deficient medium. After this point the medium was aspirated and the differentiated cells adhere to 
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the slides and are washed 3 times with PBS solution that has been incubated at 37oC for 5 min each 
wash.  
Fixing the cells proceeded with a 3.7 % (v/v) solution of paraformaldehyde in PBS for 15 minutes at 
room temperature. They were then washed three times with PBS for 5 minutes. 
 If antibodies are to be used to label cellular components then the cells must first be permeabilised 
with 0.1 % Triton X-100 in PBS. Then the cells are washed with 3 % (w/v) BSA in PBS to block non-
specific binding of the antibodies, prior to overnight incubation with primary antibody. Incubation 
with secondary antibody after this connects the fluorophore to specific protein target. 
If the cells are being labelled with a probe this can occur either of two ways: 
1. For the organophosphate probes the cells were incubated with 25 µM of probe for 1 hour 
prior to washing and fixation. 
2. For the DZX probe incubation occurs with 100 µM of probe in fully supplemented DMEM for 
1 hour, prior to washing and fixation. Optimal results were then achieved by washing the 
cells with PBS then quickly flashing the cells with UV light for <2 seconds. Washing with PBS 
removes excess probe solution. 
The slides are washed with PBS three times then allowed to air dry. Vectashield© mounting medium 
containing 4,6-diamidino-2-phenylindole (DAPI) is then applied to the slides. This is a nuclear 
counterstain allowing for cell visualisation. Glass cover-slips were then applied and sealed using 
colourless nail varnish. Visualisation was then achieved with an Olympus DP71 fluorescent 
microscope equipped with an argon/krypton laser.   
5.3.13 De-Staining of Gel Spots and Preparation for MS 
Proteins identified as being labelled with probe after 2D gel technique were picked out of the gels 
using a scalpel and placed in a 1 ml Eppendorf™ tube containing the dehydration solution (50 mM 
ammonium bicarbonate, equal volumes of deionised water and acetonitrile).  
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The cut-out spots were incubated for 5 min at 37 °C in the solution under gentle agitation. The 
supernatant was aspirated and replaced with fresh dehydration solution. Incubation at room 
temperature for 15 min with gentle agitation then followed and the gel spots were then dehydrated 
by adding 100% acetonitrile to the mixture for a further 5 minutes. The supernatant was then 
removed and replaced with dehydration solution for 5 minutes. The process of addition of 
acetonitrile followed by addition of dehydration solution and incubation was repeated three times. 
The gels were then rehydrated with deionised water for 5 minutes.  
The gel pieces were then reduced and alkylated with the respective buffers. Reducing buffer (25 mM 
dithiothreitol in 25 mM (NH4)HCO3) was added and then incubated at 56oC for 20 minutes. The gel 
then cools to room temperature and reducing buffer was pipetted off before the addition of the 
alkylating buffer (55 mM iodoacetamide in 25 mM (NH4)HCO3). Incubation of the gel spots at room 
temperature for 20 minutes then occurs in the dark. The alkylating before is removed, and the gel 
pieces washed with 20 volumes of Millipore water for 30 seconds. Final dehydration occurs with 5 
minutes of dehydration solution followed by addition of 100% acetonitrile. The particles are then 
dried in a vacuum centrifuge. 
The gel spots are then sent to the John van Gheest research centre for digestion with trypsin, 
preparation by ZipTip reverse phase chromatography and then spotted onto a steel mass 
spectrometry target plate with ɑ-Cyano-4-hydroxycinnamic acid 5.0 mg/ml (Bruker), 50 % v/v 
acetonitrile, 0.1 % v/v TFA (CHCA) matrix solution.  
5.3.14 Coomassie Blue Staining 
Gels were fixed with 20 ml Coomassie Brilliant Blue dye (Fisher scientific) after washing with distilled 
water to remove any left-over running buffer. The gels were incubated with the blue dye for 12 
hours, at which point the dye was removed and the gels were washed three time with distilled 
water. The gels were then left in water for 24 hours at room temperature so that excess dye leaches 
into the water. Washing a final time reveals the stained protein bands in the gel. 
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5.3.15 Statistical Analysis of Cell Viability Assays 
Statistical analysis of the LDH and MTT assays was performed using Prism software (GraphPad 7 
version 7, California, USA). Statistical significance was determined by one-way t-tests, or ANOVA for 
the diazoxide tests. 
An unpaired parametric Students t-test, compares the two data sets for significance (control vs 
treatment). This was performed according to the software guidelines. The significance of the 
differences could further be demonstrated with comparison of a two tailed P value between two 
sets of data, P < 0.05 statistically significant, highlighted with an asterisk (*).  
IC50 values (concentrations of drug producing 50% of the maximal inhibition), were derived from 
both LDH and MTT assays were obtained using the Prism software which assists curve fitting.  
Error bars for the data sets are presented as the mean ± standard error of mean (SEM). The number 
of separate experiments are represented by the character n in the text.  
5.3.16 Protease Activity Assays 
The measurement of protease activity on a substrate of Nɑ-benzoyl-DL-arginine-p-nitroanilide (L-
BAPNA) takes place in a 96-well plate. For the calibration curve, different concentrations of trypsin 
were added to a 96-well plate which was read at 415 nm as a zero point. L-BAPNA solution (10 µl) 
was added (0.1% (w/v) BAPNA in distilled water), and readings were taken every minute for 15 
minutes.  
For the inhibition assay, 25 µg of trypsin (from porcine pancreas, SigmaAldrich, UK) was incubated 
on ice with a trypsin inhibitor solution (TRIS buffer pH 6.8) or control solution of TRIS buffer. 100 µl 
of each solution was added in triplicate to a well on the plate and 10 µL of BAPNA solution was 
added to each well with readings being taken over a 15-minute interval.   
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5.4.1 Appendix 1: Computational Methods 
Calculations were performed with Gaussian 09, Revision E.01.S1 Geometry optimizations and thermal 
contributions to energies were computed in the gas phase with the functional wB97xD;S2 the 6–
31G(d,p) basis set was used for all atoms.S3 Stationary points were identified as minima through 
analytical frequency calculations. The energies reported in the main text are Gibbs energies. 
Table S1. Computed relative energies for ring open cations A and B, and 
the ring closed molecules C and D. Structures were optimised and energies 
calculated at the wB97xD/6-31G(d,p) level of theory. 
 SCF energy 
SCF + ZP 
energy 
SCF + 
thermal 
energy 
SCF + 
thermal 
enthalpy 
SCF + 
thermal 
free 
energy 
A 0.0 0.0 0.0 0.0 0.0 
B 262.9 254.2 253.7 253.7 254.6 
C 0.0 0.0 0.0 0.0 0.0 
D 254.2 245.9 245.5 245.5 245.0 
 
Computed Cartesian coordinates (Å) and energies (hartrees) 
A 
SCF Energy (gas phase)= -
1263.039477 
Zero-point correction= 0.43169300 
Thermal correction to Energy= 
0.45722300 
Thermal correction to Enthalpy= 
0.45816700 
Thermal correction to Gibbs Free 
Energy= 0.37550800 
 
C    -3.63584  -0.16168  -0.28158 
C    -3.58417  -1.58468  -0.09543 
C    -2.31709  -2.19793  -0.00939 
C    -1.17738  -1.42741  -0.09964 
C    -1.20968  -0.02255  -0.28243 
C    -2.49550   0.57770  -0.36633 
O    -0.00036  -2.08390  -0.00915 
C     1.17689  -1.42765  -0.09963 
C     1.20948  -0.02284  -0.28240 
C    -0.00007   0.68499  -0.34509 
C     2.31637  -2.19850  -0.00942 
C     3.58361  -1.58556  -0.09545 
C     3.63560  -0.16262  -0.28159 
C     2.49541   0.57707  -0.36633 
C     0.00023   2.15528  -0.59114 
O     0.00120   3.64825   2.74016 
C     0.00052   2.63918   1.86164 
O    -0.00018   1.47558   2.19819 
C     0.00059   3.10285   0.44512 
C     0.00103   4.46446   0.13561 
C     0.00110   4.88685  -1.18787 
C     0.00069   3.94808  -2.21382 
C     0.00024   2.58875  -1.91657 
N    -4.72050  -2.31006  -0.00760 
C    -6.02532  -1.66952  -0.11206 
C    -4.64910  -3.75109   0.18379 
N     4.71976  -2.31129  -0.00765 
C     6.02474  -1.67107  -0.11198 
C     4.64793  -3.75230   0.18349 
H    -4.59167   0.33868  -0.35498 
H    -2.19797  -3.26315   0.12823 
H    -2.56140   1.65116  -0.50519 
H     2.19698  -3.26369   0.12819 
H     4.59150   0.33758  -0.35506 
H     2.56168   1.65050  -0.50525 
H     0.00130   5.18757   0.94239 
H     0.00150   5.94681  -1.41598 
H     0.00076   4.27060  -3.24945 
H    -0.00008   1.85505  -2.71617 
H    -6.17314  -0.93134   0.68285 
H    -6.15407  -1.17994  -1.08295 
H    -6.80044  -2.42707  -0.01393 
H    -4.14136  -4.23846  -0.65592 
H    -4.12149  -4.00016   1.11070 
H    -5.65675  -4.15656   0.25113 
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H     6.17255  -0.93275   0.68280 
H     6.79967  -2.42877  -0.01346 
H     6.15383  -1.18173  -1.08294 
H     4.14003  -4.23939  -0.65629 
H     5.65546  -4.15810   0.25072 
H     4.12029  -4.00142   1.11037 
H     0.00101   3.25567   3.62418 
 
B  
SCF Energy (gas phase)= -
1282.47814082 
Zero-point correction= 0.47161700 
Thermal correction to Energy= 
0.49928300 
Thermal correction to Enthalpy= 
0.50022700 
Thermal correction to Gibbs Free 
Energy= 0.41281900 
 
C    -3.41541  -0.78176  -0.57755 
C    -3.18191  -2.16778  -0.28841 
C    -1.85038  -2.59118  -0.10235 
C    -0.82205  -1.67599  -0.19365 
C    -1.03394  -0.30451  -0.47384 
C    -2.38180   0.10130  -0.66611 
O     0.42608  -2.15858  -0.01087 
C     1.50644  -1.35046  -0.08442 
C     1.35902   0.03101  -0.36100 
C     0.07209   0.56112  -0.53466 
C     2.73188  -1.94723   0.12316 
C     3.90568  -1.16672   0.07948 
C     3.77392   0.23859  -0.18259 
C     2.55232   0.80327  -0.38815 
C    -0.10985   1.99382  -0.90089 
C    -0.54206   2.95465   0.02569 
C    -0.67813   4.28125  -0.38603 
C    -0.41845   4.65001  -1.70129 
C    -0.01198   3.69081  -2.62162 
C     0.14708   2.36849  -2.22013 
C    -0.78223   2.51920   1.44605 
O    -0.19904   1.54621   1.90840 
N    -1.66337   3.25729   2.16136 
C    -1.97979   2.92526   3.53773 
N     5.12182  -1.71968   0.28304 
N    -4.21294  -3.03875  -0.20393 
C    -5.58480  -2.59012  -0.39982 
C    -3.95780  -4.44139   0.08726 
C     6.32736  -0.90163   0.25274 
C     5.23614  -3.14322   0.56273 
H    -4.42386  -0.42353  -0.73316 
H    -1.59701  -3.61957   0.11259 
H    -2.58367   1.14271  -0.89115 
H     2.75157  -3.00858   0.32606 
H     4.65214   0.86906  -0.20800 
H     2.47624   1.86918  -0.56981 
H    -0.95306   5.04474   0.33472 
H    -0.52367   5.68660  -2.00188 
H     0.19051   3.96881  -3.65008 
H     0.47220   1.61818  -2.93389 
H    -2.23949   3.93147   1.68498 
H    -2.76536   2.16524   3.60086 
H    -1.08341   2.53298   4.01758 
H    -2.30678   3.82507   4.06041 
H    -5.87323  -1.84460   0.34854 
H    -5.72887  -2.16598  -1.39900 
H    -6.25543  -3.44137  -0.29918 
H    -3.46942  -4.56268   1.06037 
H    -4.90315  -4.97974   0.11476 
H    -3.32833  -4.89841  -0.68415 
H     6.46113  -0.42383  -0.72314 
H     6.30711  -0.12960   1.02880 
H     7.19194  -1.53702   0.43492 
H     4.69997  -3.41178   1.47965 
H     4.84381  -3.74230  -0.26609 
H     6.28522  -3.39885   0.69784 
 
C 
SCF Energy (gas phase)= -
1262.62049498 
Zero-point correction= 0.41778400 
Thermal correction to Energy= 
0.44259600 
Thermal correction to Enthalpy= 
0.44354000 
Thermal correction to Gibbs Free 
Energy= 0.36224600 
 
C    -3.66624  -0.11245  -0.11170 
C    -3.59124  -1.51489   0.06172 
C    -2.31860  -2.09957   0.09651 
C    -1.17674  -1.31409  -0.02721 
C    -1.23998   0.06580  -0.18779 
C    -2.51478   0.63778  -0.22868 
O    -0.00002  -2.00174   0.03073 
C     1.17671  -1.31410  -0.02719 
C     1.23997   0.06578  -0.18777 
C     0.00000   0.90118  -0.36069 
C     2.31856  -2.09960   0.09652 
C     3.59120  -1.51495   0.06172 
C     3.66623  -0.11250  -0.11167 
C     2.51478   0.63774  -0.22865 
C     0.00001   2.13951   0.51329 
O     0.00005   3.49352  -2.70458 
C     0.00005   2.82527  -1.70441 
O     0.00002   1.46953  -1.71578 
C     0.00003   3.26417  -0.28788 
C     0.00005   4.54878   0.24249 
C     0.00004   4.67057   1.62683 
C     0.00002   3.53103   2.44215 
C     0.00001   2.25045   1.89654 
N    -4.73137  -2.27873   0.20016 
C    -4.61978  -3.72021   0.22863 
C    -6.02841  -1.67213  -0.00891 
N     4.73133  -2.27877   0.20020 
C     4.61976  -3.72025   0.22880 
C     6.02836  -1.67219  -0.00908 
H    -4.62439   0.38801  -0.15928 
H    -2.17400  -3.16470   0.21598 
H    -2.60154   1.71203  -0.36415 
H     2.17393  -3.16473   0.21595 
H     4.62439   0.38796  -0.15921 
H     2.60156   1.71200  -0.36410 
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H     0.00007   5.41327  -0.41289 
H     0.00006   5.65397   2.08519 
H     0.00002   3.65195   3.52096 
H    -0.00002   1.36794   2.52809 
H    -4.00577  -4.05151   1.07426 
H    -5.61092  -4.15729   0.35311 
H    -4.17825  -4.12692  -0.69271 
H    -6.21895  -0.87854   0.72301 
H    -6.13628  -1.24279  -1.01505 
H    -6.80258  -2.42894   0.12062 
H     5.61087  -4.15731   0.35354 
H     4.00558  -4.05146   1.07434 
H     4.17841  -4.12708  -0.69259 
H     6.80253  -2.42902   0.12029 
H     6.21905  -0.87863   0.72283 
H     6.13605  -1.24282  -1.01522 
 
D 
SCF Energy (gas phase)= 
1282.07297745 
Zero-point correction= 0.45833200 
Thermal correction to Energy= 
0.48540600 
Thermal correction to Enthalpy= 
0.48635000 
Thermal correction to Gibbs Free 
Energy= 0.39805700 
 
C    -3.67007  -0.15648  -0.13231 
C    -3.59365  -1.54843   0.10771 
C    -2.31955  -2.12242   0.20640 
C    -1.17766  -1.33491   0.08783 
C    -1.24254   0.03560  -0.13440 
C    -2.51798   0.59519  -0.24422 
O     0.00032  -2.01612   0.20626 
C     1.17814  -1.33441   0.08912 
C     1.24275   0.03606  -0.13325 
C     0.00000   0.89221  -0.28161 
C     2.32023  -2.12149   0.20884 
C     3.59420  -1.54710   0.11148 
C     3.67031  -0.15532  -0.12939 
C     2.51808   0.59601  -0.24235 
C    -0.00066   2.06499   0.68860 
C    -0.00059   3.26162  -0.00935 
C    -0.00119   4.48785   0.64013 
C    -0.00188   4.48313   2.03145 
C    -0.00195   3.27594   2.73875 
C    -0.00135   2.05122   2.07507 
C     0.00018   2.97133  -1.46978 
O     0.00050   3.76569  -2.39447 
N     0.00048   1.60391  -1.57065 
C     0.00146   0.90541  -2.82890 
N     4.73497  -2.31187   0.24979 
N    -4.73397  -2.31373   0.24365 
C    -4.61608  -3.75065   0.34800 
C    -6.02795  -1.72295  -0.01881 
C     6.02778  -1.72257  -0.02225 
C     4.61712  -3.74942   0.34660 
H    -4.62871   0.33568  -0.23152 
H    -2.17331  -3.18134   0.37167 
H    -2.60066   1.66280  -0.42863 
H     2.17409  -3.18045   0.37385 
H     4.62884   0.33706  -0.22841 
H     2.60057   1.66356  -0.42719 
H    -0.00113   5.40931   0.06738 
H    -0.00236   5.42190   2.57602 
H    -0.00250   3.29576   3.82423 
H    -0.00141   1.11414   2.62304 
H     0.89309   0.27584  -2.92174 
H    -0.88877   0.27392  -2.92194 
H     0.00081   1.65697  -3.61906 
H    -4.14381  -4.19989  -0.53780 
H    -4.02729  -4.03610   1.22789 
H    -5.60840  -4.18786   0.46269 
H    -6.24103  -0.90363   0.67790 
H    -6.11349  -1.33137  -1.04248 
H    -6.80151  -2.47900   0.11894 
H     6.10974  -1.33856  -1.04916 
H     6.24272  -0.89815   0.66764 
H     6.80214  -2.47717   0.11901 
H     4.02421  -4.03861   1.22234 
H     4.14937  -4.19525  -0.54341 
H     5.60904  -4.18665   0.46476 
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Inc., Wallingford CT, 2013. 
S2. J.-D. Chai and M. Head-Gordon, Phys. Chem. Chem. Phys., 2008, 10, 6615. 
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